<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Adv</journal-id><journal-id journal-id-type="iso-abbrev">Sci Adv</journal-id><journal-id journal-id-type="publisher-id">sciadv</journal-id><journal-id journal-id-type="hwp">advances</journal-id><journal-title-group><journal-title>Science Advances</journal-title></journal-title-group><issn pub-type="epub">2375-2548</issn><publisher><publisher-name>American Association for the Advancement of Science</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40106559</article-id><article-id pub-id-type="pmc">PMC12101717</article-id>
<article-id pub-id-type="publisher-id">adq3971</article-id><article-id pub-id-type="doi">10.1126/sciadv.adq3971</article-id><article-categories><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biomedicine and Life Sciences</subject></subj-group><subj-group subj-group-type="legacy-article-type"><subject>SciAdv r-articles</subject></subj-group><subj-group subj-group-type="overline"><subject>Structural Biology</subject></subj-group></article-categories><title-group><article-title>Structure and dynamics determine G protein coupling specificity at a
class A GPCR</article-title><alt-title alt-title-type="short">Molecular mechanism of G protein coupling
specificity at a class A GPCR</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0627-2288</contrib-id><name><surname>Casiraghi</surname><given-names>Marina</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-funding-acquisition/">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.credit.niso.org/Contributor_Roles/Visualization">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-original-draft/">Writing - original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="afn1" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0277-3018</contrib-id><name><surname>Wang</surname><given-names>Haoqing</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.credit.niso.org/Contributor_Roles/Visualization">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-original-draft/">Writing - original draft</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6287-7551</contrib-id><name><surname>Brennan</surname><given-names>Patrick C.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.credit.niso.org/Contributor_Roles/Visualization">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-original-draft/">Writing - original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Habrian</surname><given-names>Chris</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.credit.niso.org/Contributor_Roles/Visualization">Visualization</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7892-599X</contrib-id><name><surname>H&#x000fc;bner</surname><given-names>Harald</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.credit.niso.org/Contributor_Roles/Visualization">Visualization</role><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7055-2439</contrib-id><name><surname>Schmidt</surname><given-names>Maximilian F.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.credit.niso.org/Contributor_Roles/Visualization">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-original-draft/">Writing - original draft</role><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0513-3158</contrib-id><name><surname>Maul</surname><given-names>Luis</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4811-4632</contrib-id><name><surname>Pani</surname><given-names>Biswaranjan</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9310-8349</contrib-id><name><surname>Bahriz</surname><given-names>Sherif M. F. M.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.credit.niso.org/Contributor_Roles/Visualization">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-original-draft/">Writing - original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Bing</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref><xref rid="aff7" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Staffen</surname><given-names>Nico</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.credit.niso.org/Contributor_Roles/Visualization">Visualization</role><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2352-685X</contrib-id><name><surname>Assafa</surname><given-names>Tufa E.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role><xref rid="aff8" ref-type="aff">
<sup>8</sup>
</xref><xref rid="afn2" ref-type="author-notes">&#x02021;</xref><xref rid="afn3" ref-type="author-notes">&#x000a7;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0002-3834-8048</contrib-id><name><surname>Chen</surname><given-names>Bohan</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role><xref rid="aff9" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>White</surname><given-names>Elizabeth</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1702-8619</contrib-id><name><surname>Sunahara</surname><given-names>Roger K.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.credit.niso.org/Contributor_Roles/Visualization">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-original-draft/">Writing - original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff9" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0805-4049</contrib-id><name><surname>Inoue</surname><given-names>Asuka</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-funding-acquisition/">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role><xref rid="aff10" ref-type="aff">
<sup>10</sup>
</xref><xref rid="aff11" ref-type="aff">
<sup>11</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1786-9143</contrib-id><name><surname>Xiang</surname><given-names>Yang K.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-funding-acquisition/">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.credit.niso.org/Contributor_Roles/Visualization">Visualization</role><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref><xref rid="aff7" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1472-7545</contrib-id><name><surname>Lefkowitz</surname><given-names>Robert J.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-funding-acquisition/">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.credit.niso.org/Contributor_Roles/Visualization">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><xref rid="aff12" ref-type="aff">
<sup>12</sup>
</xref><xref rid="aff13" ref-type="aff">
<sup>13</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Isacoff</surname><given-names>Ehud Y.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-funding-acquisition/">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.credit.niso.org/Contributor_Roles/Visualization">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff14" ref-type="aff">
<sup>14</sup>
</xref><xref rid="aff15" ref-type="aff">
<sup>15</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8034-4492</contrib-id><name><surname>Nucci</surname><given-names>Nathaniel</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-funding-acquisition/">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.credit.niso.org/Contributor_Roles/Visualization">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff16" ref-type="aff">
<sup>16</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4127-197X</contrib-id><name><surname>Gmeiner</surname><given-names>Peter</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-funding-acquisition/">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="cor1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8173-4879</contrib-id><name><surname>Lerch</surname><given-names>Michael T.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-funding-acquisition/">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="cor1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5958-3990</contrib-id><name><surname>Kobilka</surname><given-names>Brian K.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-funding-acquisition/">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.credit.niso.org/Contributor_Roles/Visualization">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-original-draft/">Writing - original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor1" ref-type="corresp">*</xref></contrib><aff id="aff1"><label><sup>1</sup></label>Department of Molecular and Cellular
Physiology, Stanford University School of Medicine, Stanford, CA, USA.</aff><aff id="aff2"><label><sup>2</sup></label>Department of Biophysics, Medical College
of Wisconsin, Milwaukee, WI, USA.</aff><aff id="aff3"><label><sup>3</sup></label>Department of Chemistry and Pharmacy,
Medicinal Chemistry, Friedrich-Alexander-Universit&#x000e4;t
Erlangen-N&#x000fc;rnberg, Erlangen, Germany.</aff><aff id="aff4"><label><sup>4</sup></label>FAU NeW, Erlangen, Germany.</aff><aff id="aff5"><label><sup>5</sup></label>Department of Medicine, Duke University
Medical Center, Durham, NC, USA.</aff><aff id="aff6"><label><sup>6</sup></label>Department of Pharmacology, University of
California, Davis, Davis, CA, USA.</aff><aff id="aff7"><label><sup>7</sup></label>VA Northern California Health Care System,
Mather, CA, USA.</aff><aff id="aff8"><label><sup>8</sup></label>Department of Chemistry and Biochemistry,
University of California, Santa Cruz, Santa Cruz, CA, USA.</aff><aff id="aff9"><label><sup>9</sup></label>Department of Pharmacology, University of
California San Diego School of Medicine, La Jolla, CA, USA.</aff><aff id="aff10"><label><sup>10</sup></label>Graduate School of Pharmaceutical
Sciences, Tohoku University, 6-3, Aoba, Aramaki, Aoba-ku, Sendai, Miyagi
980-8578, Japan.</aff><aff id="aff11"><label><sup>11</sup></label>Graduate School of Pharmaceutical
Sciences, Kyoto University, 46-29 Yoshida-Shimo-Adachi-cho, Sakyo-ku, Kyoto
606-8501, Japan.</aff><aff id="aff12"><label><sup>12</sup></label>Department of Biochemistry, Duke
University Medical Center, Durham, NC, USA.</aff><aff id="aff13"><label><sup>13</sup></label>HHMI, Duke University Medical Center,
Durham, NC, USA.</aff><aff id="aff14"><label><sup>14</sup></label>Department of Molecular and Cell
Biology, University of California, Berkeley, Berkeley, CA, USA.</aff><aff id="aff15"><label><sup>15</sup></label>Helen Wills Neuroscience Institute,
University of California, Berkeley, Berkeley, CA, USA.</aff><aff id="aff16"><label><sup>16</sup></label>Department of Physics and Astronomy and
Department of Biological and Biomedical Biosciences, Rowan University,
Glassboro, NJ, USA.</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Corresponding author. Email: <email xlink:href="peter.gmeiner@fau.de">peter.gmeiner@fau.de</email> (P.G.);
<email xlink:href="mlerch@mcw.edu">mlerch@mcw.edu</email> (M.T.L.); <email xlink:href="kobilka@stanford.edu">kobilka@stanford.edu</email>
(B.K.K.)</corresp><fn id="afn1" fn-type="present-address"><label>&#x02020;</label><p>Present address: Department of Biosciences, Universit&#x000e0; degli Studi di
Milano, Milano, Italy.</p></fn><fn id="afn2" fn-type="present-address"><label>&#x02021;</label><p>Present address: Department of Chemistry and Chemical Biology, Cornell
University, Baker Laboratory, Ithaca, NY 14853, USA.</p></fn><fn id="afn3" fn-type="present-address"><label>&#x000a7;</label><p>Present address: National Biomedical Resource for Advanced ESR Spectroscopy,
Cornell University, Baker Laboratory, Ithaca, NY 14853, USA.</p></fn></author-notes><pub-date pub-type="collection"><day>21</day><month>3</month><year>2025</year></pub-date><pub-date publication-format="electronic" date-type="pub"><day>19</day><month>3</month><year>2025</year></pub-date><volume>11</volume><issue>12</issue><elocation-id>eadq3971</elocation-id><history>
<date date-type="received"><day>11</day><month>5</month><year>2024</year></date>
<date date-type="accepted"><day>11</day><month>2</month><year>2025</year></date>
</history><permissions><copyright-statement>Copyright &#x000a9; 2025 The Authors, some rights reserved;
exclusive licensee American Association for the Advancement of Science. No claim
to original U.S. Government Works. Distributed under a Creative Commons
Attribution License 4.0 (CC BY).</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Authors</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense" start_date="2025-03-19">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the
<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative
Commons Attribution license</ext-link>, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="sciadv.adq3971.pdf"/><abstract><p>G protein&#x02013;coupled receptors (GPCRs) exhibit varying degrees of selectivity
for different G protein isoforms. Despite the abundant structures of
GPCR&#x02013;G protein complexes, little is known about the mechanism of G
protein coupling specificity. The &#x003b2;<sub>2</sub>-adrenergic receptor is an
example of GPCR with high selectivity for G&#x003b1;s, the stimulatory G protein
for adenylyl cyclase, and much weaker for the G&#x003b1;i family of G proteins
inhibiting adenylyl cyclase. By developing a G&#x003b1;i-biased agonist (LM189),
we provide structural and biophysical evidence supporting that distinct
conformations at ICL2 and TM6 are required for coupling of the different G
protein subtypes G&#x003b1;s and G&#x003b1;i. These results deepen our
understanding of G protein specificity and bias and can accelerate the design of
ligands that select for preferred signaling pathways.</p></abstract><abstract abstract-type="teaser"><p>Structural and conformational changes determine GPCR signaling bias and G protein
coupling specificity.</p></abstract><funding-group><award-group id="award1821913"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical
Sciences</institution></institution-wrap>
</funding-source><award-id>GM083118</award-id></award-group><award-group id="award1939542"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100006770</institution-id><institution>American Chemical Society Petroleum Research
Fund</institution></institution-wrap>
</funding-source><award-id>61678-UR6</award-id></award-group><award-group id="award1821912"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009619</institution-id><institution>Japan Agency for Medical Research and
Development</institution></institution-wrap>
</funding-source><award-id>JP22ama121038 and JP22zf0127007</award-id></award-group><award-group id="award1646397"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010661</institution-id><institution>Horizon 2020 Framework Programme</institution></institution-wrap>
</funding-source><award-id>799376</award-id></award-group><award-group id="award1821915"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002241</institution-id><institution>Japan Science and Technology Agency</institution></institution-wrap>
</funding-source><award-id>JPMJFR215T and JPMJMS2023</award-id></award-group><award-group id="award1646398"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef"/><institution>NIH</institution></institution-wrap>
</funding-source><award-id>R01NS028471</award-id></award-group><award-group id="award1646399"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef"/><institution>NIH</institution></institution-wrap>
</funding-source><award-id>R01GM135581</award-id></award-group><award-group id="award1646400"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef"/><institution>NIH</institution></institution-wrap>
</funding-source><award-id>R01NS119826</award-id></award-group><award-group id="award1646401"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef"/><institution>NIH</institution></institution-wrap>
</funding-source><award-id>HL162825</award-id></award-group><award-group id="award1646404"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef"/><institution>American Heart Association (AHA)</institution></institution-wrap>
</funding-source><award-id>915188</award-id></award-group><award-group id="award1939543"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef"/><institution>NIH</institution></institution-wrap>
</funding-source><award-id>S10 OD025260</award-id></award-group><award-group id="award1646402"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef"/><institution>NIH</institution></institution-wrap>
</funding-source><award-id>MH134119</award-id></award-group><award-group id="award1646408"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef"/><institution>VA MERIT Grant</institution></institution-wrap>
</funding-source><award-id>IK6BX005753</award-id></award-group><award-group id="award1646409"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef"/><institution>VA MERIT Grant</institution></institution-wrap>
</funding-source><award-id>I01BX005100</award-id></award-group><award-group id="award1821914"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef"/><institution>NIH</institution></institution-wrap>
</funding-source><award-id>F31 HL164002</award-id></award-group><award-group id="award1646403"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef"/><institution>NSF</institution></institution-wrap>
</funding-source><award-id>MCB-1942957</award-id></award-group><award-group id="award1646405"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef"/><institution>National Heart, Lung, and Blood Institute,
NIH</institution></institution-wrap>
</funding-source><award-id>R01HL0160371609</award-id></award-group><award-group id="award1646406"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef"/><institution>DFG, German Research Foundation</institution></institution-wrap>
</funding-source><award-id>GRK 1910</award-id></award-group><award-group id="award1646407"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef"/><institution>Deutsche Forschungsgemeinschaft (DFG, German Research
Foundation</institution></institution-wrap>
</funding-source><award-id>GM 13/14-1</award-id></award-group><award-group id="award1821911"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef"/><institution>Society for the Promotion of Science</institution></institution-wrap>
</funding-source><award-id>JP21H04791 and JP24K2128</award-id></award-group></funding-group></article-meta></front><body><sec sec-type="introduction" disp-level="1"><title>INTRODUCTION</title><p>There are more than 800 members of the G protein&#x02013;coupled receptor (GPCR)
superfamily (<xref rid="R1" ref-type="bibr"><italic toggle="yes">1</italic></xref>), yet they
couple with varying efficacy to only four G protein subfamilies (G&#x003b1;s,
G&#x003b1;i/o, G&#x003b1;q/11, and G&#x003b1;12/13) to activate distinct downstream
signaling cascades (<xref rid="R2" ref-type="bibr"><italic toggle="yes">2</italic></xref>). In
recent years, the structures of more than 400 GPCR&#x02013;G protein complexes with
different G protein subtypes have been reported (<xref rid="R3" ref-type="bibr"><italic toggle="yes">3</italic></xref>&#x02013;<xref rid="R9" ref-type="bibr"><italic toggle="yes">9</italic></xref>). However, the molecular determinants of
GPCR&#x02013;G protein coupling specificity remain largely unknown (<xref rid="R10" ref-type="bibr"><italic toggle="yes">10</italic></xref>&#x02013;<xref rid="R14" ref-type="bibr"><italic toggle="yes">14</italic></xref>). In addition, mutagenesis
and phylogenetic analysis have found no correlation between sequence and coupling
selectivity (<xref rid="R15" ref-type="bibr"><italic toggle="yes">15</italic></xref>, <xref rid="R16" ref-type="bibr"><italic toggle="yes">16</italic></xref>). Biophysical
investigations have shown that GPCRs are inherently flexible, existing in an
equilibrium of multiple conformations (<xref rid="R17" ref-type="bibr"><italic toggle="yes">17</italic></xref>&#x02013;<xref rid="R20" ref-type="bibr"><italic toggle="yes">20</italic></xref>). Depending on their efficacy, ligands can shift
this equilibrium toward specific states, facilitating the coupling of signaling
partners. However, partner-specific states are likely transient, low-probability
conformations that cannot be trapped by structural methods such as x-ray
crystallography or cryo&#x02013;electron microscopy (cryo-EM). Therefore, additional
biophysical studies are needed to complement the information provided by structures
and to delineate the transient yet important conformational states stabilized in the
absence of bound G proteins (<xref rid="R21" ref-type="bibr"><italic toggle="yes">21</italic></xref>&#x02013;<xref rid="R24" ref-type="bibr"><italic toggle="yes">24</italic></xref>).</p><p>A deeper understanding of the mechanism at the basis of G protein specificity is
essential for the development of drugs that preferentially activate a single G
protein subtype. This could reduce the potential adverse effects associated with the
activation of multiple G protein isoforms. In this context, the development of
biased ligands that preferentially activate a single G protein subtype is highly
desirable as a tool to better characterize GPCR signaling and for therapeutic
purposes. However, our understanding of the molecular determinants underlying biased
signaling is still fragmentary, suggesting the need for a more detailed description
of the conformational states adopted by receptors bound to biased ligands (<xref rid="R21" ref-type="bibr"><italic toggle="yes">21</italic></xref>&#x02013;<xref rid="R24" ref-type="bibr"><italic toggle="yes">24</italic></xref>).</p><p>We chose the &#x003b2;<sub>2</sub>-adrenergic receptor (&#x003b2;<sub>2</sub>AR) as a
prototypical class A GPCR to investigate G protein specificity and biased signaling.
&#x003b2;<sub>2</sub>AR and &#x003b2;<sub>1</sub>-adrenergic receptors
(&#x003b2;<sub>1</sub>AR) are GPCRs expressed in cardiac myocytes and play
essential roles in the regulation of cardiac function by the sympathetic nervous
system. &#x003b2;<sub>1</sub>AR and &#x003b2;<sub>2</sub>AR primarily couple to the
stimulatory G protein for adenylyl cyclase G&#x003b1;s, to increase heart rate and
contractility (<xref rid="R25" ref-type="bibr"><italic toggle="yes">25</italic></xref>).
&#x003b2;<sub>2</sub>AR also binds to the G&#x003b1;i subtype, the inhibitory G
protein for adenylyl cyclase; activation of G&#x003b1;i by the &#x003b2;<sub>2</sub>AR
can counteract the effects of G&#x003b1;s activation on heart rate and contractility
(<xref rid="R26" ref-type="bibr"><italic toggle="yes">26</italic></xref>).
&#x003b2;<sub>2</sub>AR signaling through G&#x003b1;i can also lead to activation
of MAPK/ERK and PI-3K pathways. Chronic stimulation of the G&#x003b1;s pathway leads
to pathologic changes in the heart including myocyte apoptosis, which ultimately
leads to congestive heart failure. In contrast, &#x003b2;<sub>2</sub>AR activation of
G&#x003b1;i has a cardioprotective effect by activating the PI3K-Akt signaling
cascade (<xref rid="R27" ref-type="bibr"><italic toggle="yes">27</italic></xref>, <xref rid="R28" ref-type="bibr"><italic toggle="yes">28</italic></xref>). However, increased
G&#x003b1;i signaling by the &#x003b2;<sub>2</sub>AR has also been linked to the
acceleration of pathologic changes in nonischemic models of heart failure (<xref rid="R29" ref-type="bibr"><italic toggle="yes">29</italic></xref>), underlying the importance
of understanding the molecular basis of the promiscuous signaling through both
G&#x003b1;s and G&#x003b1;i.</p><p>G&#x003b1;s recruitment to the &#x003b2;<sub>2</sub>AR has been characterized by
structural and spectroscopic methods, including NMR and DEER spectroscopy (<xref rid="R4" ref-type="bibr"><italic toggle="yes">4</italic></xref>, <xref rid="R17" ref-type="bibr"><italic toggle="yes">17</italic></xref>, <xref rid="R18" ref-type="bibr"><italic toggle="yes">18</italic></xref>, <xref rid="R23" ref-type="bibr"><italic toggle="yes">23</italic></xref>, <xref rid="R30" ref-type="bibr"><italic toggle="yes">30</italic></xref>&#x02013;<xref rid="R33" ref-type="bibr"><italic toggle="yes">33</italic></xref>). In contrast, limited information is available
regarding the binding of G&#x003b1;i to the &#x003b2;<sub>2</sub>AR. Receptor
phosphorylation has been proposed to play a role in G&#x003b1;i recruitment at the
&#x003b2;<sub>2</sub>AR (<xref rid="R34" ref-type="bibr"><italic toggle="yes">34</italic></xref>). However, previous biochemical studies showed that
in vitro receptor phosphorylation with protein kinase A (PKA) failed to enhance
G&#x003b1;i coupling to the receptor (<xref rid="R35" ref-type="bibr"><italic toggle="yes">35</italic></xref>). In this study, in vitro receptor
phosphorylation with PKA failed to enhance G protein recruitment to the
&#x003b2;<sub>2</sub>AR with all the G&#x003b1;i protein subtypes tested
(G&#x003b1;i<sub>1</sub>, G&#x003b1;i<sub>2</sub>, and G&#x003b1;i<sub>3</sub>).
Moreover, previous investigations in neonatal cardiac myocytes showed a biphasic
coupling of the &#x003b2;<sub>2</sub>AR to Gs followed by Gi. In this experiments, Gi
coupling was not affected by the PKA inhibitor PKI (<xref rid="R36" ref-type="bibr"><italic toggle="yes">36</italic></xref>).</p><p>In this work, we identified a G&#x003b1;i-biased agonist (LM189) for the
&#x003b2;<sub>2</sub>AR and investigated the mechanism for its signaling bias
using a combination of structural and biophysical methods. We observed that relative
to nonbiased agonists, LM189 stabilizes a distinct conformation in TM6 and increases
the dynamics of ICL2, explaining the preferential G&#x003b1;i bias mediated by LM189
at this receptor system.</p></sec><sec sec-type="results" disp-level="1"><title>RESULTS</title><sec disp-level="2"><title>Development of the G&#x003b1;i-biased ligand LM189</title><p>Structures of GPCRs coupled to the inhibitory G protein Gi show a smaller outward
movement of TM6 compared to Gs and Gq/11 complexes (<xref rid="R3" ref-type="bibr"><italic toggle="yes">3</italic></xref>&#x02013;<xref rid="R7" ref-type="bibr"><italic toggle="yes">7</italic></xref>, <xref rid="R9" ref-type="bibr"><italic toggle="yes">9</italic></xref>, <xref rid="R37" ref-type="bibr"><italic toggle="yes">37</italic></xref>). This has been attributed to the smaller
size of the C terminus of the &#x003b1;5 helix of G&#x003b1;i compared to the
bulkier &#x003b1;5 of the G&#x003b1;s and G&#x003b1;q subtypes (<xref rid="R9" ref-type="bibr"><italic toggle="yes">9</italic></xref>, <xref rid="R13" ref-type="bibr"><italic toggle="yes">13</italic></xref>). A smaller outward displacement of TM6
is also observed in the crystal structure of the &#x003b2;<sub>2</sub>AR bound to
the partial agonist salmeterol (<xref rid="R38" ref-type="bibr"><italic toggle="yes">38</italic></xref>). To screen for ligands that could stabilize
the &#x003b2;<sub>2</sub>AR-Gi complex for structure determination, we compared
the effect of salmeterol with other &#x003b2;<sub>2</sub>AR agonists for the
coupling to Gs and Gi using the GTPase-Glo Assay (<xref rid="R32" ref-type="bibr"><italic toggle="yes">32</italic></xref>) (<xref rid="F1" ref-type="fig">Fig. 1,
A and B</xref>) (note that we will use Gs and Gi, instead of G&#x003b1;s and
G&#x003b1;i, when referring to the heterotrimer). Salmeterol is a
subtype-selective &#x003b2;<sub>2</sub>AR partial agonist for Gs activation
relative to epinephrine, the endogenous &#x003b2;<sub>2</sub>AR hormone also
known as adrenaline (<xref rid="F1" ref-type="fig">Fig. 1, A and C</xref>).
Unexpectedly, the GTPase (guanosine triphosphatase) assay showed that salmeterol
is more efficacious than epinephrine for &#x003b2;<sub>2</sub>AR coupling to Gi
(<xref rid="F1" ref-type="fig">Fig. 1B</xref>). Salmeterol is a long-acting
&#x003b2;<sub>2</sub>AR agonist (LABA) composed of a saligenin ethanolamine
pharmacophore and an aryloxy alkyl tail (<xref rid="R38" ref-type="bibr"><italic toggle="yes">38</italic></xref>, <xref rid="R39" ref-type="bibr"><italic toggle="yes">39</italic></xref>) (<xref rid="F1" ref-type="fig">Fig.
1C</xref>). The high subtype selectivity for &#x003b2;<sub>2</sub>AR is
mediated by binding of the salmeterol tail in the receptor extracellular
vestibule (also known as the exosite) (<xref rid="R38" ref-type="bibr"><italic toggle="yes">38</italic></xref>). Salbutamol, another &#x003b2;<sub>2</sub>AR
partial agonist that shares the same saligenin ring as salmeterol but lacks the
aryloxy alkyl tail, did not display high efficacy for Gi (<xref rid="F1" ref-type="fig">Fig. 1, A to C</xref>). This suggests that the increased
G&#x003b1;i efficacy of salmeterol is, in part, mediated by its tail (<xref rid="F1" ref-type="fig">Fig. 1C</xref>).</p><fig position="float" id="F1" fig-type="image" specific-use="distribute"><label>Fig. 1.</label><caption><title>Ligand efficacy at the &#x003b2;<sub>2</sub>AR.</title><p>(<bold>A</bold> and <bold>B</bold>) Luminescence GTPase-Glo assay. Ligand
efficacy reflects the ability of the ligand-bound receptor to promote
turnover of the G protein cycle. The reaction starts when
&#x003b2;<sub>2</sub>AR, bound to different ligands, is incubated
with Gs (A) or Gi (B). At the end of the reaction, lower bars correspond
to higher GTPase activity. (A) Salmeterol is a subtype-selective
&#x003b2;<sub>2</sub>AR partial agonist for Gs activation relative to
other agonist such as epinephrine and formoterol
(****<italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001). LM189 is as
efficacious as epinephrine at Gs turnover (ns,
<italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.96). In (B), salmeterol is more
efficacious than epinephrine for &#x003b2;<sub>2</sub>AR coupling to Gi
(**<italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.003). LM189 is more
efficacious than epinephrine and salmeterol at coupling to Gi
(****<italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.0001). Experiments were
performed as biological triplicates and results were plotted using
GraphPad Prism. <italic toggle="yes">P</italic> values were calculated using the
unpaired <italic toggle="yes">t</italic> test analysis on GraphPad Prism, assuming
Gaussian distributions.
ns&#x000a0;=&#x000a0;<italic toggle="yes">P</italic>&#x000a0;&#x0003e;&#x000a0;0.05,
*<italic toggle="yes">P</italic>&#x000a0;&#x02264;&#x000a0;0.05,
**<italic toggle="yes">P</italic>&#x000a0;&#x02264;&#x000a0;0.01,
***<italic toggle="yes">P</italic>&#x000a0;&#x02264;&#x000a0;0.001,
****<italic toggle="yes">P</italic>&#x000a0;&#x02264;&#x000a0;0.0001. Data are
represented as the mean&#x000a0;&#x000b1;&#x000a0;SD. (<bold>C</bold>)
Structures of &#x003b2;<sub>2</sub>AR ligands. From the left, epinephrine
(adrenaline) is the endogenous catecholamine neurotransmitter.
Salbutamol is a partial agonist belonging to the short-acting
&#x003b2;<sub>2</sub>AR agonists (SABAs). Salmeterol is a long-acting
&#x003b2;<sub>2</sub>AR partial agonist (LABA), which exhibits a long
duration of action and is used in the chronic management of asthma.
Salmeterol has the same saligenin head group as salbutamol. LM189 was
developed by replacing the saligenin moiety of salmeterol with a
catechol group (red square).</p></caption><graphic xlink:href="sciadv.adq3971-f1" position="float"/></fig><p>To better understand the increased efficacy of salmeterol for the coupling of
&#x003b2;<sub>2</sub>AR to Gi, we sought to determine the cryo-EM structure
of the complex. Despite our efforts, we could not obtain the structure of the
salmeterol-bound &#x003b2;<sub>2</sub>AR-Gi complex. We identified conditions
that led to a biochemically stable interaction; however, the complex dissociated
upon sample vitrification. To further enhance the ligand efficacy for G&#x003b1;i
activation, we designed alternative ligands starting from the salmeterol
scaffold. One of the ligands tested, named LM189, proved to be more efficacious
than salmeterol at Gi turnover (<xref rid="F1" ref-type="fig">Fig. 1, B and
C</xref>). LM189 shares the tail region of salmeterol, while the saligenin
moiety has been replaced by the catechol group, similar to epinephrine (<xref rid="F1" ref-type="fig">Fig. 1C</xref>). LM189 is more efficacious than
epinephrine and salmeterol at coupling to Gi (<xref rid="F1" ref-type="fig">Fig.
1B</xref>) and as efficacious as epinephrine at Gs turnover (<xref rid="F1" ref-type="fig">Fig. 1A</xref>). LM189 is equally efficacious for the
Gi<sub>1</sub>, Gi<sub>2</sub>, and Gi<sub>3</sub> subtypes (fig. S1, A and
B). For further experiments, we decided to focus on the Gi<sub>1</sub> subtype
that will henceforth be referred to as Gi. Similar results in the GTPase assay
were obtained with receptor reconstituted in high-density lipoproteins (HDLs;
fig. S1C).</p><p>To quantify the degree of bias of LM189, we performed nano-bioluminescence
resonance energy transfer (BRET) experiments between &#x003b2;<sub>2</sub>AR-Rluc
and mini-Gs-venus and mini-Gs/i-venus (fig. S1D). We obtained dose-response
curves for Gs and Gi activation in the presence of epinephrine, the endogenous
&#x003b2;<sub>2</sub>AR ligand that we chose as reference, formoterol and
LM189. We used the Operational Model equation (<xref rid="R40" ref-type="bibr"><italic toggle="yes">40</italic></xref>, <xref rid="R41" ref-type="bibr"><italic toggle="yes">41</italic></xref>) in GraphPad Prism to fit the data and
determine the Log<italic toggle="yes">R</italic> values [equivalent to
log(<italic toggle="yes">t</italic>/KA) ratios] (fig. S1D). We then calculated
&#x00394;Log(&#x003c4;/KA) ratios, SEM, and relative effectiveness considering
epinephrine as the reference ligand (<xref rid="R40" ref-type="bibr"><italic toggle="yes">40</italic></xref>, <xref rid="R41" ref-type="bibr"><italic toggle="yes">41</italic></xref>) (fig. S1D).
&#x00394;&#x00394;Log(&#x003c4;/KA) ratios and bias factors (BFs) for LM189
activation of Gi were also determined. On the basis of our calculations,
formoterol is weakly biased at Gi (BF&#x000a0;=&#x000a0;3.7, fig. S1D), while
LM189 shows notable bias toward Gi (BF&#x000a0;=&#x000a0;24, fig. S1D).</p><p>We further characterized LM189-mediated &#x003b2;-arrestin recruitment profile,
which we found similar to epinephrine (fig. S1E). On the basis of radioligand
binding measurements, LM189 shows very high affinity for the
&#x003b2;<sub>2</sub>AR (<italic toggle="yes">K<sub>i</sub></italic>&#x000a0;=&#x000a0;0.063
nM) but can also bind to the &#x003b2;<sub>1</sub>AR with lower affinity
(<italic toggle="yes">K</italic><sub>i</sub>&#x000a0;=&#x000a0;28 nM) (fig. S1F and table
S1). Collectively, our experimental data support the higher efficacy of LM189
over balanced ligands at Gi recruitment to the &#x003b2;<sub>2</sub>AR.</p></sec><sec disp-level="2"><title>Structure of the LM189-bound &#x003b2;<sub>2</sub>AR-Gi complex</title><p>To determine the binding mode of LM189 and the structural determinants of Gi
coupling, we obtained the structure of the &#x003b2;<sub>2</sub>AR-Gi complex by
cryo-EM to a global resolution of 2.9 &#x000c5; (<xref rid="F2" ref-type="fig">Fig. 2, A and B</xref>, and figs. S2 and S3, A to F). The overall structure
of the LM189-&#x003b2;<sub>2</sub>AR-Gi complex is similar to the previously
determined BI-167107&#x02013;&#x003b2;<sub>2</sub>AR-Gs crystal structure (<xref rid="R4" ref-type="bibr"><italic toggle="yes">4</italic></xref>) (<xref rid="F2" ref-type="fig">Fig. 2B</xref>). The position of the &#x003b1;5 helix in the
&#x003b2;<sub>2</sub>AR-Gi structure closely resembles the
&#x003b2;<sub>2</sub>AR-Gs complex, in contrast to other GPCR-Gi complexes
such as the &#x003bc;OR-Gi (<xref rid="R3" ref-type="bibr"><italic toggle="yes">3</italic></xref>&#x02013;<xref rid="R5" ref-type="bibr"><italic toggle="yes">5</italic></xref>) (<xref rid="F2" ref-type="fig">Fig.
2C</xref>). Conversely, TM6 of the receptor in the &#x003b2;<sub>2</sub>AR-Gi
complex displays a larger outward movement, more similar to the one observed in
the &#x003b2;<sub>2</sub>AR-Gs structure rather than the smaller TM6 opening
reported for other GPCR-Gi structures (<xref rid="R3" ref-type="bibr"><italic toggle="yes">3</italic></xref>&#x02013;<xref rid="R5" ref-type="bibr"><italic toggle="yes">5</italic></xref>) (<xref rid="F2" ref-type="fig">Fig.
2C</xref>). Similar to the &#x003b2;<sub>2</sub>AR-Gs structure, Phe
139<sup>34.51</sup> of &#x003b2;<sub>2</sub>AR ICL2 inserts into the
hydrophobic pocket of Gi, formed by Phe 191 and Leu 194 of the &#x003b2;1 strand,
Phe 336, Thr 340, Ile 343, Ile 344 of the &#x003b1;5 C terminus (<xref rid="F2" ref-type="fig">Fig. 2D</xref>). However, compared to the Gs structure,
engagement of Gi to the &#x003b2;<sub>2</sub>AR is mediated by far fewer contacts
between the G protein &#x003b1;5 and ICL2, TM3, and TM5 of the receptor,
accounting for the diminished efficacy and less stable interaction of the
&#x003b2;<sub>2</sub>AR with Gi (<xref rid="F2" ref-type="fig">Fig.
2D</xref>).</p><fig position="float" id="F2" fig-type="image" specific-use="distribute"><label>Fig. 2.</label><caption><title>Structure of the LM189-bound &#x003b2;<sub>2</sub>AR-Gi
complex.</title><p>(<bold>A</bold>) Cryo-EM density map of the LM189-bound
&#x003b2;<sub>2</sub>AR-Gi-scfv16 complex. (<bold>B</bold>) Cryo-EM
structure of LM189-bound &#x003b2;<sub>2</sub>AR-Gi complex and crystal
structure of BI-167107&#x02013;bound &#x003b2;<sub>2</sub>AR-Gs (<xref rid="R4" ref-type="bibr"><italic toggle="yes">4</italic></xref>) (3SN6).
&#x003b2;<sub>2</sub>AR bound to Gi is colored orange, G&#x003b1;i is
in olive green, G&#x003b2; is in cyan, G&#x003b3; is in magenta, and
scfv-16 is in gray. &#x003b2;<sub>2</sub>AR bound to Gs is colored green,
and G&#x003b1;s is in slate. (<bold>C</bold>) Relative orientation of
receptor TM6 and &#x003b1;5 helix of the &#x003b2;<sub>2</sub>AR-Gi
(orange), &#x003b2;<sub>2</sub>AR-Gs (green), and &#x003bc;OR-Gi (blue)
(<xref rid="R3" ref-type="bibr"><italic toggle="yes">3</italic></xref>) complex
structures. (<bold>D</bold>) Top: &#x003b1;5 engagement of Gi and the
interactions formed with the ICL2, TM3, and TM5 of
&#x003b2;<sub>2</sub>AR. &#x003b2;<sub>2</sub>AR is colored orange, and
G&#x003b1;i is in olive green. Bottom: &#x003b1;5 engagement of Gs and the
interactions formed with the ICL2, TM3, and TM5 of
&#x003b2;<sub>2</sub>AR. &#x003b2;<sub>2</sub>AR is colored green, and
G&#x003b1;s is in slate. Polar contacts within 4 &#x000c5; are
highlighted. (<bold>E</bold>) Structural differences between the
LM189-bound &#x003b2;<sub>2</sub>AR-Gi complex and BI-167107&#x02013;bound
&#x003b2;<sub>2</sub>AR-Gs (<xref rid="R4" ref-type="bibr"><italic toggle="yes">4</italic></xref>). Top left blue panel: The PAM
cmpd-6FA (<xref rid="R42" ref-type="bibr"><italic toggle="yes">42</italic></xref>,
<xref rid="R43" ref-type="bibr"><italic toggle="yes">43</italic></xref>)
(yellow), binding at the top of ICL2. Lower left magenta panel: When
bound to Gi, ICL2 of &#x003b2;<sub>2</sub>AR adopts a slightly different
conformation compared to Gs. Top right red panel: By monitoring TM6
rotation at Glu<sup>268</sup>, the TM6 helix is slightly less rotated in
the &#x003b2;<sub>2</sub>AR-Gi structure compared to
&#x003b2;<sub>2</sub>AR-Gs (~3 &#x000c5;). Carazolol-bound
inactive-state &#x003b2;<sub>2</sub>AR is colored gray (2RH1) (<xref rid="R44" ref-type="bibr"><italic toggle="yes">44</italic></xref>),
salmeterol-bound &#x003b2;<sub>2</sub>AR in complex with Nb71 is colored
wheat (6MXT) (<xref rid="R38" ref-type="bibr"><italic toggle="yes">38</italic></xref>), LM189-bound &#x003b2;<sub>2</sub>AR-Gi
complex is colored orange, and BI-167107&#x02013;bound
&#x003b2;<sub>2</sub>AR-Gs (3SN6) (<xref rid="R4" ref-type="bibr"><italic toggle="yes">4</italic></xref>) is colored green. Lower right brown
panel: TM5 of the &#x003b2;<sub>2</sub>AR-Gi complex is one helix turn
shorter than TM5 of the &#x003b2;<sub>2</sub>AR-Gs structure, avoiding a
steric clash between the tip of TM5 and the connecting loop between the
a4 helix and b6 strand of Gi.</p></caption><graphic xlink:href="sciadv.adq3971-f2" position="float"/></fig><p>Although overall very similar, the &#x003b2;<sub>2</sub>AR-Gi structure is most
divergent from the &#x003b2;<sub>2</sub>AR-Gs complex at the intracellular
surface, in particular at ICL2, TM6, and TM5 (<xref rid="F2" ref-type="fig">Fig.
2E</xref> and fig. S3, A to F). To increase complexing efficiency, the
&#x003b2;<sub>2</sub>AR-Gi complex was obtained with the aid of the PAM
cmpd-6FA, which helps to stabilize ICL2 in the &#x003b1;-helical active-state
conformation (<xref rid="R42" ref-type="bibr"><italic toggle="yes">42</italic></xref>, <xref rid="R43" ref-type="bibr"><italic toggle="yes">43</italic></xref>) (<xref rid="F2" ref-type="fig">Fig. 2E</xref> and fig. S3, B and D). Therefore, our ICL2
structure may differ from that in a complex formed in the absence of cmpd-6FA
(discussed further below). We do observe slight differences in the ICL2
active-state conformation of &#x003b2;<sub>2</sub>AR-Gi compared to
&#x003b2;<sub>2</sub>AR-Gs, in particular at residues Lys
140<sup>34.52</sup>, Tyr 141<sup>34.53</sup>, and Gln 142<sup>34.54</sup> (<xref rid="F2" ref-type="fig">Fig. 2E</xref> and fig. S3, B and D). TM6 of
&#x003b2;<sub>2</sub>AR coupled to Gi is very similar to the
&#x003b2;<sub>2</sub>AR-Gs structure, with an almost identical outward
movement (<xref rid="F2" ref-type="fig">Fig. 2E</xref> and fig. S3E). However,
by monitoring TM6 helix rotation at residue Glu 268<sup>6.28</sup>, we observed
a slightly smaller outward rotation in the &#x003b2;<sub>2</sub>AR-Gi complex
compared to Gs (<xref rid="F2" ref-type="fig">Fig. 2E</xref>), resulting in a
~3-&#x000c5; difference in the outward tilt of Glu 268<sup>6.28</sup>.</p><p>In the &#x003b2;<sub>2</sub>AR-Gs structure, the cytoplasmic end of TM5 undergoes
a two-turn elongation compared to the inactive state. In contrast, the
intracellular end of the TM5 helix of &#x003b2;<sub>2</sub>AR-Gi elongates only
one turn (<xref rid="R4" ref-type="bibr"><italic toggle="yes">4</italic></xref>, <xref rid="R44" ref-type="bibr"><italic toggle="yes">44</italic></xref>) (<xref rid="F2" ref-type="fig">Fig. 2E</xref> and fig. S3, C and F); the cryo-EM density map
suggests that this region is highly flexible. This can be attributed to the
weaker network of contacts established between TM5 and Gi, mostly consisting of
the hydrogen bonds between Asp 341 (Gi), Gln 229<sup>5.58</sup> and Lys
232<sup>5.61</sup> (&#x003b2;<sub>2</sub>AR) (<xref rid="F2" ref-type="fig">Fig. 2D</xref>). These interactions are present in the
&#x003b2;<sub>2</sub>AR-Gs structure as well, together with three additional
hydrogen bonds that help to stabilize the complex (<xref rid="R4" ref-type="bibr"><italic toggle="yes">4</italic></xref>). The shorter TM5 helix prevents a steric
clash with the connector loop of the &#x003b1;4-&#x003b2;6 strand of Gi, which
moves 6 &#x000c5; closer to the receptor compared to the corresponding loop in Gs
(<xref rid="R3" ref-type="bibr"><italic toggle="yes">3</italic></xref>) (<xref rid="F2" ref-type="fig">Fig. 2E</xref> and fig. S3F). Thus, the different TM5
conformations might be important determinants of G protein selectivity and might
play a role in the initial steps of G protein coupling.</p></sec><sec disp-level="2"><title>LM189 restricts the conformational heterogeneity of the ligand binding
pocket</title><p>LM189 shares the same tail region as salmeterol, making similar hydrophobic and
van der Waals interactions within the &#x003b2;<sub>2</sub>AR exosite (<xref rid="R38" ref-type="bibr"><italic toggle="yes">38</italic></xref>). LM189 also shares the
same catechol head group of epinephrine, which forms hydrogen bonds with Asp
113<sup>3.32</sup>, Asn 312<sup>7.39</sup>, Ser 203<sup>5.42</sup>, Ser
207<sup>5.46</sup> and Asn 293<sup>6.55</sup> (<xref rid="F3" ref-type="fig">Fig. 3, A to C</xref>). This polar network has been shown to be important
for ligand efficacy at the &#x003b2;<sub>2</sub>AR, and mutations of these
residues have an impact on G protein and &#x003b2;-arrestin recruitment (<xref rid="R38" ref-type="bibr"><italic toggle="yes">38</italic></xref>). We conducted
molecular dynamics (MD) simulations to investigate the role of these polar
interactions in ligand efficacy and bias. Rotameric analysis of Ser
207<sup>5.46</sup> and Asn 293<sup>6.55</sup> showed that ligand-receptor
interactions in the orthosteric pocket of LM189-bound &#x003b2;<sub>2</sub>AR
were less heterogeneous and more stable compared to epinephrine-bound
&#x003b2;<sub>2</sub>AR (<xref rid="F3" ref-type="fig">Fig. 3D</xref>). Ser
207<sup>5.46</sup> and Asn 293<sup>6.55</sup> clearly adopted a favored
conformation for LM189-coupled receptor, whereas a broader ensemble of rotamers
was sampled in the presence of epinephrine (<xref rid="F3" ref-type="fig">Fig.
3D</xref>). For LM189, a very stable hydrogen bond network was formed
between the ligand and Ser 203<sup>5.42</sup>, Ser 207<sup>5.46</sup>, and Asn
293<sup>6.55</sup> (<xref rid="F3" ref-type="fig">Fig. 3E</xref>). Moreover,
Asn 293<sup>6.55</sup> also formed a stable network with Tyr 308<sup>7.35</sup>
and Ser 204<sup>5.43</sup> (<xref rid="F3" ref-type="fig">Fig. 3E</xref>). In
contrast, epinephrine stabilized a weaker polar network, resulting in the loss
of the Asn 293<sup>6.55</sup> and Ser 203<sup>5.42</sup> interaction with the
meta-OH group during our simulations (<xref rid="F3" ref-type="fig">Fig.
3E</xref>).</p><fig position="float" id="F3" fig-type="image" specific-use="distribute"><label>Fig. 3.</label><caption><title>Ligand-binding pocket of the LM189-bound &#x003b2;<sub>2</sub>AR-Gi
complex.</title><p>(<bold>A</bold> to <bold>C</bold>) The orthosteric pocket (left) and
exosite (right) of &#x003b2;<sub>2</sub>AR bound to LM189 (A),
epinephrine (B), and salmeterol (C). (A) LM189 is colored yellow, and
&#x003b2;<sub>2</sub>AR in the &#x003b2;<sub>2</sub>AR-Gi structure is
colored orange. (B) Epinephrine is colored pink, and epinephrine-bound
&#x003b2;<sub>2</sub>AR in complex with Nb80 (4LDO) (<xref rid="R67" ref-type="bibr"><italic toggle="yes">67</italic></xref>) is colored
aquamarine. (C) Salmeterol is colored blue, and salmeterol-bound
&#x003b2;<sub>2</sub>AR in complex with Nb71 (6MXT) (<xref rid="R38" ref-type="bibr"><italic toggle="yes">38</italic></xref>) is colored
slate. H-bonds are showed as dashed lines. (<bold>D</bold> and
<bold>E</bold>) Molecular dynamics simulations of active-state
&#x003b2;<sub>2</sub>AR-Gi bound to LM189 or epinephrine. (D) Rotamer
analysis of Ser<sup>5.46</sup> and Asn<sup>6.55</sup> of LM189-bound
(orange, top) and epinephrine-bound (aquamarine, bottom)
&#x003b2;<sub>2</sub>AR-Gi. (E) Histograms represent hydrogen-bond
formation frequencies as a fraction of time in three 2-&#x003bc;s MD
simulations. &#x003b2;<sub>2</sub>AR-Gi is represented in orange, and
epinephrine-bound &#x003b2;<sub>2</sub>AR-Gi is in aquamarine.
(<bold>F</bold> and <bold>G</bold>) MD simulations at the
intracellular cavity of &#x003b2;<sub>2</sub>AR. (F) Left: Comparison of
the cryo-EM structure of the LM189-bound &#x003b2;<sub>2</sub>AR (orange)
and a representative MD snapshot of the LM189-bound
&#x003b2;<sub>2</sub>AR (yellow). Right: Plot shows the progression of
the distance between the C&#x003b3; of Asp130<sup>3.49</sup> and OH of
Tyr141<sup>ICL2</sup> over the course of 4 &#x003bc;s. (G) Left:
Comparison of the epinephrine-bound &#x003b2;<sub>2</sub>AR model (pink,
based on the BI-167107&#x02013;bound &#x003b2;<sub>2</sub>AR crystal
structure, PDB: 3SN6) and a representative MD snapshot of the epi-bound
&#x003b2;<sub>2</sub>AR model (wheat). Right: Plot shows the
progression of the distance between the C&#x003b3; of
Asp130<sup>3.49</sup> and OH of Tyr141<sup>ICL2</sup> over the
course of 4.9 &#x003bc;s.</p></caption><graphic xlink:href="sciadv.adq3971-f3" position="float"/></fig><p>Additional MD simulations at the extracellular region of &#x003b2;<sub>2</sub>AR
bound to the ligands epinephrine, LM189, and salmeterol indicated a more
flexible ECL3 in the epinephrine-bound state coupled to Gs (red box in fig. S3G)
compared to LM189-coupled receptor, which displayed similar ECL3 motions to
salmeterol-bound &#x003b2;<sub>2</sub>AR (fig. S3G). In addition, we observed
higher flexibility of ECL1 and ECL2 when &#x003b2;<sub>2</sub>AR was coupled to
Gi (fig. S3G). Collectively, our MD simulations suggest that LM189 restricts the
conformational heterogeneity of the ligand-binding pocket compared to the more
flexible configuration in the presence of epinephrine.</p><p>Because the &#x003b2;<sub>2</sub>AR-Gi and &#x003b2;<sub>2</sub>AR-Gs structures
mostly diverge at ICL2, we conducted MD simulations at the intracellular cavity
of the receptor to investigate ICL2 conformational changes in Gs- and Gi-bound
receptors. Simulations of the LM189-&#x003b2;<sub>2</sub>AR-Gi and
epinephrine-&#x003b2;<sub>2</sub>AR-Gs complexes after removal of the
respective G proteins showed partial unwinding of the ICL2 helical structure
(<xref rid="F3" ref-type="fig">Fig. 3, F and G</xref>). We observed greater
ICL2 mobility when the receptor was bound to LM189, as shown by the
repositioning of residue Tyr 141<sup>ICL2</sup> (<xref rid="F3" ref-type="fig">Fig. 3, F and G</xref>). This suggests increased ICL2 dynamics in the
absence of cmpd-6FA and G proteins. Because MD simulation timescales are too
short (nanoseconds to microseconds) to fully characterize the conformational
changes occurring at the intracellular cavity (milliseconds), we decided to
conduct additional biophysical measurements to better describe the intracellular
rearrangements implicated in G protein specificity.</p></sec><sec disp-level="2"><title>The role of ICL2 in G protein specificity</title><p>Hydrogen deuterium exchange mass spectrometry studies indicate that ICL2
interaction with the hydrophobic core of the G protein &#x003b1; subunit is one
of the first steps in the receptor&#x02013;G protein interaction (<xref rid="R13" ref-type="bibr"><italic toggle="yes">13</italic></xref>, <xref rid="R31" ref-type="bibr"><italic toggle="yes">31</italic></xref>, <xref rid="R33" ref-type="bibr"><italic toggle="yes">33</italic></xref>). Previous biophysical and structural
investigations have shown that ICL2 of &#x003b2;<sub>2</sub>AR forms a loop in
the inactive state (<xref rid="R44" ref-type="bibr"><italic toggle="yes">44</italic></xref>)
and a helix in the active-state conformation (<xref rid="R4" ref-type="bibr"><italic toggle="yes">4</italic></xref>). In our &#x003b2;<sub>2</sub>AR-Gi complex,
ICL2 forms a partial helix (<xref rid="F2" ref-type="fig">Fig. 2, D and
E</xref>). However, as noted above, this might be due to the presence of the
cmpd-6FA PAM, which binds on top of ICL2 and stabilizes the helical conformation
(<xref rid="R42" ref-type="bibr"><italic toggle="yes">42</italic></xref>, <xref rid="R43" ref-type="bibr"><italic toggle="yes">43</italic></xref>). Previous NMR studies
suggest that ICL2 does not form a helix when coupled to Gi (<xref rid="R14" ref-type="bibr"><italic toggle="yes">14</italic></xref>). We used continuous
wave&#x02013;electron paramagnetic resonance (CW-EPR) spectroscopy to investigate
ICL2 conformational dynamics, to better understand its implication for G protein
selectivity at the &#x003b2;<sub>2</sub>AR. The EPR spectral line shape is
sensitive to protein motion on the nanosecond timescale. For properly placed
labels, conformational exchange that takes place on the microsecond or longer
timescale results in a composite line shape composed of the weighted sum of
spectral components arising from different conformational states (<xref rid="R45" ref-type="bibr"><italic toggle="yes">45</italic></xref>). We monitored the
conformational dynamics at ICL2 by site-directed spin labeling of Q142C, a
residue located in the middle of ICL2, which served as a conformational reporter
(<xref rid="F4" ref-type="fig">Fig. 4A</xref>).</p><fig position="float" id="F4" fig-type="image" specific-use="distribute"><label>Fig. 4.</label><caption><title>CW-EPR studies of ICL2 of &#x003b2;<sub>2</sub>AR.</title><p>(<bold>A</bold>) A minimal-cysteine version of the &#x003b2;<sub>2</sub>AR
with an acetamido-PROXYL spin-label side chain shown at the mutated
Q142C residue on ICL2 for EPR studies. Inactive-state
&#x003b2;<sub>2</sub>AR (2RH1) (<xref rid="R44" ref-type="bibr"><italic toggle="yes">44</italic></xref>) is colored gray, and active-state
&#x003b2;<sub>2</sub>AR (3SN6) (<xref rid="R4" ref-type="bibr"><italic toggle="yes">4</italic></xref>) is colored green. (<bold>B</bold>)
Superimposed CW-EPR spectra of &#x003b2;<sub>2</sub>AR in the apo,
LM189-bound, and Gi- and Gs-protein bound conditions. The regions of the
low-field line dominated by mobile and immobile components are
indicated. (<bold>C</bold>) Superimposed CW-EPR spectra in the apo,
LM189-bound, and BI-167107&#x02013;bound receptor in complex with Gi.
(<bold>D</bold>) Superimposed CW-EPR spectra in the apo,
LM189-bound, and BI-167107&#x02013;bound receptor in complex with Gs. All
spectra are area normalized and color coded as indicated.</p></caption><graphic xlink:href="sciadv.adq3971-f4" position="float"/></fig><p>We collected CW spectra for the unliganded (apo) receptor and for
&#x003b2;<sub>2</sub>AR bound to the biased ligand LM189, the full agonist
BI-167107, and the partial agonist salmeterol (fig. S4A). The spectrum of the
apo receptor is dominated by a component reflecting the high mobility of the
spin label, with a minor component reflecting an immobilized state (<xref rid="F4" ref-type="fig">Fig. 4B</xref> and fig. S4A). On the basis of prior
structural evidence, the mobile and immobile components are taken to reflect the
loop and helical states of ICL2, respectively. Thus, the CW spectrum of the apo
receptor indicates the presence of an equilibrium between a loop and the helical
state of ICL2 (<xref rid="F4" ref-type="fig">Fig. 4B</xref> and fig. S4A).
Ligand binding did not substantially change the CW spectral line shape compared
to the apo receptor, except for the case of LM189, where we observed an increase
in the population of the mobile spectral component (<xref rid="F4" ref-type="fig">Fig. 4B</xref> and fig. S4, A and B), in agreement with our
MD simulations (<xref rid="F3" ref-type="fig">Fig. 3F</xref>). Upon G protein
coupling, we observed a decrease in the mobile component population and a
concomitant increase in the immobile component (<xref rid="F4" ref-type="fig">Fig. 4, C and D</xref>, and fig. S4, A and D), a change consistent with
ICL2 transition from loop to helix. This shift was greater for Gs than for Gi
coupling (<xref rid="F4" ref-type="fig">Fig. 4, C and D</xref>). Helix formation
upon Gs coupling was more pronounced in the salmeterol and LM189 conditions
(<xref rid="F4" ref-type="fig">Fig. 4D</xref> and fig. S4, A, B, and D).
This suggests similar conformational dynamics at ICL2 of the receptor bound to
LM189 and salmeterol upon Gs coupling.</p><p>Together, these observations suggest that ICL2 of &#x003b2;<sub>2</sub>AR adopts a
stable helix conformation when bound to Gs, while being more dynamic when bound
to ligands and Gi. F139 of ICL2 of &#x003b2;<sub>2</sub>AR inserts within the G
protein hydrophobic pocket formed by the &#x003b1;N/&#x003b2;1 hinge,
&#x003b2;2/&#x003b2;3 loop, and &#x003b1;5 (<xref rid="F2" ref-type="fig">Fig.
2D</xref>). The persistence of the unstructured ICL2 conformation upon Gi
coupling, when compared with Gs coupling, correlates with the less stable
interactions that we observe in the &#x003b2;<sub>2</sub>AR-Gi structure (<xref rid="F2" ref-type="fig">Fig. 2D</xref>). Because ICL2 participates in the
initial G protein recognition and engagement with the receptor, together with
the &#x003b1;5 and distal C terminus of the G protein, different ICL2
conformations might also be associated with structurally distinct mechanisms for
primary versus secondary G protein coupling. This agrees with previous NMR and
mass spectrometry findings that propose a different role for ICL2 in G protein
recruitment for Gs- and Gi-coupled receptors (<xref rid="R13" ref-type="bibr"><italic toggle="yes">13</italic></xref>, <xref rid="R14" ref-type="bibr"><italic toggle="yes">14</italic></xref>, <xref rid="R31" ref-type="bibr"><italic toggle="yes">31</italic></xref>, <xref rid="R33" ref-type="bibr"><italic toggle="yes">33</italic></xref>).</p></sec><sec disp-level="2"><title>LM189 stabilizes a Gi-specific TM6 conformation</title><p>TM6 outward movement has been investigated with a variety of biophysical methods
to monitor GPCR activation (<xref rid="R17" ref-type="bibr"><italic toggle="yes">17</italic></xref>, <xref rid="R18" ref-type="bibr"><italic toggle="yes">18</italic></xref>, <xref rid="R32" ref-type="bibr"><italic toggle="yes">32</italic></xref>). TM6 opening in the
&#x003b2;<sub>2</sub>AR-Gi complex is very similar to the one observed in the
&#x003b2;<sub>2</sub>AR-Gs structure (<xref rid="F2" ref-type="fig">Fig.
2E</xref>) and does not explain the increased efficacy of LM189 for
G&#x003b1;i recruitment. We used fluorescence spectroscopy to investigate the
conformational dynamics induced by LM189 and other &#x003b2;<sub>2</sub>AR
ligands. For these studies, the receptor was labeled with monobromo-bimane at
the cytoplasmic end of TM6 (mBBr-&#x003b2;<sub>2</sub>AR) (<xref rid="R46" ref-type="bibr"><italic toggle="yes">46</italic></xref>, <xref rid="R47" ref-type="bibr"><italic toggle="yes">47</italic></xref>) (<xref rid="F5" ref-type="fig">Fig.
5A</xref>). As previously observed, salmeterol-bound receptor induced an
intermediate TM6 opening, while BI-167107 promoted a larger TM6 movement, which
translated into a shift of the probe to a more polar and solvent-exposed
environment, characterized by a drop in fluorescence intensity and a red shift
in &#x003bb;<sub>max</sub> (<xref rid="R38" ref-type="bibr"><italic toggle="yes">38</italic></xref>) (<xref rid="F5" ref-type="fig">Fig. 5B</xref>).
The LM189-bound receptor showed an even larger decrease in
monobromo(trimethylammonio)bimane (mBBr) intensity, suggesting a larger TM6
opening compared to the full agonist BI-167107, or a larger fraction of the
receptor in an active conformation (<xref rid="F5" ref-type="fig">Fig.
5B</xref>). We observed similar results in experiments performed in lipid
nanodiscs (HDL particles, fig. S5A), with a slightly less-pronounced shift in
&#x003bb;<sub>max</sub> for LM189 compared to BI-167107. This suggests that
the TM6 conformation stabilized by LM189 is different in its degree of opening
and/or rotation from the conformations previously observed with other
&#x003b2;<sub>2</sub>AR agonists.</p><fig position="float" id="F5" fig-type="image" specific-use="distribute"><label>Fig. 5.</label><caption><title>Investigations of TM6 conformational dynamics.</title><p>(<bold>A</bold> and <bold>B</bold>) Fluorescence spectroscopy
measurements of &#x003b2;<sub>2</sub>AR TM6 conformations. (A) Side and
intracellular views of &#x003b2;<sub>2</sub>AR labeled with mBBr on
Cys265 of TM6. Inactive-state &#x003b2;<sub>2</sub>AR (2RH1) (<xref rid="R44" ref-type="bibr"><italic toggle="yes">44</italic></xref>) is colored
gray, and active-state &#x003b2;<sub>2</sub>AR (3SN6) (<xref rid="R4" ref-type="bibr"><italic toggle="yes">4</italic></xref>) is colored
green. (B) Steady-state fluorescence emission spectra of mBBr-labeled
&#x003b2;<sub>2</sub>AR purified in LMNG/CHS in the presence and
absence of ligands. The spectra are normalized relative to apo
(unliganded) receptor (gray). (<bold>C</bold> to <bold>F</bold>) TM4/6
DEER measurements of &#x003b2;<sub>2</sub>AR purified in LMNG/CHS in the
presence of ligands and G proteins. (C) Side and intracellular views of
the receptor labeling sites on TM4 and TM6. Inactive-state
&#x003b2;<sub>2</sub>AR (2RH1) (<xref rid="R44" ref-type="bibr"><italic toggle="yes">44</italic></xref>) is colored gray, and active-state
&#x003b2;<sub>2</sub>AR (3SN6) (<xref rid="R4" ref-type="bibr"><italic toggle="yes">4</italic></xref>) is colored green. (D) Ligand
dependence of TM4/6 distance distributions. (E) G protein dependence of
distance distributions of BI-167107&#x02013;bound receptor. (F) G protein
dependence of distance distributions of the LM189-bound receptor.
Distance distributions are color coded as indicated.</p></caption><graphic xlink:href="sciadv.adq3971-f5" position="float"/></fig><p>To better characterize LM189 conformational changes and their role in biased
signaling and G protein specificity, we combined double electron-electron
resonance (DEER) spectroscopy and single-molecule F&#x000f6;rster resonance
energy transfer (smFRET) investigations. For DEER studies, we used a
minimal-cysteine version of &#x003b2;<sub>2</sub>AR, spin labeled with
iodoacetoamido-PROXYL (IAP) at the intracellular TM4/TM6 helices (N148C/L266C)
(<xref rid="R17" ref-type="bibr"><italic toggle="yes">17</italic></xref>) (<xref rid="F5" ref-type="fig">Fig. 5C</xref>). The distance distribution for the unliganded
(apo) receptor (gray in <xref rid="F5" ref-type="fig">Fig. 5D</xref> and fig.
S5, B to E) displays two main peaks centered at approximatively 32 and 39
&#x000c5; as well as a smaller peak at 50 &#x000c5; corresponding to a minor
active-state population. Addition of the partial agonist salmeterol (purple in
<xref rid="F5" ref-type="fig">Fig. 5D</xref> and fig. S5, B and E) broadens
the distribution and shifts the most probable distance to ~41 &#x000c5;,
indicative of a conformationally heterogeneous position of TM6 at an
intermediate opening relative to both inactive and active distances. As
previously reported (<xref rid="R17" ref-type="bibr"><italic toggle="yes">17</italic></xref>), the ultrahigh-affinity full agonist BI-167107
(blue in <xref rid="F5" ref-type="fig">Fig. 5D</xref> and fig. S5E) promoted a
more open TM6 conformation (~45 &#x000c5;) but failed to stabilize a fully
outward active-state conformation observed in the &#x003b2;<sub>2</sub>AR-Gs
structure. Consistent with our bimane studies, we observed a greater TM6 outward
movement in the presence of LM189, with a distance distribution dominated by a
relatively narrow and monomodal peak at ~47 &#x000c5;, in contrast with
the broader distributions measured in the salmeterol and BI-167107 conditions
(red in <xref rid="F5" ref-type="fig">Fig. 5D</xref> and fig. S5E).</p><p>Next, we sought to evaluate the effect of the G proteins Gs and Gi on
&#x003b2;<sub>2</sub>AR distance distributions. Gi addition to
salmeterol-coupled receptor resulted in a broad distance distribution, only
marginally stabilizing the Gi-occupied conformation (fig. S5B). The incomplete
shift to fully G protein&#x02013;occupied receptor observed in the presence of
salmeterol is likely due to the partial agonist efficacy of the ligand. In the
presence of Gs, salmeterol-bound receptor exhibited a longer most probable
distance, ~50 &#x000c5;, in agreement with the
BI-167107&#x02013;&#x003b2;<sub>2</sub>AR-Gs data (fig. S5, B and D). G
protein coupling to BI-167107&#x02013;bound receptor resulted in the
stabilization of two distinct distance distributions for Gi and Gs, with most
probable distances of ~47 and ~48 &#x000c5;, respectively (<xref rid="F5" ref-type="fig">Fig. 5E</xref> and fig. S5, C to E). These
distributions are broader, more multimodal, and present greater probability
density in the 30- to 40-&#x000c5; range than those for the LM189-coupled
receptor bound to G proteins. The addition of Gi to LM189-coupled
&#x003b2;<sub>2</sub>AR (~46 &#x000c5; most probable distance) (light
blue in <xref rid="F5" ref-type="fig">Fig. 5F</xref>) populated a distance
distribution with a great degree of overlap with that of the LM189-coupled
receptor alone (red in <xref rid="F5" ref-type="fig">Fig. 5, D and F</xref>, and
fig. S5E). In contrast, Gs coupling to LM189-bound &#x003b2;<sub>2</sub>AR
resulted in a longer most probable distance (~49 &#x000c5;) (brown in
<xref rid="F5" ref-type="fig">Fig. 5F</xref>), corresponding to a further
~3 &#x000c5; shift compared to Gi-bound receptor. On the basis of these
observations, LM189 may be Gi-biased because it stabilizes a TM6 outward
conformation corresponding to the Gi-competent state, facilitating Gi
recruitment. Conversely, Gs stabilizes a longer most probable distance,
suggesting that TM6 populates slightly different conformations when the receptor
is bound to Gi or Gs (<xref rid="F5" ref-type="fig">Fig. 5, D to F</xref>, and
fig. S5, B to E).</p><p>For smFRET studies, the minimal cysteine &#x003b2;<sub>2</sub>AR construct was
labeled at the intracellular TM4/TM6 with the donor and acceptor fluorophores
DY549P1 and Alexa Fluor 647. Labeled &#x003b2;<sub>2</sub>AR was subsequently
surface immobilized and imaged using an objective&#x02013;total internal
reflection fluorescence (TIRF) microscope (<xref rid="R48" ref-type="bibr"><italic toggle="yes">48</italic></xref>, <xref rid="R49" ref-type="bibr"><italic toggle="yes">49</italic></xref>). Similar to our DEER results, the apo
(unliganded) receptor mainly populated two high-FRET states centered at
~0.9 and 0.7 FRET, corresponding to the close proximity of helices TM4
and TM6, typical of the inactive receptor (black in <xref rid="F6" ref-type="fig">Fig. 6, A and B</xref>). Individual FRET traces also showed
rare excursions to lower FRET states, ranging from ~0.2 to ~0.6
FRET (black in <xref rid="F6" ref-type="fig">Fig. 6B</xref>). Also, in agreement
with our DEER data, upon addition of the full agonist BI-167107 (blue in <xref rid="F6" ref-type="fig">Fig. 6, A and B</xref>), an intermediate state at
~0.6 FRET became the predominant population, at the expense of the
inactive higher FRET states. We also observed a modest increase in the low-FRET
values at ~0.2, suggesting the enhancement of the proportion of the
receptor in the active state, where the donor and acceptor fluorophores on TM4
and TM6 are further apart (blue in <xref rid="F6" ref-type="fig">Fig. 6, A and
B</xref>). The smFRET states observed in the apo and BI-167107 conditions
are in agreement with previous smFRET studies (<xref rid="R32" ref-type="bibr"><italic toggle="yes">32</italic></xref>). However, compared to previous smFRET
investigations on the &#x003b2;<sub>2</sub>AR (<xref rid="R32" ref-type="bibr"><italic toggle="yes">32</italic></xref>), we were able to resolve transitions
between distinct receptor states (inactive, intermediate, and active) (<xref rid="F6" ref-type="fig">Fig. 6, A and B</xref>). This was possible by using
the donor/acceptor fluorophore pair DY549P1/Alexa Fluor 647, which combine a
slightly longer F&#x000f6;rster radius compared to the previously used Cy3B/Cy7
(<xref rid="R32" ref-type="bibr"><italic toggle="yes">32</italic></xref>) with notably
improved signal quality, mostly due to the increased brightness of Alexa Fluor
647 over Cy7.</p><fig position="float" id="F6" fig-type="image" specific-use="distribute"><label>Fig. 6.</label><caption><title>SmFRET distributions of TM6 conformational dynamics.</title><p>(<bold>A</bold> to <bold>C</bold>) SmFRET measurements of
&#x003b2;<sub>2</sub>AR labeled on TM4/6 with donor and acceptor
fluorophores. (A) Unliganded (apo,
<italic toggle="yes">N</italic>&#x000a0;=&#x000a0;269) receptor, in black, mostly
populates the inactive states (<italic toggle="yes">~</italic>0.9 and 0.7),
corresponding to high FRET. BI-167107 (blue,
<italic toggle="yes">N</italic>&#x000a0;=&#x000a0;265), a &#x003b2;<sub>2</sub>AR full
agonist, mostly populates the intermediate state of the receptor
(<italic toggle="yes">~</italic>0.6) and marginally stabilizes a state at
~0.2 FRET efficiency. The LM189-bound receptor (red,
<italic toggle="yes">N</italic>&#x000a0;=&#x000a0;181) populates the intermediate
state at <italic toggle="yes">~</italic>0.6 to a smaller degree, in favor of
the low-FRET population (~0.3). (B) Representative FRET traces
and transitions in the apo, BI-167107, LM189, and the LM189-bound
receptor coupled to Gi and scfv-16. (C) Upon Gi coupling, the active
state (~0.3), corresponding to low FRET, becomes predominant
(light blue, <italic toggle="yes">N</italic>&#x000a0;=&#x000a0;105).</p></caption><graphic xlink:href="sciadv.adq3971-f6" position="float"/></fig><p>Upon addition of the biased agonist LM189, we observed the coexistence of two
major FRET populations: the intermediate one at ~0.6 FRET efficiency and
a low-FRET state at ~0.3 FRET, which, based on our DEER measurements, we
attribute to the outward TM6 conformation stabilized in the presence of LM189
(red in <xref rid="F5" ref-type="fig">Figs. 5D</xref> and <xref rid="F6" ref-type="fig">6, A and B</xref>). The increase in the ~0.3 FRET
state was at the expense of the intermediate-FRET population, which appeared to
be less dominant for the LM189-bound receptor compared to the BI-167107
condition (<xref rid="F6" ref-type="fig">Fig. 6A</xref>). While BI-167107 only
has a minor tail in the low-FRET conformation, LM189 populates the ~0.3
FRET state ~40% of the time, even without the addition of G protein
(<xref rid="F6" ref-type="fig">Fig. 6A</xref>). This conformation
corresponds to the Gi-competent state, as observed upon coupling of Gi in
complex with scfv-16 to the LM189-bound receptor, shifting TM6 to the low-FRET
peak (~0.3 FRET) almost completely (light blue in <xref rid="F6" ref-type="fig">Fig. 6, B and C</xref>). Collectively, our DEER and smFRET
data suggest that LM189 is a Gi-biased ligand because, unlike other agonists, it
very effectively stabilizes the Gi-competent conformation, thereby facilitating
Gi recruitment. While we observed one main peak in the DEER distance
distribution for the receptor bound to LM189 (<xref rid="F5" ref-type="fig">Fig.
5D</xref>), we detected two populations upon LM189 addition in our smFRET
measurements (<xref rid="F6" ref-type="fig">Fig. 6A</xref>). It is possible that
the two conformations observed by smFRET exhibit subtle differences in TM6
position or local environment, and while these motions are amplified by the
smFRET environmental sensitive dyes used in this study, they are not observable
as TM4 to TM6 distance changes in DEER. This is also supported by our ensemble
fluorescence experiments (<xref rid="F5" ref-type="fig">Fig. 5B</xref> and fig.
S5A), indicating that the LM189-stabilized TM6 conformation diverges in its
degree of opening and helix rotation from the other ligands.</p></sec></sec><sec sec-type="discussion" disp-level="1"><title>DISCUSSION</title><p>Despite the large number of structures available for GPCRs in complex with different
G protein subtypes (<xref rid="R3" ref-type="bibr"><italic toggle="yes">3</italic></xref>&#x02013;<xref rid="R6" ref-type="bibr"><italic toggle="yes">6</italic></xref>), the molecular determinants of G protein
coupling specificity remain elusive. This is because specificity is hypothesized to
be determined at the level of intermediate receptor conformations, which, due to
their transient nature, are usually not accessible by traditional structural
methods. In this context, GPCR agonists that are able to select specific signaling
pathways, also called biased agonists, can drive the G protein coupling preference
for a specific GPCR.</p><p>In this work, we aimed at a better understanding of the role of ligand efficacy and
bias for G protein coupling specificity. We studied the binding of
&#x003b2;<sub>2</sub>AR to its main G protein, G&#x003b1;s, and its secondary G
protein, G&#x003b1;i, using a combination of structural and biophysical methods. We
identified salmeterol (<xref rid="R38" ref-type="bibr"><italic toggle="yes">38</italic></xref>),
a &#x003b2;<sub>2</sub>AR partial agonist for Gs binding, as a full agonist for the
recruitment of Gi with an efficacy greater than the native agonist epinephrine
(<xref rid="F1" ref-type="fig">Fig. 1, A to C</xref>). On the basis of the
salmeterol scaffold, we developed LM189, a Gi-biased agonist according to our Glo
assay and BRET investigations (<xref rid="F1" ref-type="fig">Fig. 1</xref> and fig.
S1). For BRET assays, we used mini-G proteins, engineered G proteins that only
contain the GTPase domains of G&#x003b1; subunits. While the results obtained by BRET
experiments are in agreement with our Glo assay investigations, it is important to
highlight that the differences measured with the use of mini-G proteins do not
necessarily reflect receptor selectivity in the context of more physiological
systems, where fully reconstituted G protein heterotrimers better reflect receptor
specificity profile.</p><p>LM189 was used to obtain the cryo-EM structure of the &#x003b2;<sub>2</sub>AR-Gi
complex (<xref rid="F2" ref-type="fig">Fig. 2</xref> and fig. S2). The orthosteric
binding pocket of the LM189-&#x003b2;<sub>2</sub>AR-Gi structure is very similar to
the binding pocket of &#x003b2;<sub>2</sub>AR in the presence of salmeterol and
epinephrine (<xref rid="F3" ref-type="fig">Fig. 3, A to C</xref>). This suggests
that the G protein specificity mechanism exerted by the biased ligand LM189 is
rather mediated by intermediate receptor conformations that involve the core and the
intracellular cavity of the receptor. We observed the major differences between the
&#x003b2;<sub>2</sub>AR-Gi structure and the previously obtained
&#x003b2;<sub>2</sub>AR-Gs complex at the intracellular ICL2, TM6, and TM5 (<xref rid="F2" ref-type="fig">Fig. 2E</xref>). Different conformations at ICL2, TM5,
and TM6 have been reported in other GPCR&#x02013;G protein complexes for receptors
that can couple to both Gs and Gi, indicating that these intracellular domains might
be involved in the initial recognition and engagement of distinct G protein subtypes
(<xref rid="R7" ref-type="bibr"><italic toggle="yes">7</italic></xref>, <xref rid="R8" ref-type="bibr"><italic toggle="yes">8</italic></xref>, <xref rid="R33" ref-type="bibr"><italic toggle="yes">33</italic></xref>). In the &#x003b2;<sub>2</sub>AR-Gs complex, we
observed a ~3-&#x000c5; TM6 further opening compared to the Gi-bound structure
(<xref rid="F2" ref-type="fig">Fig. 2E</xref>). This structural difference has
also been measured by DEER (<xref rid="F5" ref-type="fig">Fig. 5, E and F</xref>).
In agreement with previous GPCR&#x02013;G protein structures, Gs and Gq,11,12,13
coupling is associated with a wider G protein-binding pocket relative to Gi-coupled
structures, to accommodate the bulkier C terminus of the &#x003b1;5 helix of the Gs
and Gq isoforms and still allow the interaction with the less bulky Gi &#x003b1;5
helix (<xref rid="R9" ref-type="bibr"><italic toggle="yes">9</italic></xref>, <xref rid="R13" ref-type="bibr"><italic toggle="yes">13</italic></xref>, <xref rid="R50" ref-type="bibr"><italic toggle="yes">50</italic></xref>). Because the size of the G protein binding
pocket in the receptor intracellular core may reflect the receptor&#x02019;s ability
to couple to multiple G proteins, it has been hypothesized that receptors that
canonically couple to Gs (and Gq,11,12,13) are generally more promiscuous than those
that are classified as Gi coupled (<xref rid="R11" ref-type="bibr"><italic toggle="yes">11</italic></xref>). It should however be noted that the stable
nucleotide-free &#x003b2;<sub>2</sub>AR-Gs complex used in cryo-EM studies may
contain structural changes in the G protein binding that are not observed in the
transient nucleotide-free state in vivo (<xref rid="R51" ref-type="bibr"><italic toggle="yes">51</italic></xref>). In addition, previous smFRET investigations
have found evidence for at least one transient intermediate state in the process of
complex formation (<xref rid="R32" ref-type="bibr"><italic toggle="yes">32</italic></xref>).
Therefore, biophysical studies done in the absence of G proteins provide more
accurate information about the ligand-specific structural changes in the cytoplasmic
surface that determine coupling specificity.</p><p>To investigate the receptor conformations at the basis of G protein specificity and
the role of the biased ligand LM189, we conducted spectroscopic investigations at
the intracellular ICL2 and TM6 of the receptor using CW-EPR, fluorescence
spectroscopy, DEER, and smFRET. To note, these experiments were conducted in the
absence of cmpd-6FA, the PAM used for structure stabilization of the
&#x003b2;<sub>2</sub>AR-Gi complex. CW-EPR investigations indicate that the
loop-helix equilibrium of ICL2 is shifted toward the helical state to a greater
degree by Gs binding compared with Gi binding (<xref rid="F4" ref-type="fig">Fig. 4,
B to D</xref>, and fig. S4, B to D), in agreement with previous NMR
investigations (<xref rid="R14" ref-type="bibr"><italic toggle="yes">14</italic></xref>). To
note, when &#x003b2;<sub>2</sub>AR was bound to LM189, we observed an increase in the
mobile component of the CW-EPR spectra, a conformational transition that might be
relevant for the initial stages of G protein recognition (<xref rid="F4" ref-type="fig">Fig. 4B</xref> and fig. S4, B to D). In agreement with CW-EPR
measurements, MD simulations at the LM189-&#x003b2;<sub>2</sub>AR-Gi structure also
show ICL2 unwinding upon removal of Gi, indicating that ICL2 conformational
transitions may be involved in G protein coupling specificity (<xref rid="F3" ref-type="fig">Fig. 3, F and G</xref>).</p><p>Fluorescence spectroscopy studies with a probe at the intracellular end of TM6 of
&#x003b2;<sub>2</sub>AR suggested the presence of a distinct conformation for
LM189-occupied receptor compared to other nonbiased agonists, characterized by a
larger TM6 outward movement (<xref rid="F5" ref-type="fig">Fig. 5B</xref> and fig.
S5A). DEER experiments showed that LM189-coupled &#x003b2;<sub>2</sub>AR populates a
notably similar TM4/TM6 distance distribution to that observed upon addition of the
G protein Gi, suggesting that LM189 stabilizes the same receptor TM6 conformation as
Gi (<xref rid="F5" ref-type="fig">Fig. 5, D and F</xref>). This may explain the
preferential G&#x003b1;i recruitment observed in our experimental data by the biased
ligand LM189 (<xref rid="F1" ref-type="fig">Fig. 1</xref> and fig. S1). In agreement
with our structural work, which revealed a difference in rotation of the
intracellular end of TM6 in the &#x003b2;<sub>2</sub>AR-Gs structure compared to
&#x003b2;<sub>2</sub>AR-Gi (<xref rid="F2" ref-type="fig">Fig. 2E</xref>), DEER
measurements showed an additional ~3-&#x000c5; TM6 structural change upon Gs
binding (<xref rid="F5" ref-type="fig">Fig. 5F</xref>), indicating slightly
different conformations for receptor bound to different G protein subtypes (<xref rid="F5" ref-type="fig">Fig. 5F</xref> and fig. S5, B to D). By smFRET, we
detected a predominant intermediate state (~0.6 FRET) for the TM4 to TM6
labeling sites of &#x003b2;<sub>2</sub>AR in the presence of the full agonist
BI-167107 (<xref rid="F6" ref-type="fig">Fig. 6, A and B</xref>). In contrast, we
observed two FRET states for receptor bound to LM189, the intermediate-FRET state
(~0.6 FRET) and a low-FRET state (~0.3 FRET), the latter populated
even in the absence of the G protein (<xref rid="F6" ref-type="fig">Fig. 6, A and
B</xref>). Binding of the G protein Gi shifted the equilibrium of the
LM189-bound receptor toward the ~0.3 FRET population (<xref rid="F6" ref-type="fig">Fig. 6, B and C</xref>), corroborating our finding that LM189 is
a Gi-biased agonist for its ability to stabilize the Gi-competent conformation.</p><p>In this study, we observed that, relative to nonbiased agonists, the biased ligand
LM189 stabilizes a distinct, specific TM6 conformation (<xref rid="F5" ref-type="fig">Figs. 5, B and D</xref>, and <xref rid="F6" ref-type="fig">6A</xref>) and increases ICL2 dynamics (<xref rid="F4" ref-type="fig">Fig. 4, B
to D</xref>). Altogether, our investigations reveal that distinct conformations
at ICL2 and TM6 of &#x003b2;<sub>2</sub>AR are required for the binding of the
different G protein subtypes G&#x003b1;s and G&#x003b1;i, underlying the importance of
receptor conformational dynamics for coupling specificity and promiscuity.
Altogether, these results deepen our understanding of G protein specificity and bias
and can be useful in the design of ligands that select for preferred signaling
pathways.</p></sec><sec sec-type="materials|methods" disp-level="1"><title>MATERIALS AND METHODS</title><sec disp-level="2"><title>Expression and purification of the &#x003b2;<sub>2</sub>AR</title><p>The &#x003b2;<sub>2</sub>AR construct named PN1 was used for all experiments
except EPR, DEER, and smFRET investigations. PN1 was expressed and purified as
previously described (<xref rid="R35" ref-type="bibr"><italic toggle="yes">35</italic></xref>). Briefly, receptor was expressed in
<italic toggle="yes">Spodoptera frugiperda</italic> (<italic toggle="yes">Sf9</italic>) insect cells
(Expression Systems, cell line IPLB-Sf-21-AE, catalog number 94-001S) using the
baculovirus method, and media was supplemented with 1 &#x003bc;M alprenolol.
Cells expressing &#x003b2;<sub>2</sub>AR were harvested and lysed as previously
described (<xref rid="R35" ref-type="bibr"><italic toggle="yes">35</italic></xref>). The
receptor was solubilized from membranes using 20 mM hydroxy-ethylpiperazine
ethane sulfonic acid (Hepes), pH 7.4, 100 mM sodium chloride (NaCl), 1%
<italic toggle="yes">n</italic>-dodecyl-&#x003b2;-<sc>d</sc>-maltopyranoside (DDM), 0.03%
cholesteryl hemisuccinate (CHS), 2 mM MgCl<sub>2</sub>, 1 &#x003bc;M alprenolol,
and protease inhibitors. Membranes were homogenized with a douncer and the
soluble fraction was isolated by centrifugation and applied to an M1 anti-FLAG
immunoaffinity resin. The receptor bound to the resin was extensively washed
with 20 mM Hepes, pH 7.4, 350 mM NaCl, 0.1% DDM, 0.01% CHS, 10 &#x003bc;M
alprenolol, and protease inhibitors to lower the detergent concentration. To
exchange detergent from 0.1% DDM/0.01% CHS to 0.01% (w/v) lauryl maltose
neopentyl glycol (LMNG, Anatrace)/0.001% CHS, the receptor was extensively
washed with a progressive gradient of DDM: LMNG buffer. In parallel, while the
receptor was bound to the resin, alprenolol was removed by washing with
saturating concentrations of the low-affinity antagonist atenolol. Because of
the fast dissociation kinetics of atenolol from the &#x003b2;<sub>2</sub>AR,
subsequent washes with ligand-free buffer yielded unliganded
&#x003b2;<sub>2</sub>AR. The receptor was then eluted in a buffer consisting
of 20 mM Hepes, pH 7.4, 150 mM NaCl, 0.01% LMNG/0.001% CHS, FLAG peptide, and 5
mM EDTA. Receptor was further purified by size exclusion chromatography (SEC;
Superdex 200 10/300 gel filtration column) in buffer containing 20 mM Hepes, pH
7.4, 150 mM NaCl, and 0.01% LMNG/0.001% CHS. Last, &#x003b2;<sub>2</sub>AR was
concentrated to 250&#x000a0;&#x003bc;M, flash frozen after the addition of 20%
glycerol, and stored in &#x02212;80&#x000b0;C.</p><p>As we did not perform an additional purification step using alprenolol resin, the
functional fraction of purified receptor was assessed by direct coupling of
purified &#x003b2;<sub>2</sub>AR to the cognate G protein Gs. Immediately after
purification and SEC, PN1 was labeled with mBBr in the presence of 100 &#x003bc;M
tris(2-carboxyethyl)phosphine (TCEP). Excess dye was removed by SEC and the
labeled receptor was incubated with 10&#x000d7; molar ratio of the agonist ligand
BI<italic toggle="yes">-</italic>167107 for 30 min. Subsequently, a 1:1 ratio of Gs
protein was added for 1 hour, followed by overnight treatment with apyrase (1
unit, NEB) on ice. Following SEC, 80% of the receptor purified in 0.1% DDM,
0.01% CHS, and 90% of &#x003b2;<sub>2</sub>AR in 0.01% LMNG/0.001% CHS was
attested to be functional, as capable to bind to Gs and to run as a single
mono-disperse peak on SEC.</p><p>To favor Gi coupling, we avoided working with buffers containing CHS (<xref rid="R35" ref-type="bibr"><italic toggle="yes">35</italic></xref>). To perform the
experiments in this work, &#x003b2;<sub>2</sub>AR was extensively diluted into
buffers not containing CHS or reconstituted onto HDLs along with neutrally
charged lipids. For cryo-EM purposes, &#x003b2;<sub>2</sub>AR was purified in 20
mM Hepes, pH 7.4, 150 mM NaCl, 0.1% DDM, and 0.01% CHS as previously described
and subsequently exchanged to LMNG/cholesterol micelles to avoid the use of CHS.
LMNG [5% (w/v)] and 2 mol % cholesterol were prepared by overnight stirring
followed by sonication in buffer containing 200 mM Hepes, pH 7.4. While bound to
M1-Flag during purification, &#x003b2;<sub>2</sub>AR was buffer exchanged onto 20
mM Hepes, pH 7.4, 150 mM NaCl, and 0.01% LMNG/0.003% cholesterol micelles. After
the exchange, the receptor was washed with atenolol and eluted from the M1-Flag.
All subsequent steps took place as previously described, using LMNG/cholesterol
buffers instead of LMNG/CHS.</p></sec><sec disp-level="2"><title>Expression, purification, and labeling of the &#x003b2;<sub>2</sub>AR for
CW-EPR and DEER experiments</title><p>For CW-EPR experiments, we used the &#x003b2;<sub>2</sub>AR minimal cysteine
background construct called &#x003b2;2&#x00394;5, which has the following
mutations: C77V, C265A, C327S, C378A, and C406A (<xref rid="R17" ref-type="bibr"><italic toggle="yes">17</italic></xref>). In addition, &#x003b2;2&#x00394;5 has an
N-terminal FLAG sequence and a hexahistidine sequence at the C terminus, as well
as methionine substitutions M96T and M98T to increase expression levels.</p><p>For DEER investigations, we used the &#x003b2;<sub>2</sub>AR minimal cysteine
background construct &#x003b2;2&#x00394;6, which carries an extra mutation at
C341L, removing the palmitoylation site. Cysteine mutations at desired locations
were reintroduced in the &#x003b2;2&#x00394;5 and &#x003b2;2&#x00394;6 backgrounds
to site-specifically label these constructs for CW-EPR and DEER. To monitor ICL2
rearrangements by CW-EPR, Q142C on ICL2 was inserted into a &#x003b2;2&#x00394;5
background. For DEER investigations, we used the previously established
&#x003b2;2&#x00394;6 148C/266C construct, with reintroduced cysteines at residues
N148C and L266C (<xref rid="R32" ref-type="bibr"><italic toggle="yes">32</italic></xref>).
The single-cysteine mutants N148C and L266C were also produced for control
experiments to monitor nitroxide probe mobility and optimal labeling
conditions.</p><p>All &#x003b2;2&#x00394;5 and &#x003b2;2&#x00394;6 constructs used for EPR and DEER
were cloned into the pcDNA-Zeo-tetO vector as previously described (<xref rid="R22" ref-type="bibr"><italic toggle="yes">22</italic></xref>). Constructs were
transfected into the suspension cell line tetracycline-inducible Expi293 cells
(Thermo Fisher Scientific, catalog number A14635), stably expressing the
tetracycline repressor (<xref rid="R52" ref-type="bibr"><italic toggle="yes">52</italic></xref>). Expifectamine transfection kit (Thermo Fisher
Scientific) was used to transfect the cells according to the
manufacturer&#x02019;s recommendations. Two days posttransfection, receptor
expression was induced with doxycycline (4 mg/ml, 5 mM sodium butyrate) in the
presence of 2 &#x003bc;M alprenolol. Thirty hours postinduction, the cells were
harvested by centrifugation and the pellet was frozen in liquid nitrogen and
stored at &#x02212;80&#x000b0;C. The receptor was subsequently purified in DDM/CHS
and exchanged to LMNG/CHS as described above. After elution from the M1-Flag
column, the receptor was labeled with the spin label reagent IAP in the presence
of 100 &#x003bc;M TCEP in buffer containing 20 mM Hepes, pH 7.4, 150 mM NaCl, and
0.01% LMNG/0.001% CHS. Twenty-five&#x02013;fold molar excess of IAP was added to
40 &#x003bc;M &#x003b2;2&#x00394;6 receptor for 3 hours at room temperature (RT).
For &#x003b2;2&#x00394;5, 10-fold molar excess of IAP was added for 2 hours at RT.
After quenching of the reaction with 5 mM final <sc>l</sc>-cysteine, the
receptor was separated from the excess spin label by SEC (Superdex 200 10/300
gel filtration column) in SEC buffer (20 mM Hepes, pH 7.4, 150 mM NaCl, and
0.01% LMNG) prepared with D<sub>2</sub>O and not containing CHS.</p></sec><sec disp-level="2"><title>Expression, purification, and labeling of the &#x003b2;<sub>2</sub>AR for
smFRET experiments</title><p>The &#x003b2;2&#x00394;6 148C/266C construct was used for smFRET experiments.
Expression and purification of &#x003b2;2&#x00394;6 148C/266C were carried out as
described for the DEER experiments. For smFRET labeling, receptor eluted from
M1-Flag was diluted to 10&#x000a0;&#x003bc;M in 20 mM Hepes, pH 7.4, 150 mM NaCl,
and 0.01% LMNG/0.001% CHS, and 100 &#x003bc;M TCEP was added for 20 min. Labeling
was conducted in the presence of 2&#x000a0;&#x003bc;M atenolol and was initiated
by the addition of 10&#x000d7; of the pre-mixed fluorescent dye pair DY559P1 and
Alexa Fluor 647, at 1:1 ratio. After 1 hour at RT, the reaction was quenched
with 5 mM&#x000a0;<sc>l</sc>-cysteine. Further sample purification and TCEP and
dye removal were performed by SEC (Superdex 200 10/300 gel filtration column) in
20 mM Hepes, pH 7.4, 150 mM NaCl, and 0.01% LMNG buffer. Pulled fractions were
concentrated to 15&#x000a0;&#x003bc;M and frozen in liquid nitrogen with 20%
glycerol for subsequent smFRET experiments.</p></sec><sec disp-level="2"><title>Expression, purification, and labeling of the &#x003b2;<sub>2</sub>AR receptor
for fluorescence spectroscopy</title><p>We used the PN1 construct for steady-state ensemble fluorescence experiments. PN1
was expressed in <italic toggle="yes">sf9</italic> cells, purified and exchanged to LMNG as
previously described (<xref rid="R35" ref-type="bibr"><italic toggle="yes">35</italic></xref>). For labeling, 100 &#x003bc;M TCEP was added for 20
min to 10&#x000a0;&#x003bc;M PN1 in 20 mM Hepes, pH 7.4, 150 mM NaCl, and 0.01%
MNG buffer. Labeling was initiated by the addition of 20&#x000d7; mBBr for 45 min
at RT. The reaction was quenched with excess of <sc>l</sc>-cysteine and the
sample was further purified by SEC (Superdex 200 10/300 gel filtration column)
in 20 mM Hepes, pH 7.4, 150 mM NaCl, and 0.01% LMNG buffer. Purified and labeled
&#x003b2;<sub>2</sub>AR fractions were concentrated and flash-frozen for
subsequent experiments or for reconstitution into HDLs.</p></sec><sec disp-level="2"><title>HDL reconstitution</title><p>&#x003b2;<sub>2</sub>AR was reconstituted into HDL particles as previously
described (<xref rid="R35" ref-type="bibr"><italic toggle="yes">35</italic></xref>). Briefly,
receptor was mixed with the MSP1D1 belt protein in a 1:10 receptor:MSP molar
ratio and with lipids (3:2 POPC/POPE or POPC/POPG) in a 1:40 MSP:lipids molar
ratio. After 2 hours of incubation at 4&#x000b0;C, Biobeads (Bio-Rad) were added
at a ratio of 1:10 lipids:beads and incubated for 4 hours at 4&#x000b0;C to
remove the detergent. Upon Biobeads removal by centrifugation, empty discs were
separated from &#x003b2;<sub>2</sub>AR-containing discs by M1-flag affinity
chromatography and subsequent SEC (Superdex 200 10/300 gel filtration column) in
20 mM Hepes, pH 7.4, and 100 mM NaCl. HDLs were concentrated to
30&#x000a0;&#x003bc;M, flash-frozen in liquid nitrogen, and stored at
&#x02212;80&#x000b0;C for future use.</p></sec><sec disp-level="2"><title>Expression and purification of heteromeric
G&#x003b1;<sub>1</sub>&#x003b2;<sub>1</sub>&#x003b3;<sub>2</sub></title><p>Heterotrimeric Gi was expressed and purified as previously described (<xref rid="R3" ref-type="bibr"><italic toggle="yes">3</italic></xref>) with some modifications.
Briefly, heterotrimeric Gi was expressed in <italic toggle="yes">Trichoplusia ni</italic>
insect cells using the baculovirus method (Expression Systems, catalog number
94-002S). Two viruses were used to infect the insect cells, one encoding the
wild-type human G&#x003b1;<sub>1</sub> subunit and another one encoding the
wild-type human &#x003b2;<sub>1</sub>&#x003b3;<sub>2</sub> subunits. The cells
were harvested 48 hours posttransfection and the pellet was flash-frozen with
liquid nitrogen and stored at &#x02212;80&#x000b0;C. Cells lysis was conducted in
10 mM tris, pH 7.4, 100 mM magnesium chloride (MgCl<sub>2</sub>), 5 mM
&#x003b2;-mercaptoethanol (&#x003b2;ME), 20 mM GDP, and protease inhibitors.
Membranes were isolated by centrifugation and solubilized using a douncer in 20
mM Hepes, pH 7.4, 100 mM NaCl, 1% sodium cholate, 0.05% DDM, 5 mM magnesium
chloride, 5 mM &#x003b2;ME, 20 mM GDP, 20 U calf intestinal alkaline phosphatase,
and protease inhibitors. After the addition of 20 mM imidazole, the
solubilization mixture was stirred for 1 hour at 4&#x000b0;C. After
centrifugation, the supernatant was loaded on a Ni-NTA chromatography column,
extensively washed in 0.05% DDM buffer to remove the cholate. Subsequently, a
progressive gradient of DDM:MNG buffer was used to exchange the detergent from
DDM to 0.05% LMNG. After elution in the presence of 250 mM imidazole, the
purified heterotrimer was dephosphorylated by lambda protein phosphatase (NEB),
calf intestinal phosphatase (NEB), and antarctic phosphatase (NEB) in the
presence of 1 mM MnCl<sub>2</sub> for 1 hour on ice. Gi heterotrimer was
separated from excess betagamma using a MonoQ 10/100 GL column (GE Healthcare).
The protein was diluted to lower the imidazole concentration and loaded onto the
column in 20 mM Hepes, pH 7.4, 50 mM NaCl, 1 mM MgCl<sub>2</sub>, 0.05% LMNG,
100 mM TCEP, and 20 mM GDP. The heterotrimer was eluted with a linear gradient
of 0% to 50% with buffer containing 1 M NaCl. Eluted fractions were concentrated
to 200 to 250&#x000a0;&#x003bc;M, and after the addition of 20% glycerol, the
protein was flash-frozen and stored at &#x02212;80&#x000b0;C.</p></sec><sec disp-level="2"><title>Development and synthesis of LM189</title><sec disp-level="3"><title>
NMR analyses
</title><p>The analytical characterization of LM-189 was performed by <sup>1</sup>H-NMR
at 600 MHz and <sup>13</sup>C-NMR at 151 MHz. Determination of chemical
shifts [parts per million (ppm)] was done in relation to the solvent used
(CD<sub>3</sub>OD). The NMR samples were measured under nitrogen
atmosphere to avoid decomposition of the catecholaminergic product. The
usual abbreviations are used for signal multiplicities: s (singlet), d
(doublet), t (triplet), q (quartet), quint (quintet), sext (sextet), and
sept (septet). Coupling constants are given in hertz.</p></sec><sec disp-level="3"><title>
Polarimetry
</title><p>Specific optical rotations were measured using a JASCO P-2000 polarimeter.
Chamber path length: 100 mm, chamber volume: maximum 1.2 ml. The target
compound was measured in the form of a clear solution in methanol.</p></sec><sec disp-level="3"><title>
UHPLC-MS
</title><p>Liquid chromatography&#x02013;mass spectrometry (LC-MS) analyses were
conducted using a Dionex UltiMate 3000 UHPLC system with an RS diode array
detector for the wavelengths 220 and 254 nm. A binary solvent system
(mixture of 0.1% aqueous formic acid and methanol) was used as the eluent.
Column: Kinetex C8 (75 &#x000d7; 2.1 mm, 2.6 &#x003bc;m, 0.3 ml/min flow rate)
or ZORBAX ECLIPSE XDB-C8 (100 &#x000d7; 3.0 mm, 3.5 &#x003bc;m, 0.4 ml/min
flow rate). Mass detection was performed on a Bruker Amazon SL mass
spectrometer [electron spray ionization (ESI)].</p></sec><sec disp-level="3"><title>
High-resolution MS
</title><p>High-resolution MS (HRMS) measurements were performed on a Bruker timsTOF Pro
device.</p></sec><sec disp-level="3"><title>
Preparative RP-HPLC
</title><p>The target compound was purified by preparative, reverse-phase HPLC, applying
mixtures of 0.1% aqueous trifluoroacetic acid and acetonitrile as organic
component. The separations were conducted on a preparative HPLC AGILENT
SERIES 1100 system equipped with a variable wavelength detector (VWD), on an
AGILENT HPLC 1260 Infinity system with a VWD or on an AGILENT HPLC 1260
Infinity II system with a VWD. Column: ZORBAX ECLIPSE XDB-C8 (150 &#x000d7;
21.5 mm, 5 &#x003bc;m).</p></sec><sec disp-level="3"><title>
Analytical RP-HPLC
</title><p>Analytical HPLC runs for purity control were conducted on an AGILENT 1200
series with DAD detector and peak detection at 220, 230, 254, and 280 nm.
The used column was a ZORBAX ECLIPSE XDB-C8 (100 &#x000d7; 4.6 mm, 5
&#x003bc;m) with a flow rate of 0.5 ml/min. The column thermostat was set to
20&#x000b0;C to obtain uniform results. The binary solvent systems either
consisted of 0.1% aqueous TFA&#x000a0;+ acetonitrile or 0.1% aqueous
TFA&#x000a0;+&#x000a0;methanol. The following two eluent systems were
used:</p><p>System 1A: 0.1% aqueous trifluoroacetic acid + acetonitrile, 0.5 ml/min: 5%
acetonitrile from 0 to 3 min, to 95% at 18 min, 95% from 18 to 24 min, to 5%
at 27 min, 5% from 27 to 30 min.</p><p>System 1B: 0.1% aqueous trifluoroacetic acid + methanol, 0.5 ml/min: 5%
methanol from 0 to 3 min, to 95% at 18 min, 95% from 18 to 24 min, to 5% at
27 min, 5% from 27 to 30 min.</p></sec></sec><sec disp-level="2"><title>(<italic toggle="yes">R</italic>)-4-(1-hydroxy-2-((6-(4-phenylbutoxy)hexyl)amino)ethyl)benzene-1,2-diol
&#x000d7; TFA (LM-189)</title><p>
<inline-graphic xlink:href="sciadv.adq3971-fx1.jpg"/>
</p><p>(4-((6-Bromohexyl)oxy)butyl)benzene (66.0 mg, 0.21 mmol) was dissolved in
dimethyl sulfoxide (DMSO; 1 ml) in a microwave tube. To this solution,
(<italic toggle="yes">R</italic>)-norepinephrine freebase (100 mg, 0.59 mmol) was added.
The vial was set under nitrogen atmosphere, sealed with an aluminum crimp cap
and heated to 70&#x000b0;C for 7 hours under light protection. Then, the reaction
was stirred at RT overnight (18 hours) and directly added to a stoichiometric
excess of 0.3% TFA solution. The mixture was frozen and lyophilized. The crude
compound was purified by preparative HPLC (ZORBAX ECLIPSE XDB-C8, 0.1%
TFA&#x000a0;+&#x000a0;10% acetonitrile to 95% acetonitrile at 10 min, peak eluted
at 7 min) to give the target compound LM-189 as a yellow-orange oil (59.0 mg,
55% yield).</p><p>Analytical data were in agreement with the literature (racemate of LM-189) (<xref rid="R53" ref-type="bibr"><italic toggle="yes">53</italic></xref>, <xref rid="R54" ref-type="bibr"><italic toggle="yes">54</italic></xref>).</p><p>[&#x003b1;]<sub>D</sub><sup>26</sup>
<bold>&#x02212;</bold>17.8 (<italic toggle="yes">c</italic>&#x000a0;=&#x000a0;1.27 in
methanol)</p><p>ESI-HRMS Calculated for C<sub>24</sub>H<sub>36</sub>NO<sub>4</sub>: mass/charge
ratio (<italic toggle="yes">m/z</italic>) 402.2639 [M&#x000a0;+&#x000a0;H]<sup>+</sup></p><p>Found: <italic toggle="yes">m/z</italic> 402.2638 [M&#x000a0;+&#x000a0;H]<sup>+</sup>.</p><p><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x003b4; (ppm): 7.25&#x02013;7.21
(m, 2H, <italic toggle="yes">meta</italic>-H phenyl), 7.16 (d,
<italic toggle="yes">J</italic>&#x000a0;=&#x000a0;7.4 Hz, 2H, <italic toggle="yes">ortho</italic>-H phenyl),
7.13 (t, <italic toggle="yes">J</italic>&#x000a0;=&#x000a0;7.3 Hz, 1H, <italic toggle="yes">para</italic>-H
phenyl), 6.86 (d, <italic toggle="yes">J</italic>&#x000a0;=&#x000a0;1.5 Hz 1H, catechol H3),
6.77 (d, <italic toggle="yes">J</italic>&#x000a0;=&#x000a0;8.1 Hz, 1H, catechol H6), 6.73 (dd,
<italic toggle="yes">J</italic>&#x000a0;=&#x000a0;8.1, 1.5 Hz, 1H, catechol H5), 4.79 (dd,
<italic toggle="yes">J</italic>&#x000a0;=&#x000a0;9.9, 3.2 Hz, 1H,
C<underline>H</underline>OH), 3.44 (t,
<italic toggle="yes">J</italic>&#x000a0;=&#x000a0;6.5 Hz, 2H, phenylbutyl hexyl ether
C<underline>H</underline><sub><underline>2</underline></sub>O), 3.42 (t,
<italic toggle="yes">J</italic>&#x000a0;=&#x000a0;6.5 Hz, 2H, phenylbutyl hexyl ether
C<underline>H</underline><sub><underline>2</underline></sub>O), 3.11 (dd,
<italic toggle="yes">J</italic>&#x000a0;=&#x000a0;12.5, 3.4 Hz, 1H,
CH(OH)C<underline>H</underline><sub>2</sub>N), 3.06 (dd,
<italic toggle="yes">J</italic>&#x000a0;=&#x000a0;12.5, 10.0 Hz, 1H,
CH(OH)C<underline>H</underline><sub>2</sub>N), 3.01 (t,
<italic toggle="yes">J</italic>&#x000a0;=&#x000a0;8.0 Hz, 2H, hexylene
NHC<underline>H</underline><sub><underline>2</underline></sub>) 2.62 (t,
<italic toggle="yes">J</italic>&#x000a0;=&#x000a0;7.6 Hz, 2H, phenylbutyl
PhC<underline>H</underline><sub><underline>2</underline></sub>),
1.74&#x02013;1.64 (m, 4H, phenylbutyl hexyl ether
C<underline>H</underline><sub><underline>2</underline></sub>),
1.61&#x02013;1.55 (m, 4H, phenylbutyl hexyl ether
C<underline>H</underline><sub><underline>2</underline></sub>),
1.44&#x02013;1.39 (m, 4H, phenylbutyl hexyl ether
C<underline>H</underline><sub><underline>2</underline></sub>).</p><p><sup>13</sup>C NMR (151 MHz, CD<sub>3</sub>OD) &#x003b4; (ppm): 146.7, 146.6,
143.7, 133.7, 129.4, 129.3, 126.7, 118.5, 116.4, 114.1, 71.8, 71.6, 70.0, 55.3,
48.9, 36.7, 30.5, 30.3, 29.3, 27.4, 27.0, 26.8.</p><p>HPLC <italic toggle="yes">t</italic><sub>R</sub>&#x000a0;=&#x000a0;16.4 min (system 1A), purity
97% (254 nm), 98% (280 nm).</p><p><italic toggle="yes">t</italic><sub>R</sub>&#x000a0;=&#x000a0;11.7 min (system 1B), purity 98%
(254 nm), 98% (280 nm).</p></sec><sec disp-level="2"><title>GTP turnover assay</title><p>The GTP turnover assay was adapted from the GTPase-Glo assay (Promega) as
described previously (<xref rid="R32" ref-type="bibr"><italic toggle="yes">32</italic></xref>). To monitor Gs turnover, PN1 in 0.01% LMNG (75 nM
final) was incubated for 1 hour at RT with 10&#x000d7; ligand excess in in 20 mM
Hepes, pH 7.5, 100 mM NaCl, 0.01% MNG, and 20&#x000a0;&#x003bc;M GTP. When
complexing with Gi, PN1 was used at 1&#x000a0;&#x003bc;M final concentration. For
HDL experiments, we used 300 nM receptor in discs in 20 mM Hepes, pH 7.5, 100 mM
NaCl, and 20&#x000a0;&#x003bc;M GTP. To start the reaction, G protein (1 &#x003bc;M
for Gi AND 0.5&#x000a0;&#x003bc;M for Gs) in buffer containing 20 mM Hepes, pH
7.4, 100 mM NaCl, 20 mM MgCl<sub>2</sub>, 200 &#x003bc;M TCEP, 0.01% LMNG, and 20
&#x003bc;M GDP was added to receptor in MNG. For HDL experiments, we used
0.5&#x000a0;&#x003bc;M G protein in 20 mM Hepes, pH 7.4, 100 mM NaCl, 20 mM
MgCl<sub>2</sub>, 200 &#x003bc;M TCEP, 0.04% DDM, AND 20 &#x003bc;M GDP. The
reaction was carried over for 1 hour to monitor Gi turnover and for 10 min for
Gs. After incubation at RT, GTPase-Glo reagent supplemented with 10 mM adenosine
5&#x02032;-diphosphate (ADP) was added to the reaction and incubated for 30 min
at RT. Detection reagent was then added and incubated for 10 min at RT before
luminescence detection using a MicroBeta<sup>2</sup> microplate counter
(PerkinElmer). Experiments were performed as biological triplicates and results
were plotted using GraphPad Prism. <italic toggle="yes">P</italic> values were calculated
using the unpaired <italic toggle="yes">t</italic> test analysis on GraphPad Prism, assuming
Gaussian distributions.
NS&#x000a0;=&#x000a0;<italic toggle="yes">P</italic>&#x000a0;&#x0003e;&#x000a0;0.05,
*<italic toggle="yes">P</italic>&#x000a0;&#x02264;&#x000a0;0.05,
**<italic toggle="yes">P</italic>&#x000a0;&#x02264;&#x000a0;0.01,
***<italic toggle="yes">P</italic>&#x000a0;&#x02264;&#x000a0;0.001, and
****<italic toggle="yes">P</italic>&#x000a0;&#x02264;&#x000a0;0.0001.</p></sec><sec disp-level="2"><title>Radioligand binding assay with membranes from HEK cells</title><p>Binding affinities toward the human &#x003b2;<sub>1</sub>AR and
&#x003b2;<sub>2</sub>AR were determined as described previously (<xref rid="R55" ref-type="bibr"><italic toggle="yes">55</italic></xref>, <xref rid="R56" ref-type="bibr"><italic toggle="yes">56</italic></xref>). Human embryonic kidney (HEK) 293T
cells were transiently transfected with the cDNA for &#x003b2;<sub>1</sub>AR and
&#x003b2;<sub>2</sub>AR (obtained from the cDNA Resource Center, <ext-link xlink:href="http://www.cdna.org" ext-link-type="uri">www.cdna.org</ext-link>). Membranes were prepared showing receptor densities of
3.2 pmol/mg protein (<italic toggle="yes">B</italic><sub>max</sub> for
&#x003b2;<sub>1</sub>AR) and 2.3&#x000a0;&#x000b1;&#x000a0;0.64 pmol/mg protein
(<italic toggle="yes">B</italic><sub>max</sub> for &#x003b2;<sub>2</sub>AR) and binding
affinities for the radioligand [<sup>3</sup>H]CGP12,177 (specific activity, 51
Ci/mmol; PerkinElmer, Rodgau, Germany) of 0.070 nM
(<italic toggle="yes">K</italic><sub>d</sub> for &#x003b2;<sub>1</sub>AR) and
0.095&#x000a0;&#x000b1;&#x000a0;0.02 nM (<italic toggle="yes">K</italic><sub>d</sub> for
&#x003b2;<sub>2</sub>AR). Competition binding experiments were performed by
incubating membranes in binding buffer (25 mM Hepes, 5 mM MgCl<sub>2</sub>, 1 mM
EDTA, and 0.006% bovine serum albumin at pH 7.4) at a final protein
concentration of 3 to 10 &#x003bc;g per well, together with the radioligand
(final concentration, 0.2 nM) and varying concentrations of the competing
ligands for 60 min at 37&#x000b0;C. Nonspecific binding was determined in the
presence of unlabeled CGP12,177 at a final concentration of 10 &#x003bc;M.
Protein concentration was established using the method of Lowry
<italic toggle="yes">et&#x000a0;al.</italic> (<xref rid="R57" ref-type="bibr"><italic toggle="yes">57</italic></xref>). For data analysis the resulting
competition curves were analyzed by nonlinear regression using the algorithms
implemented in PRISM 10.0 (GraphPad Software, San Diego, CA) to provide an
IC<sub>50</sub> value, which was subsequently transformed into a
<italic toggle="yes">K</italic><sub>i</sub> value using the equation of Cheng and Prusoff
(<xref rid="R58" ref-type="bibr"><italic toggle="yes">58</italic></xref>) (table S1).
Mean <italic toggle="yes">K</italic><sub>i</sub> values were calculated from 7 to 11 single
experiments each performed in triplicates.</p></sec><sec disp-level="2"><title>&#x003b2;-Arrestin-2 recruitment (PathHunter assay)</title><p>Determination of receptor-stimulated &#x003b2;-arrestin-2 recruitment was
performed applying the PathHunter assay (DiscoverX, Birmingham, UK), which is
based on the measurement of fragment complementation of &#x003b2;-galactosidase
as previously described (<xref rid="R55" ref-type="bibr"><italic toggle="yes">55</italic></xref>, <xref rid="R59" ref-type="bibr"><italic toggle="yes">59</italic></xref>). In detail, HEK293T cells stably expressing
the enzyme acceptor tagged &#x003b2;-arrestin-2 fusion protein were transfected
with the cDNA for &#x003b2;<sub>1</sub>AR and &#x003b2;<sub>2</sub>AR, each fused
to the ProLink-PK1 fragment for enzyme complementation and transferred into
384-well microplates. Measurement started by incubating cells with epinephrine
or LM189 for 90 min and was stopped by the addition of the detection mixture.
Chemoluminescence was monitored with a Clariostar plate reader (BMG, Ortenberg,
Germany) and analyzed by normalizing the raw data relative to basal activity
(0%) and the maximum effect of norepinephrine (100%). Dose-response curves were
analyzed applying the algorithms for four-parameter nonlinear regression
implemented in Prism 10.0 (GraphPad LLC, CA) to yield EC<sub>50</sub> and
<italic toggle="yes">E</italic><sub>max</sub> values (table S1). Mean EC<sub>50</sub> and
<italic toggle="yes">E</italic><sub>max</sub> values were calculated from 6 to 17
independent experiments each conducted in duplicate.</p></sec><sec disp-level="2"><title>Formation and purification of the &#x003b2;<sub>2</sub>AR-Gi-scfv16 complex
for cryo-EM</title><p>PN1 in 0.01% LMNG/2 mol % cholesterol was incubated with sevenfold molar excess
of LM189 ligand for 30 min at RT. Cmpd-6FA PAM (<xref rid="R42" ref-type="bibr"><italic toggle="yes">42</italic></xref>, <xref rid="R43" ref-type="bibr"><italic toggle="yes">43</italic></xref>) was then added at sevenfold molar excess
and incubated for an additional 30 min at RT. A 1.3-fold molar excess of Gi was
added together with 100&#x000a0;&#x003bc;M TCEP and incubated for 2 hours at RT.
Afterward, 2-fold molar excess of scfv16 was added to the complex and incubated
for 1.5 hours on ice. Apyrase (1-unit, NEB) was then added, and the complex was
incubated overnight on ice. The following day, the complex was diluted in 20 mM
Hepes, pH 7.4, 100 mM NaCl, 0.01% MNG/2 mol % cholesterol, 0.0033% GDN,
10&#x000a0;&#x003bc;M LM189, 1&#x000a0;&#x003bc;M cmpd-6FA, and 3 mM Ca<sup>2+</sup>
and loaded onto M1 anti-FLAG affinity chromatography. Detergent concentration
was lowered by washing with buffer containing 20 mM Hepes, pH 7.4, 100 mM NaCl,
0.001% MNG/2 mol % cholesterol 0.00025% GDN, 2 mM Ca<sup>2+</sup>,
10&#x000a0;&#x003bc;M ligand, and 1&#x000a0;&#x003bc;M cmpd-6FA. Complex was eluted
in 20 mM Hepes, pH 7.4, 100 mM NaCl, 0.00075% MNG/2 mol % cholesterol, 0.00025%
GDN, FLAG peptide, 5 mM EDTA, 10&#x000a0;&#x003bc;M LM189, and 1&#x000a0;&#x003bc;M
cmpd-6FA. TCEP (100&#x000a0;&#x003bc;M), 3 mM MgCl<sub>2</sub>, and 1:1 (Gi:scfv)
molar ratio of scfv16 were added to the complex immediately after elution. Free
receptor was separated from the complex by SEC on a Superdex 200 10/300 increase
column in 20 mM Hepes, pH 7.4, 100 mM NaCl, 0.00075% MNG/2 mol %, 0.00025% GDN,
FLAG peptide, 5 mM EDTA, 1&#x000a0;&#x003bc;M LM189, and 0.1&#x000a0;&#x003bc;M
cmpd-6FA. Peak fractions were concentrated to 15 to 20 mg/ml, filtered, and used
for EM experiments.</p></sec><sec disp-level="2"><title>Cryo-EM data collection and processing</title><p>Three-microliter aliquot of the &#x003b2;2AR-Gi-scfv16 complex was applied onto
glow-discharged 300 mesh grids (Ultraufoil R1.2/1.3 or Quantifoil R1.2/1.3) and
vitrified using a Vitrobot Mark IV (Thermo Fisher Scientific) under 100%
humidity and 4&#x000b0;C conditions. Cryo-EM data were collected on a Titan Krios
electron microscope operating at 300 kV and equipped with a K3 direct electron
detector. Movies were acquired with a calibrated pixel size of 1.111
&#x000c5;/pixel and a total dose of ~52.5 electrons/&#x000c5;<sup>2</sup>,
fractionated across 50 frames (fig. S2 and table S2).</p><p>Data processing was performed using RELION 3.1.2 and cryoSPARC 3.3.2 (<xref rid="R60" ref-type="bibr"><italic toggle="yes">60</italic></xref>). Initially, motion
correction was carried out on the movies using RELION&#x02019;s built-in
implementation, followed by contrast transfer function (CTF) estimation using
CTFFIND4 (<xref rid="R61" ref-type="bibr"><italic toggle="yes">61</italic></xref>).
Reference-based particle picking used previously determined GPCR&#x02013;G
protein 2D classes. For the ultrafoil grid dataset, 3,659,953 particles were
picked, subjected to 2D classification to remove low-quality particles, and
further sorted through two rounds of 3D classification. This process yielded
265,559 particles and a 3.4-&#x000c5;-resolution structure after 3D refinement.
In the case of the quantifoil grid dataset, 5,327,360 particles were picked,
followed by one round of 2D classification and 3D classification, resulting in
513,747 particles and a 3.4-&#x000c5;-resolution structure. The two datasets were
then merged, and a 3D classification without image alignment was performed,
leaving 477,875 particles and a 3.3-&#x000c5;-resolution structure after 3D
refinement.</p><p>Subsequent steps included CtfRefine, particle polishing, and the application of a
mask to exclude the micelle and flexible &#x003b1;-helical domain. The final
structure reached 2.9 &#x000c5; resolution. The particles were then imported into
cryoSPARC for nonuniform refinement, and the resulting map was sharpened using
the Phenix autosharpen function to enhance map quality (<xref rid="R62" ref-type="bibr"><italic toggle="yes">62</italic></xref>). Last, local resolution estimation and
3D Fourier shell correlation (3DFSC) were used to assess the local resolution
and orientation distribution of the final dataset (<xref rid="R63" ref-type="bibr"><italic toggle="yes">63</italic></xref>) (fig. S2).</p></sec><sec disp-level="2"><title>Model building and refinement</title><p>The individual structures of &#x003b2;<sub>2</sub>AR, Gi heterotrimer, and scfv16
were independently docked into the final sharpened map. Model and geometric
restraints for LM189 and cmpd-6FA were generated using the Phenix elbow tool
(<xref rid="R64" ref-type="bibr"><italic toggle="yes">64</italic></xref>). In addition,
four cholesterol molecules were built into densities corresponding to previously
identified cholesterol binding sites (<xref rid="R65" ref-type="bibr"><italic toggle="yes">65</italic></xref>). The model was iteratively refined and
validated through multiple rounds of Phenix real-space refinement and manual
refinement in Coot (table S2) (<xref rid="R66" ref-type="bibr"><italic toggle="yes">66</italic></xref>).</p></sec><sec disp-level="2"><title>MD simulations</title><p>Simulations of the &#x003b2;<sub>2</sub>AR-Gi complex were based on the herein
reported LM189-bound &#x003b2;<sub>2</sub>AR-Gi cryo-EM. The ligand LM189 was
either kept in the orthosteric binding site or replaced by epinephrine by
structurally aligning the cryo-EM with the epinephrine-bound
&#x003b2;<sub>2</sub>AR-Nb6B9 structure [Protein Data Bank (PDB) ID: 4LDO]
(<xref rid="R67" ref-type="bibr"><italic toggle="yes">67</italic></xref>) and
transferring the coordinates of epinephrine. Simulations of the
&#x003b2;<sub>2</sub>AR-Gs complex were based on the BI-167107&#x02013;bound
&#x003b2;<sub>2</sub>AR-Gs crystal structure (PDB ID: 3SN6) (<xref rid="R4" ref-type="bibr"><italic toggle="yes">4</italic></xref>). To obtain the
LM189-bound and epinephrine-bound &#x003b2;<sub>2</sub>AR-Gs complexes, the
coordinates of BI-167107 were removed and replaced by the coordinates of LM189
and epinephrine after structurally aligning the herein reported LM189-bound
&#x003b2;<sub>2</sub>AR-Gi cryo-EM or the epinephrine-bound
&#x003b2;<sub>2</sub>AR-Nb6B9 structure (PDB ID: 4LDO) onto the
&#x003b2;<sub>2</sub>AR crystal structure, respectively. For further
comparison, the salmeterol-bound &#x003b2;<sub>2</sub>AR-Nb71 structure (PDB ID:
6MXT) was subjected to MD simulations.</p><p>The five receptor complexes (LM189-&#x003b2;<sub>2</sub>AR-Gi,
LM189-&#x003b2;<sub>2</sub>AR-Gs, epinephrine-&#x003b2;<sub>2</sub>AR-Gs,
epinephrine-&#x003b2;<sub>2</sub>AR-Gi, and
salmeterol-&#x003b2;<sub>2</sub>AR-Nb71) were further prepared using UCSF Chimera
(<xref rid="R68" ref-type="bibr"><italic toggle="yes">68</italic></xref>). To save
computational resources, we conducted all MD simulations without intracellular
proteins but applied position restraints on all receptor residues within 5
&#x000c5; of the G protein or the Nb71 to maintain the respective conformation of
the &#x003b2;<sub>2</sub>AR. The three missing amino acids 176 to 178 in the ECL2
of the &#x003b2;<sub>2</sub>AR-Gs crystal structure (PDB ID: 3SN6) were modeled
by means of MODELLER (<xref rid="R69" ref-type="bibr"><italic toggle="yes">69</italic></xref>), hydrogens were added, auxiliary proteins were
removed, and chain termini were capped with neutral acetyl and methylamide
groups. Except for Asp<sup>2.50</sup> and Glu<sup>3.41</sup>, all titratable
residues were left in their dominant protonation state at pH 7.0.
Asp<sup>2.50</sup> has been suggested to be protonated in the active state
(<xref rid="R70" ref-type="bibr"><italic toggle="yes">70</italic></xref>), and residue
Glu<sup>3.41</sup> directly contacts the lipid interface and therefore will
also exist predominantly in its protonated state (<xref rid="R71" ref-type="bibr"><italic toggle="yes">71</italic></xref>, <xref rid="R72" ref-type="bibr"><italic toggle="yes">72</italic></xref>). Thus, these residues were protonated in MD
simulations. LM189, epinephrine, and salmeterol were protonated at the secondary
amine allowing the formation of the canonical salt bridge to Asp<sup>3.32</sup>
conserved in aminergic GPCRs.</p><p>Parameter topology and coordinate files of the four receptor complexes were built
up using the leap module of AMBER18 (<xref rid="R73" ref-type="bibr"><italic toggle="yes">73</italic></xref>). Parameters for ligands were assigned using
antechamber (<xref rid="R73" ref-type="bibr"><italic toggle="yes">73</italic></xref>).
Therefore, the structures of LM189, epinephrine, and salmeterol were optimized
by means of Gaussian16 (<xref rid="R74" ref-type="bibr"><italic toggle="yes">74</italic></xref>) at the B3LYP/6-31G(d) level (attributing a
formal charge of +1), charges were calculated at the HF/6-31G(d) level, and atom
point charges were assigned according to the restrained electrostatic potential
procedure (<xref rid="R75" ref-type="bibr"><italic toggle="yes">75</italic></xref>). Energy
minimization was performed applying 500 steps of steepest decent followed by
4500 steps of conjugate gradient. The protein structures were aligned to the
Orientation of Proteins in Membranes (<xref rid="R76" ref-type="bibr"><italic toggle="yes">76</italic></xref>) Gs-bound structure of
&#x003b2;<sub>2</sub>AR (PDB ID: 3SN6). Each complex was inserted into a
pre-equilibrated membrane of dioleyl-phosphatidylcholine (DOPC) lipids by means
of the GROMACS tool g_membed (<xref rid="R77" ref-type="bibr"><italic toggle="yes">77</italic></xref>). Subsequently, water molecules were
replaced by sodium and chloride ions to give a neutral system with 0.15 M NaCl.
The final system dimensions were roughly 80 &#x000c5;&#x000a0;by 80
&#x000c5;&#x000a0;by 100 &#x000c5; (<xref rid="R68" ref-type="bibr"><italic toggle="yes">68</italic></xref>), containing about 156 lipids, 58 sodium
ions, 67 chloride ions, and about 13,200 water molecules. For all simulations,
the general AMBER force field (<xref rid="R78" ref-type="bibr"><italic toggle="yes">78</italic></xref>) (GAFF2) was used for ligands, the lipid14
force field (<xref rid="R79" ref-type="bibr"><italic toggle="yes">79</italic></xref>) for
DOPC molecules, and ff14SB (<xref rid="R80" ref-type="bibr"><italic toggle="yes">80</italic></xref>) for the protein residues. The SPC/E water model
(<xref rid="R81" ref-type="bibr"><italic toggle="yes">81</italic></xref>) was
applied.</p><p>Simulations were performed using GROMACS 2021.1 (<xref rid="R82" ref-type="bibr"><italic toggle="yes">82</italic></xref>&#x02013;<xref rid="R84" ref-type="bibr"><italic toggle="yes">84</italic></xref>). The simulation systems were energy
minimized and equilibrated in the NVT ensemble at 310 K for 1 ns followed by the
NPT ensemble for 1 ns with harmonic restraints of 10.0
kcal&#x000b7;mol<sup>&#x02212;1</sup> on protein and ligands. In the NVT
ensemble, the V-rescale thermostat was used. In the NPT ensemble, the Berendsen
barostat, a surface tension of 22 dyn&#x000b7;cm<sup>&#x02212;1</sup> and a
compressibility of 4.5&#x000a0;&#x000d7;&#x000a0;10<sup>&#x02013;5</sup>
bar<sup>&#x02212;1</sup> were applied. During the equilibration and the
subsequent productive MD runs, position restraints of 10.0
kcal&#x000b7;mol<sup>&#x02212;1</sup> were applied on the
&#x003b2;<sub>2</sub>AR residues within 5 &#x000c5; of the G protein
interface.</p><p>Multiple simulations were started from the final snapshot of the equilibration
procedure for each of the four receptor complexes, resulting in productive MD
simulation runs of 3&#x000a0;&#x000d7;&#x000a0;2 &#x003bc;s for each simulation
system. Simulations were performed using periodic boundary conditions and a time
step of 2 fs with bonds involving hydrogen constrained using LINCS (<xref rid="R85" ref-type="bibr"><italic toggle="yes">85</italic></xref>). Long-range
electrostatic interactions were computed using particle mesh Ewald method (<xref rid="R86" ref-type="bibr"><italic toggle="yes">86</italic></xref>) with interpolation of
order 4 and a fast Fourier transform (FFT) grid spacing of 1.6 &#x000c5;.
Nonbonded interactions were cut off at 12.0 &#x000c5;. The analysis of the
trajectories was performed using the CPPTRAJ module (<xref rid="R87" ref-type="bibr"><italic toggle="yes">87</italic></xref>) of AMBER18. Interaction frequencies,
distances, and dihedrals were plotted using Matplotlib 2.2.2 (<xref rid="R88" ref-type="bibr"><italic toggle="yes">88</italic></xref>).</p><p>The equilibrated LM189-bound &#x003b2;<sub>2</sub>AR-Gi and epinephrine-bound
&#x003b2;<sub>2</sub>AR-Gs complexes were further subjected to unrestrained
MD simulations. In these simulations, following the same protocols outlined
above, the position restraints on residues near the G protein interface were
removed to allow for greater conformational flexibility. For the
epinephrine-bound &#x003b2;<sub>2</sub>AR binary complex, 16 independent
replicates were performed, with simulation times ranging from 500 ns to 6.4
&#x003bc;s. For the LM189-bound &#x003b2;<sub>2</sub>AR binary complex, 10
independent replicates were conducted, with simulation times ranging from 600 ns
to 11 &#x003bc;s.</p></sec><sec disp-level="2"><title>CW-EPR spectroscopy</title><p>&#x003b2;2&#x00394;5 with the Q142C mutation was expressed, purified, and labeled
as described above. Frozen SEC pure receptor aliquots in 20 mM Hepes, pH 7.4,
100 mM NaCl, and 0.01% LMNG were thawed and incubated with ligands at 10&#x000d7;
molar excess for 1 hour at RT; buffer matched or G protein was added at
2&#x000d7; molar excess to aliquots after 1-hour ligand incubation and incubated
for another 2 hours. Apyrase (1 unit, NEB) was added for an additional 1.5
hours. Samples were then loaded into a quartz capillary [0.9 mm inner diameter
(ID), 1.3 mm outer diameter (OD); #2-000-050, Drummond Scientific Company] with
a volume of approximately 30 &#x003bc;l. CW-EPR spectroscopy was performed at
X-band (~9.46 GHz) on a Bruker Magnettech ESR5000 spectrometer at RT.
Spectra were recorded at a microwave power of 36 mW with 100-kHz field
modulation at a modulation amplitude of 0.1 mT, a scan width of 20 mT, and a
scan rate of 0.24 mT/s. CW data were aligned and baseline corrected using the
custom software programs Convert&#x00026;Align101 and Baseline048 written in
LabVIEW by C. Altenbach (University of California, Los Angeles) and freely
available upon request. Processed CW-EPR data were plotted in GraphPad Prism
9.3.1.</p></sec><sec disp-level="2"><title>DEER spectroscopy</title><p>DEER samples consisted in approximately 100 &#x003bc;M spin-labeled
&#x003b2;2&#x00394;6 N148C/L266C, 10&#x000d7; molar excess of ligand, 2&#x000d7;
molar excess of G proteins, or matched deuterated buffer. After 2 hours of
incubation with the G protein, apyrase (1 unit NEB) was added for an additional
1.5 hours. Last, glycerol-d<sub>8</sub> was added as a cryoprotectant to a final
concentration of 20% (v/v). Samples were loaded into borosilicate capillaries
(1.4 mm ID, 1.7 mm OD; VitroCom) at final volumes of 14 to 20 &#x003bc;l and
flash frozen in liquid nitrogen.</p><p>Experiments were performed at Q-band (~33.65 GHz) on a Bruker Elexsys E580
equipped with a SpinJet AWG, EN5107D2 resonator, variable-temperature
cryogen-free cooling system (ColdEdge Technologies Inc.), and either a 10-W
solid-state amplifier or a 150-W TWT amplifier (Applied Systems Engineering
Inc.). The 150-W TWT amplifier was used to improve signal-to-noise ratio with
respect to modulation for the transducer-coupled samples; data for all other
samples were collected using the 10-W amplifier. Data were collected at a
temperature of 50 K.</p><p>Dipolar evolution data were acquired using the dead-time free 4-pulse DEER
sequence
(&#x003c0;/2)<sub>obs</sub>&#x02013;(d<sub>1</sub>)&#x02013;(&#x003c0;)<sub>obs</sub>&#x02013;(d<sub>1</sub>&#x000a0;+&#x000a0;T)&#x02013;(&#x003c0;)<sub>pump</sub>&#x02013;(d<sub>2</sub>
&#x02212; T)&#x02013;(&#x003c0;)<sub>obs</sub>&#x02013;(d<sub>2</sub>)&#x02013;echo
(<xref rid="R89" ref-type="bibr"><italic toggle="yes">89</italic></xref>, <xref rid="R90" ref-type="bibr"><italic toggle="yes">90</italic></xref>) with 16-step phase
cycling (<xref rid="R91" ref-type="bibr"><italic toggle="yes">91</italic></xref>). The
parameters used for DEER experiments are listed in table S3. Gaussian shapes
were implemented for all pulses using the built-in Gaussian pulse profile in
Bruker Xepr software (<xref rid="R92" ref-type="bibr"><italic toggle="yes">92</italic></xref>); resonator bandwidth compensation was not used.
Pump pulses were applied to the maximal intensity of the field swept echo
detected absorption spectrum. Observed pulses were applied at a frequency of
either 45 or 90 MHz lower than the pump pulses for experiments performed with
the 10- or 150-W amplifier, respectively. Optimal microwave power for &#x003c0;/2
and &#x003c0; pulses was determined by adjusting pulse amplitudes for a transient
nutation experiment to achieve maximum Hahn echo inversion at the pulse lengths
being used (72 ns) (<xref rid="R93" ref-type="bibr"><italic toggle="yes">93</italic></xref>).</p><p>DEER data were processed with ComparativeDeerAnalyzer automated processing in
DeerAnalysis2021 (<xref rid="R94" ref-type="bibr"><italic toggle="yes">94</italic></xref>).
This uses two different fitting routines: neural network analysis with DEERNet
(<xref rid="R95" ref-type="bibr"><italic toggle="yes">95</italic></xref>) from Spinach
revision 5501 and Tikhonov regularization with DeerLab 0.9.1 routines (<xref rid="R96" ref-type="bibr"><italic toggle="yes">96</italic></xref>). The resulting
consensus fit is a mean of the two with a 95% confidence interval reported that
is composed of both method&#x02019;s errors. DEER time traces and distance
distributions for all samples are shown in fig. S5E; time traces are normalized
to the signal intensity at time&#x000a0;=&#x000a0;0 and distance distributions are
area normalized. DEER data were plotted in GraphPad Prism 9.3.1.</p></sec><sec disp-level="2"><title>smFRET spectroscopy</title><sec disp-level="3"><title>
smPull receptor isolation and surface display
</title><p>To inhibit nonspecific protein adsorption, flow cells for single-molecule
experiments were prepared as previously described (<xref rid="R49" ref-type="bibr"><italic toggle="yes">49</italic></xref>) using mPEG (Laysan Bio) passivated
glass coverslips (VWR) and doped with biotin PEG16. Before each experiment,
coverslips were incubated with NeutrAvidin (Thermo Fisher Scientific),
followed by 10 nM biotinylated antibody (mouse anti-FLAG, Jackson
ImmunoResearch). Between each conjugation step, the chambers were flushed to
remove free reagents. The antibody dilutions and washes were done in T50
buffer (50 mM NaCl and 10 mM tris, pH 7.5). To achieve sparse immobilization
of labeled receptors on the surface, purified labeled receptor was diluted
(ranging from 100&#x000d7; to 1000&#x000d7; dilution) and applied to
coverslips. After achieving optimum surface immobilization (~400
molecules in a 2000-&#x003bc;m<sup>2</sup> imaging area), unbound receptors
were washed out of the flow chamber and the flow cells were then washed
extensively (up to 50&#x000d7; the cell volume).</p></sec><sec disp-level="3"><title>
smFRET measurements
</title><p>Receptors were imaged for smFRET in imaging buffer consisting of 3 mM Trolox,
100 mM NaCl, 2 mM CaCl<sub>2</sub>, 20 mM Hepes, 0.01% MNG, and an oxygen
scavenging system (0.8% dextrose, 0.8 mg ml<sup>&#x02212;1</sup> glucose
oxidase, and 0.02 mg ml<sup>&#x02212;1</sup> catalase), pH 7.4. All buffers
were made in UltraPure distilled water (Invitrogen). Samples were imaged
with a 1.65 numerical aperture &#x000d7;60 objective (Olympus) on a total
internal reflection fluorescence microscope with 100 ms time resolution
unless stated otherwise. Lasers at 532 nm (Cobolt) and 633 nm (Melles Griot)
were used for donor and acceptor excitation, respectively. Fluorescence
passed through Chroma ET550lp and split into donor and acceptor signal with
a Chroma T635lpxr. FRET efficiency was calculated as
(<italic toggle="yes">I</italic><sub>A</sub>&#x000a0;&#x02212;&#x000a0;0.1<italic toggle="yes">I</italic><sub>D</sub>)/(<italic toggle="yes">I</italic><sub>D</sub>&#x000a0;+&#x000a0;<italic toggle="yes">I</italic><sub>A</sub>),
in which <italic toggle="yes">I</italic><sub>D</sub> and <italic toggle="yes">I</italic><sub>A</sub>
are the donor and acceptor intensity, respectively, after background
subtraction. Movies were recorded at 100 ms acquisition time (10 Hz) with a
Photometrics Prime 95B cMOS camera using micromanager acquisition
software.</p></sec><sec disp-level="3"><title>
smFRET data analysis
</title><p>SPARTAN version 3.7 (<xref rid="R97" ref-type="bibr"><italic toggle="yes">97</italic></xref>) was used to analyze fluorescent movies.
Donor and acceptor channels were aligned using the first 10 frames of each
movie while excluding particles closer than 3.5 pixels and using an
integration window of 12 pixels. Single-molecule intensity traces showing
single-donor and single-acceptor photobleaching with a stable total
intensity for longer than 5 s (50 frames), SNRbg &#x0003e;15, and donor acceptor
correlation coefficient&#x000a0;&#x0003c;&#x000a0;0.0 were collected (20 to 30% of
total molecules per imaging area). Individual traces were smoothed using a
nonlinear filter (<xref rid="R98" ref-type="bibr"><italic toggle="yes">98</italic></xref>) with the following filter parameters:
window&#x000a0;=&#x000a0;2, <italic toggle="yes">M</italic>&#x000a0;=&#x000a0;2, and
<italic toggle="yes">P</italic>&#x000a0;=&#x000a0;15. Each experiment was performed
&#x02265;4 times to ensure reproducibility. smFRET histograms were compiled
from &#x02265;100 molecules per condition (100 ms time resolution). Error
bars in the histograms represent the standard error from &#x02265;4
independent movies. To ensure that traces of different lengths contribute
equally, histograms from individual traces were normalized to one before
compiling. Gaussian fitting to histograms was done in Origin Pro.</p></sec><sec disp-level="3"><title>
Fluorescence spectroscopy
</title><p>Fluorescence experiments were performed on a Fluoromax 4C spectrofluorometer
(Horiba Scientific, Edison, NJ, USA) using a 5-nm excitation slit width and
a 3-nm emission slit width. Emission spectra were recorded using excitation
at 380 nm. Concentrations after mixing were as follows:
&#x003b2;<sub>2</sub>AR, 100 nM; salmeterol, 100 &#x003bc;M; LM189, 75
&#x003bc;M; BI-167107, 25 &#x003bc;M. Ligand concentrations were chosen to
achieve receptor saturation. Experiments were conducted in buffer containing
20 mM Hepes, pH 7.4, 100 mM NaCl, and 0.01% LMNG. Samples were measured
after 1 hour incubation in the dark at the final concentrations to allow
full equilibration. Measurements were performed in biological
triplicates.</p></sec><sec disp-level="3"><title>
Gi and Gs coupling in intact HEK cells
</title><p>HEK-A cells (or HEK-&#x00394;GNAS) were cotransfected with rLuc-tagged
&#x003b2;<sub>2</sub>AR (&#x003b2;<sub>2</sub>AR-rLuc8) and the
Venus-miniGs (venus mGs) sensor containing the C-terminal residues from
either G&#x003b1;<sub>s</sub> or G&#x003b1;<sub>i1</sub> (<xref rid="R11" ref-type="bibr"><italic toggle="yes">11</italic></xref>, <xref rid="R99" ref-type="bibr"><italic toggle="yes">99</italic></xref>, <xref rid="R100" ref-type="bibr"><italic toggle="yes">100</italic></xref>) and a nuclear
export signal (NES-venus-mGs) and allowed to express for 48 hours at
37&#x000b0;C in Dulbecco&#x02019;s modified Eagle&#x02019;s medium in a
CO<sub>2</sub> incubator. These chimeras will be referred to as mGs and
mGs/i. Expression vectors containing &#x003b2;<sub>2</sub>AR-rLuc8 and the
mGs chimeras were generously provided by Nevin Lambert (Augusta University
at Georgia). Transfected cells were harvested with EDTA (2 mM) in PBS,
washed (by centrifugation) in a Hepes buffered saline solution (HBSS), and
resuspended in HBSS containing 0.1% ascorbic acid and 1% DMSO. Cells were
transferred into 96-well plates (100 ml per well) and incubated for 20 min
at RT. Cells were then preincubated with coelenterazine (5 mM final) for 5
min before the addition of agonist. An agonist dose-response relationship
was performed through the addition of a 10&#x000d7; agonist concentration to
the cells, and the fluorescence emission was measured (at 485 and 530 nm)
using a Molecular Devices M5 fluorescence plate reader. The data were
collected in kinetic mode every 120 s for 30 min total. Activity values were
derived from the area under the BRET ratio (em530/em485) progress curve
between 6 and 16 min. Data were analyzed using Prism (GraphPad, La Jolla,
CA).</p></sec></sec></sec></body><back><ack><title>Acknowledgments</title><p>We thank E. Montabana for assistance with the cryo-EM data collection. We
acknowledge A. W. Kahsai for cmpd-6FA. We acknowledge National Institutes of
Health Instrumentation grant S10OD024980 in support of acquisition of the UC
Santa Cruz pulsed EPR spectrometer. We thank K. Sato, S. Nakano, and A. Inoue
(Tohoku University) for their assistance in the NanoBiT assay. We thank N.
Lambert (Augusta University) for the &#x003b2;<sub>2</sub>AR-rLuc8 and miniG
constructs as well as helpful discussion. Cryo-EM data were collected at
Stanford Cryo-Electron Microscopy Center (cEMc). The materials used in this
study can be provided by B.K.K., M.T.L., and P.G. pending scientific review and
a completed material transfer agreement. Requests for the materials should be
submitted to M.C. (mcasirag@stanford.edu), B.K.K., M.T.L., and P.G.</p><sec><p><bold>Funding:</bold> M.C. received funding from the European Union Horizon 2020
research and innovation program under the Marie Sklodowska-Curie grant agreement
no. 799376. M.C. was supported by the American Heart Association (AHA)
Postdoctoral Fellowship award number 915188. B.K.K. was supported by
R01NS028471. M.T.L. is supported by R01GM135581 and grant S10 OD025260. P.G. is
supported by the Deutsche Forschungsgemeinschaft (DFG, German Research
Foundation) grants GRK 1910 and GM 13/14-1. R.J.L. is an investigator with the
Howard Hughes Medical Institute and is supported by R01HL0160371609 from the
National Heart, Lung, and Blood Institute, NIH. P.C.B. is supported by F31
HL164002. E.Y.I. is a Weill Neurohub Investigator and is supported by
R01NS119826. N.N. was supported by NSF MCB-1942957 and American Chemical Society
Petroleum Research Fund, 61678-UR6. Y.K.X. is supported by NIH grant HL162825
and MH134119 and VA Merit grants IK6BX005753 and I01BX005100. A.I. is funded by
the Society for the Promotion of Science (JP21H04791 and JP24K2128), the Japan
Science and Technology Agency (JPMJFR215T and JPMJMS2023), and the Japan Agency
for Medical Research and Development (JP22ama121038 and JP22zf0127007). R.K.S.
is funded by National Institute of General Medical Sciences grant GM083118.</p></sec><sec><p><bold>Author contributions:</bold> Conceptualization: M.C., B.K.K., M.T.L., H.W.,
R.J.L., B.P., and P.C.B. Methodology: M.C., B.K.K., M.T.L., P.G., R.J.L., N.N.,
E.Y.I., A.I., R.K.S., H.W., B.P., P.C.B., L.M., and S.M.F.M.B. Software: H.W.
Validation: M.C., B.K.K., P.G., P.C.B., R.K.S., N.N., and S.M.F.M.B. Formal
analysis: M.C., P.C.B., R.K.S., N.N., C.H., L.M., S.M.F.M.B., and Y.K.X.
Investigation: M.C., H.W., P.C.B., N.N., H.H., L.M., M.F.S., S.M.F.M.B., B.X.,
R.K.S., T.E.A., E.W., A.I., T.E.A., N.S., A.I., and B.C. Resources: B.K.K.,
P.G., M.T.L., M.C., B.P., P.C.B., L.M., Y.K.X., and H.W. Data curation: N.N. and
H.W. Visualization: M.C., H.W., P.C.B., C.H., H.H., M.F.S., A.I., N.S., R.J.L.,
E.Y.I., N.N., S.M.F.M.B., and Y.K.X. Funding acquisition: M.C., B.K.K., M.T.L.,
P.C.B., P.G., R.J.L., E.Y.I., N.N., Y.K.X., A.I., and R.K.S. Project
administration: M.C., B.K.K., M.T.L., P.G., and R.J.L. Supervision: B.K.K.,
P.G., M.T.L., M.C., R.J.L., E.Y.I., and Y.K.X. Writing&#x02014;original draft:
M.C., B.K.K., H.W., and P.C.B. Writing&#x02014;review and editing: M.C., B.K.K.,
M.T.L., P.G., R.J.L., N.N., E.Y.I., P.C.B., B.P., A.I., N.S., L.M., M.F.S.,
A.I., B.C., and S.M.F.M.B.</p></sec><sec><p><bold>Competing interests:</bold> B.K.K. is a cofounder of and consultant for
ConfometRx Inc. R.J.L. is a founder of Trevena Inc. and a cofounder and
stockholder of Septerna. R.J.L. is also a cofounder and stockholder of Lexicon
Pharmaceuticals. B.P. is a consultant with Septerna. All other authors declare
that they have no competing interests.</p></sec><sec><p><bold>Data and materials availability:</bold> The cryo-EM density map has been
deposited in the Electron Microscopy Data Bank (EMDB) under accession code
EMD-44925, and model coordinates have been deposited in the Protein Data Bank
(PDB) under accession ID 9BUY. All data needed to evaluate the conclusions in
the paper are present in the paper and/or the Supplementary Materials.</p></sec></ack><sec sec-type="supplementary-material"><title>Supplementary Materials</title><sec><title>The PDF file includes:</title><supplementary-material position="float" content-type="local-data"><caption><p>Figs. S1 to S6</p><p>Tables S1 to S3</p><p>Legends for data S1 and S2</p></caption><media xlink:href="sciadv.adq3971_sm.pdf"/></supplementary-material></sec><sec><title>Other Supplementary Material for this manuscript includes the
following:</title><supplementary-material position="float" content-type="local-data"><caption><p>Data S1 and S2</p></caption><media xlink:href="sciadv.adq3971_data_s1_and_s2.zip"/></supplementary-material></sec></sec><ref-list><title>REFERENCES AND NOTES</title><ref id="R1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>R.</given-names>
<surname>Fredriksson</surname></string-name>,
<string-name><given-names>M. C.</given-names>
<surname>Lagerstr&#x000f6;m</surname></string-name>,
<string-name><given-names>L.-G.</given-names>
<surname>Lundin</surname></string-name>, <string-name><given-names>H.
B.</given-names>
<surname>Schi&#x000f6;th</surname></string-name></person-group>,
<article-title>The G-protein-coupled receptors in the human genome form five
main families. Phylogenetic analysis, paralogon groups, and
fingerprints</article-title>. <source>Mol. Pharmacol.</source>
<volume>63</volume>, <fpage>1256</fpage>&#x02013;<lpage>1272</lpage>
(<year>2003</year>).<pub-id pub-id-type="pmid">12761335</pub-id>
</mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>I.</given-names>
<surname>Masuho</surname></string-name>,
<string-name><given-names>O.</given-names>
<surname>Ostrovskaya</surname></string-name>,
<string-name><given-names>G. M.</given-names>
<surname>Kramer</surname></string-name>, <string-name><given-names>C.
D.</given-names>
<surname>Jones</surname></string-name>,
<string-name><given-names>K.</given-names>
<surname>Xie</surname></string-name>, <string-name><given-names>K.
A.</given-names>
<surname>Martemyanov</surname></string-name></person-group>,
<article-title>Distinct profiles of functional discrimination among G
proteins determine the actions of G protein&#x02013;coupled
receptors</article-title>. <source>Sci. Signal.</source>
<volume>8</volume>, <fpage>ra123</fpage> (<year>2015</year>).<pub-id pub-id-type="pmid">26628681</pub-id>
</mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A.</given-names>
<surname>Koehl</surname></string-name>,
<string-name><given-names>H.</given-names>
<surname>Hu</surname></string-name>,
<string-name><given-names>S.</given-names>
<surname>Maeda</surname></string-name>,
<string-name><given-names>Y.</given-names>
<surname>Zhang</surname></string-name>,
<string-name><given-names>Q.</given-names>
<surname>Qu</surname></string-name>, <string-name><given-names>J.
M.</given-names>
<surname>Paggi</surname></string-name>, <string-name><given-names>N.
R.</given-names>
<surname>Latorraca</surname></string-name>,
<string-name><given-names>D.</given-names>
<surname>Hilger</surname></string-name>,
<string-name><given-names>R.</given-names>
<surname>Dawson</surname></string-name>,
<string-name><given-names>H.</given-names>
<surname>Matile</surname></string-name>, <string-name><given-names>G. F.
X.</given-names>
<surname>Schertler</surname></string-name>,
<string-name><given-names>S.</given-names>
<surname>Granier</surname></string-name>, <string-name><given-names>W.
I.</given-names>
<surname>Weis</surname></string-name>, <string-name><given-names>R.
O.</given-names>
<surname>Dror</surname></string-name>,
<string-name><given-names>A.</given-names>
<surname>Manglik</surname></string-name>,
<string-name><given-names>G.</given-names>
<surname>Skiniotis</surname></string-name>, <string-name><given-names>B.
K.</given-names>
<surname>Kobilka</surname></string-name></person-group>,
<article-title>Structure of the &#x003bc;-opioid receptor&#x02013;Gi protein
complex</article-title>. <source>Nature</source>
<volume>558</volume>, <fpage>547</fpage>&#x02013;<lpage>552</lpage>
(<year>2018</year>).<pub-id pub-id-type="pmid">29899455</pub-id>
</mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S. G. F.</given-names>
<surname>Rasmussen</surname></string-name>, <string-name><given-names>B.
T.</given-names>
<surname>DeVree</surname></string-name>,
<string-name><given-names>Y.</given-names>
<surname>Zou</surname></string-name>, <string-name><given-names>A.
C.</given-names>
<surname>Kruse</surname></string-name>, <string-name><given-names>K.
Y.</given-names>
<surname>Chung</surname></string-name>, <string-name><given-names>T.
S.</given-names>
<surname>Kobilka</surname></string-name>, <string-name><given-names>F.
S.</given-names>
<surname>Thian</surname></string-name>, <string-name><given-names>P.
S.</given-names>
<surname>Chae</surname></string-name>,
<string-name><given-names>E.</given-names>
<surname>Pardon</surname></string-name>,
<string-name><given-names>D.</given-names>
<surname>Calinski</surname></string-name>, <string-name><given-names>J.
M.</given-names>
<surname>Mathiesen</surname></string-name>, <string-name><given-names>S.
T. A.</given-names>
<surname>Shah</surname></string-name>, <string-name><given-names>J.
A.</given-names>
<surname>Lyons</surname></string-name>,
<string-name><given-names>M.</given-names>
<surname>Caffrey</surname></string-name>, <string-name><given-names>S.
H.</given-names>
<surname>Gellman</surname></string-name>,
<string-name><given-names>J.</given-names>
<surname>Steyaert</surname></string-name>,
<string-name><given-names>G.</given-names>
<surname>Skiniotis</surname></string-name>, <string-name><given-names>W.
I.</given-names>
<surname>Weis</surname></string-name>, <string-name><given-names>R.
K.</given-names>
<surname>Sunahara</surname></string-name>, <string-name><given-names>B.
K.</given-names>
<surname>Kobilka</surname></string-name></person-group>,
<article-title>Crystal structure of the &#x003b2;2 adrenergic
receptor&#x02013;Gs protein complex</article-title>. <source>Nature</source>
<volume>477</volume>, <fpage>549</fpage>&#x02013;<lpage>555</lpage>
(<year>2011</year>).<pub-id pub-id-type="pmid">21772288</pub-id>
</mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>K.</given-names>
<surname>Krishna Kumar</surname></string-name>,
<string-name><given-names>M.</given-names>
<surname>Shalev-Benami</surname></string-name>,
<string-name><given-names>M. J.</given-names>
<surname>Robertson</surname></string-name>,
<string-name><given-names>H.</given-names>
<surname>Hu</surname></string-name>, <string-name><given-names>S.
D.</given-names>
<surname>Banister</surname></string-name>, <string-name><given-names>S.
A.</given-names>
<surname>Hollingsworth</surname></string-name>,
<string-name><given-names>N. R.</given-names>
<surname>Latorraca</surname></string-name>, <string-name><given-names>H.
E.</given-names>
<surname>Kato</surname></string-name>,
<string-name><given-names>D.</given-names>
<surname>Hilger</surname></string-name>,
<string-name><given-names>S.</given-names>
<surname>Maeda</surname></string-name>, <string-name><given-names>W.
I.</given-names>
<surname>Weis</surname></string-name>, <string-name><given-names>D.
L.</given-names>
<surname>Farrens</surname></string-name>, <string-name><given-names>R.
O.</given-names>
<surname>Dror</surname></string-name>, <string-name><given-names>S.
V.</given-names>
<surname>Malhotra</surname></string-name>, <string-name><given-names>B.
K.</given-names>
<surname>Kobilka</surname></string-name>,
<string-name><given-names>G.</given-names>
<surname>Skiniotis</surname></string-name></person-group>,
<article-title>Structure of a signaling cannabinoid receptor 1-G protein
complex</article-title>. <source>Cell</source>
<volume>176</volume>, <fpage>448</fpage>&#x02013;<lpage>458.e12</lpage>
(<year>2019</year>).<pub-id pub-id-type="pmid">30639101</pub-id>
</mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S.</given-names>
<surname>Maeda</surname></string-name>,
<string-name><given-names>Q.</given-names>
<surname>Qu</surname></string-name>, <string-name><given-names>M.
J.</given-names>
<surname>Robertson</surname></string-name>,
<string-name><given-names>G.</given-names>
<surname>Skiniotis</surname></string-name>, <string-name><given-names>B.
K.</given-names>
<surname>Kobilka</surname></string-name></person-group>,
<article-title>Structures of the M1 and M2 muscarinic acetylcholine
receptor/G-protein complexes</article-title>. <source>Science</source>
<volume>364</volume>, <fpage>552</fpage>&#x02013;<lpage>557</lpage>
(<year>2019</year>).<pub-id pub-id-type="pmid">31073061</pub-id>
</mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Y.</given-names>
<surname>Zhuang</surname></string-name>,
<string-name><given-names>P.</given-names>
<surname>Xu</surname></string-name>,
<string-name><given-names>C.</given-names>
<surname>Mao</surname></string-name>,
<string-name><given-names>L.</given-names>
<surname>Wang</surname></string-name>,
<string-name><given-names>B.</given-names>
<surname>Krumm</surname></string-name>, <string-name><given-names>X.
E.</given-names>
<surname>Zhou</surname></string-name>,
<string-name><given-names>S.</given-names>
<surname>Huang</surname></string-name>,
<string-name><given-names>H.</given-names>
<surname>Liu</surname></string-name>,
<string-name><given-names>X.</given-names>
<surname>Cheng</surname></string-name>,
<string-name><given-names>X.-P.</given-names>
<surname>Huang</surname></string-name>,
<string-name><given-names>D.-D.</given-names>
<surname>Shen</surname></string-name>,
<string-name><given-names>T.</given-names>
<surname>Xu</surname></string-name>,
<string-name><given-names>Y.-F.</given-names>
<surname>Liu</surname></string-name>,
<string-name><given-names>Y.</given-names>
<surname>Wang</surname></string-name>,
<string-name><given-names>J.</given-names>
<surname>Guo</surname></string-name>,
<string-name><given-names>Y.</given-names>
<surname>Jiang</surname></string-name>,
<string-name><given-names>H.</given-names>
<surname>Jiang</surname></string-name>,
<string-name><given-names>K.</given-names>
<surname>Melcher</surname></string-name>, <string-name><given-names>B.
L.</given-names>
<surname>Roth</surname></string-name>,
<string-name><given-names>Y.</given-names>
<surname>Zhang</surname></string-name>,
<string-name><given-names>C.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>H.
E.</given-names>
<surname>Xu</surname></string-name></person-group>,
<article-title>Structural insights into the human D1 and D2 dopamine
receptor signaling complexes</article-title>. <source>Cell</source>
<volume>184</volume>, <fpage>931</fpage>&#x02013;<lpage>942.e18</lpage>
(<year>2021</year>).<pub-id pub-id-type="pmid">33571431</pub-id>
</mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S.</given-names>
<surname>Huang</surname></string-name>,
<string-name><given-names>P.</given-names>
<surname>Xu</surname></string-name>,
<string-name><given-names>D.-D.</given-names>
<surname>Shen</surname></string-name>, <string-name><given-names>I.
A.</given-names>
<surname>Simon</surname></string-name>,
<string-name><given-names>C.</given-names>
<surname>Mao</surname></string-name>,
<string-name><given-names>Y.</given-names>
<surname>Tan</surname></string-name>,
<string-name><given-names>H.</given-names>
<surname>Zhang</surname></string-name>,
<string-name><given-names>K.</given-names>
<surname>Harps&#x000f8;e</surname></string-name>,
<string-name><given-names>H.</given-names>
<surname>Li</surname></string-name>,
<string-name><given-names>Y.</given-names>
<surname>Zhang</surname></string-name>,
<string-name><given-names>C.</given-names>
<surname>You</surname></string-name>,
<string-name><given-names>X.</given-names>
<surname>Yu</surname></string-name>,
<string-name><given-names>Y.</given-names>
<surname>Jiang</surname></string-name>,
<string-name><given-names>Y.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>D.
E.</given-names>
<surname>Gloriam</surname></string-name>, <string-name><given-names>H.
E.</given-names>
<surname>Xu</surname></string-name></person-group>, <article-title>GPCRs
steer Gi and Gs selectivity via TM5-TM6 switches as revealed by structures
of serotonin receptors</article-title>. <source>Mol. Cell</source>
<volume>82</volume>, <fpage>2681</fpage>&#x02013;<lpage>2695.e6</lpage>
(<year>2022</year>).<pub-id pub-id-type="pmid">35714614</pub-id>
</mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A.</given-names>
<surname>Qiao</surname></string-name>,
<string-name><given-names>S.</given-names>
<surname>Han</surname></string-name>,
<string-name><given-names>X.</given-names>
<surname>Li</surname></string-name>,
<string-name><given-names>Z.</given-names>
<surname>Li</surname></string-name>,
<string-name><given-names>P.</given-names>
<surname>Zhao</surname></string-name>,
<string-name><given-names>A.</given-names>
<surname>Dai</surname></string-name>,
<string-name><given-names>R.</given-names>
<surname>Chang</surname></string-name>,
<string-name><given-names>L.</given-names>
<surname>Tai</surname></string-name>,
<string-name><given-names>Q.</given-names>
<surname>Tan</surname></string-name>,
<string-name><given-names>X.</given-names>
<surname>Chu</surname></string-name>,
<string-name><given-names>L.</given-names>
<surname>Ma</surname></string-name>, <string-name><given-names>T.
S.</given-names>
<surname>Thorsen</surname></string-name>,
<string-name><given-names>S.</given-names>
<surname>Reedtz-Runge</surname></string-name>,
<string-name><given-names>D.</given-names>
<surname>Yang</surname></string-name>,
<string-name><given-names>M.-W.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>P.
M.</given-names>
<surname>Sexton</surname></string-name>,
<string-name><given-names>D.</given-names>
<surname>Wootten</surname></string-name>,
<string-name><given-names>F.</given-names>
<surname>Sun</surname></string-name>,
<string-name><given-names>Q.</given-names>
<surname>Zhao</surname></string-name>,
<string-name><given-names>B.</given-names>
<surname>Wu</surname></string-name></person-group>,
<article-title>Structural basis of G<sub>s</sub> and G<sub>i</sub>
recognition by the human glucagon receptor</article-title>.
<source>Science</source>
<volume>367</volume>, <fpage>1346</fpage>&#x02013;<lpage>1352</lpage>
(<year>2020</year>).<pub-id pub-id-type="pmid">32193322</pub-id>
</mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>T.</given-names>
<surname>Flock</surname></string-name>, <string-name><given-names>A.
S.</given-names>
<surname>Hauser</surname></string-name>,
<string-name><given-names>N.</given-names>
<surname>Lund</surname></string-name>, <string-name><given-names>D.
E.</given-names>
<surname>Gloriam</surname></string-name>,
<string-name><given-names>S.</given-names>
<surname>Balaji</surname></string-name>, <string-name><given-names>M.
M.</given-names>
<surname>Babu</surname></string-name></person-group>,
<article-title>Selectivity determinants of GPCR&#x02013;G-protein
binding</article-title>. <source>Nature</source>
<volume>545</volume>, <fpage>317</fpage>&#x02013;<lpage>322</lpage>
(<year>2017</year>).<pub-id pub-id-type="pmid">28489817</pub-id>
</mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>N.</given-names>
<surname>Okashah</surname></string-name>,
<string-name><given-names>Q.</given-names>
<surname>Wan</surname></string-name>,
<string-name><given-names>S.</given-names>
<surname>Ghosh</surname></string-name>,
<string-name><given-names>M.</given-names>
<surname>Sandhu</surname></string-name>,
<string-name><given-names>A.</given-names>
<surname>Inoue</surname></string-name>,
<string-name><given-names>N.</given-names>
<surname>Vaidehi</surname></string-name>, <string-name><given-names>N.
A.</given-names>
<surname>Lambert</surname></string-name></person-group>,
<article-title>Variable G protein determinants of GPCR coupling
selectivity</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>116</volume>, <fpage>12054</fpage>&#x02013;<lpage>12059</lpage>
(<year>2019</year>).<pub-id pub-id-type="pmid">31142646</pub-id>
</mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A.</given-names>
<surname>Inoue</surname></string-name>,
<string-name><given-names>F.</given-names>
<surname>Raimondi</surname></string-name>, <string-name><given-names>F.
M. N.</given-names>
<surname>Kadji</surname></string-name>,
<string-name><given-names>G.</given-names>
<surname>Singh</surname></string-name>,
<string-name><given-names>T.</given-names>
<surname>Kishi</surname></string-name>,
<string-name><given-names>A.</given-names>
<surname>Uwamizu</surname></string-name>,
<string-name><given-names>Y.</given-names>
<surname>Ono</surname></string-name>,
<string-name><given-names>Y.</given-names>
<surname>Shinjo</surname></string-name>,
<string-name><given-names>S.</given-names>
<surname>Ishida</surname></string-name>,
<string-name><given-names>N.</given-names>
<surname>Arang</surname></string-name>,
<string-name><given-names>K.</given-names>
<surname>Kawakami</surname></string-name>, <string-name><given-names>J.
S.</given-names>
<surname>Gutkind</surname></string-name>,
<string-name><given-names>J.</given-names>
<surname>Aoki</surname></string-name>, <string-name><given-names>R.
B.</given-names>
<surname>Russell</surname></string-name></person-group>,
<article-title>Illuminating G-protein-coupling selectivity of
GPCRs</article-title>. <source>Cell</source>
<volume>177</volume>, <fpage>1933</fpage>&#x02013;<lpage>1947.e25</lpage>
(<year>2019</year>).<pub-id pub-id-type="pmid">31160049</pub-id>
</mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>H. R.</given-names>
<surname>Kim</surname></string-name>,
<string-name><given-names>J.</given-names>
<surname>Xu</surname></string-name>,
<string-name><given-names>S.</given-names>
<surname>Maeda</surname></string-name>, <string-name><given-names>N.
M.</given-names>
<surname>Duc</surname></string-name>,
<string-name><given-names>D.</given-names>
<surname>Ahn</surname></string-name>,
<string-name><given-names>Y.</given-names>
<surname>Du</surname></string-name>, <string-name><given-names>K.
Y.</given-names>
<surname>Chung</surname></string-name></person-group>,
<article-title>Structural mechanism underlying primary and secondary
coupling between GPCRs and the Gi/o family</article-title>. <source>Nat.
Commun.</source>
<volume>11</volume>, <fpage>3160</fpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32572026</pub-id>
</mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>X.</given-names>
<surname>Ma</surname></string-name>,
<string-name><given-names>Y.</given-names>
<surname>Hu</surname></string-name>,
<string-name><given-names>H.</given-names>
<surname>Batebi</surname></string-name>,
<string-name><given-names>J.</given-names>
<surname>Heng</surname></string-name>,
<string-name><given-names>J.</given-names>
<surname>Xu</surname></string-name>,
<string-name><given-names>X.</given-names>
<surname>Liu</surname></string-name>,
<string-name><given-names>X.</given-names>
<surname>Niu</surname></string-name>,
<string-name><given-names>H.</given-names>
<surname>Li</surname></string-name>, <string-name><given-names>P.
W.</given-names>
<surname>Hildebrand</surname></string-name>,
<string-name><given-names>C.</given-names>
<surname>Jin</surname></string-name>, <string-name><given-names>B.
K.</given-names>
<surname>Kobilka</surname></string-name></person-group>,
<article-title>Analysis of &#x003b2;<sub>2</sub>AR-G<sub>s</sub> and
&#x003b2;<sub>2</sub>AR-G<sub>i</sub> complex formation by NMR
spectroscopy</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>117</volume>, <fpage>23096</fpage>&#x02013;<lpage>23105</lpage>
(<year>2020</year>).<pub-id pub-id-type="pmid">32868434</pub-id>
</mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>F.</given-names>
<surname>Horn</surname></string-name>, <string-name><given-names>E.
M.</given-names>
<surname>van der Wenden</surname></string-name>,
<string-name><given-names>L.</given-names>
<surname>Oliveira</surname></string-name>, <string-name><given-names>A.
P.</given-names>
<surname>IJzerman</surname></string-name>,
<string-name><given-names>G.</given-names>
<surname>Vriend</surname></string-name></person-group>,
<article-title>Receptors coupling to G proteins: Is there a signal behind
the sequence?</article-title>
<source>Proteins</source>
<volume>41</volume>, <fpage>448</fpage>&#x02013;<lpage>459</lpage>
(<year>2000</year>).<pub-id pub-id-type="pmid">11056033</pub-id>
</mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>G. J.</given-names>
<surname>Rodriguez</surname></string-name>,
<string-name><given-names>R.</given-names>
<surname>Yao</surname></string-name>,
<string-name><given-names>O.</given-names>
<surname>Lichtarge</surname></string-name>, <string-name><given-names>T.
G.</given-names>
<surname>Wensel</surname></string-name></person-group>,
<article-title>Evolution-guided discovery and recoding of allosteric pathway
specificity determinants in psychoactive bioamine receptors</article-title>.
<source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>107</volume>, <fpage>7787</fpage>&#x02013;<lpage>7792</lpage>
(<year>2010</year>).<pub-id pub-id-type="pmid">20385837</pub-id>
</mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A.</given-names>
<surname>Manglik</surname></string-name>, <string-name><given-names>T.
H.</given-names>
<surname>Kim</surname></string-name>,
<string-name><given-names>M.</given-names>
<surname>Masureel</surname></string-name>,
<string-name><given-names>C.</given-names>
<surname>Altenbach</surname></string-name>,
<string-name><given-names>Z.</given-names>
<surname>Yang</surname></string-name>,
<string-name><given-names>D.</given-names>
<surname>Hilger</surname></string-name>, <string-name><given-names>M.
T.</given-names>
<surname>Lerch</surname></string-name>, <string-name><given-names>T.
S.</given-names>
<surname>Kobilka</surname></string-name>, <string-name><given-names>F.
S.</given-names>
<surname>Thian</surname></string-name>, <string-name><given-names>W.
L.</given-names>
<surname>Hubbell</surname></string-name>, <string-name><given-names>R.
S.</given-names>
<surname>Prosser</surname></string-name>, <string-name><given-names>B.
K.</given-names>
<surname>Kobilka</surname></string-name></person-group>,
<article-title>Structural insights into the dynamic process of
&#x003b2;2-adrenergic receptor signaling</article-title>.
<source>Cell</source>
<volume>161</volume>, <fpage>1101</fpage>&#x02013;<lpage>1111</lpage>
(<year>2015</year>).<pub-id pub-id-type="pmid">25981665</pub-id>
</mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>R.</given-names>
<surname>Nygaard</surname></string-name>,
<string-name><given-names>Y.</given-names>
<surname>Zou</surname></string-name>, <string-name><given-names>R.
O.</given-names>
<surname>Dror</surname></string-name>, <string-name><given-names>T.
J.</given-names>
<surname>Mildorf</surname></string-name>, <string-name><given-names>D.
H.</given-names>
<surname>Arlow</surname></string-name>,
<string-name><given-names>A.</given-names>
<surname>Manglik</surname></string-name>, <string-name><given-names>A.
C.</given-names>
<surname>Pan</surname></string-name>, <string-name><given-names>C.
W.</given-names>
<surname>Liu</surname></string-name>, <string-name><given-names>J.
J.</given-names>
<surname>Fung</surname></string-name>, <string-name><given-names>M.
P.</given-names>
<surname>Bokoch</surname></string-name>, <string-name><given-names>F.
S.</given-names>
<surname>Thian</surname></string-name>, <string-name><given-names>T.
S.</given-names>
<surname>Kobilka</surname></string-name>, <string-name><given-names>D.
E.</given-names>
<surname>Shaw</surname></string-name>,
<string-name><given-names>L.</given-names>
<surname>Mueller</surname></string-name>, <string-name><given-names>R.
S.</given-names>
<surname>Prosser</surname></string-name>, <string-name><given-names>B.
K.</given-names>
<surname>Kobilka</surname></string-name></person-group>,
<article-title>The dynamic process of &#x003b2;2-adrenergic receptor
activation</article-title>. <source>Cell</source>
<volume>152</volume>, <fpage>532</fpage>&#x02013;<lpage>542</lpage>
(<year>2013</year>).<pub-id pub-id-type="pmid">23374348</pub-id>
</mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>L.</given-names>
<surname>Ye</surname></string-name>,
<string-name><given-names>N.</given-names>
<prefix>Van</prefix>
<surname>Eps</surname></string-name>,
<string-name><given-names>M.</given-names>
<surname>Zimmer</surname></string-name>, <string-name><given-names>O.
P.</given-names>
<surname>Ernst</surname></string-name>, <string-name><given-names>R.
S.</given-names>
<surname>Prosser</surname></string-name></person-group>,
<article-title>Activation of the A2A adenosine G-protein-coupled receptor by
conformational selection</article-title>. <source>Nature</source>
<volume>533</volume>, <fpage>265</fpage>&#x02013;<lpage>268</lpage>
(<year>2016</year>).<pub-id pub-id-type="pmid">27144352</pub-id>
</mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>X.</given-names>
<surname>Deupi</surname></string-name>, <string-name><given-names>B.
K.</given-names>
<surname>Kobilka</surname></string-name></person-group>,
<article-title>Energy landscapes as a tool to integrate GPCR structure,
dynamics, and function</article-title>. <source>Physiology</source>
<volume>25</volume>, <fpage>293</fpage>&#x02013;<lpage>303</lpage>
(<year>2010</year>).<pub-id pub-id-type="pmid">20940434</pub-id>
</mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names>
<surname>Okude</surname></string-name>,
<string-name><given-names>T.</given-names>
<surname>Ueda</surname></string-name>,
<string-name><given-names>Y.</given-names>
<surname>Kofuku</surname></string-name>,
<string-name><given-names>M.</given-names>
<surname>Sato</surname></string-name>,
<string-name><given-names>N.</given-names>
<surname>Nobuyama</surname></string-name>,
<string-name><given-names>K.</given-names>
<surname>Kondo</surname></string-name>,
<string-name><given-names>Y.</given-names>
<surname>Shiraishi</surname></string-name>,
<string-name><given-names>T.</given-names>
<surname>Mizumura</surname></string-name>,
<string-name><given-names>K.</given-names>
<surname>Onishi</surname></string-name>,
<string-name><given-names>M.</given-names>
<surname>Natsume</surname></string-name>,
<string-name><given-names>M.</given-names>
<surname>Maeda</surname></string-name>,
<string-name><given-names>H.</given-names>
<surname>Tsujishita</surname></string-name>,
<string-name><given-names>T.</given-names>
<surname>Kuranaga</surname></string-name>,
<string-name><given-names>M.</given-names>
<surname>Inoue</surname></string-name>,
<string-name><given-names>I.</given-names>
<surname>Shimada</surname></string-name></person-group>,
<article-title>Identification of a conformational equilibrium that
determines the efficacy and functional selectivity of the &#x003bc;-opioid
receptor</article-title>. <source>Angew. Chem. Int. Ed. Engl.</source>
<volume>54</volume>, <fpage>15771</fpage>&#x02013;<lpage>15776</lpage>
(<year>2015</year>).<pub-id pub-id-type="pmid">26568421</pub-id>
</mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>L. M.</given-names>
<surname>Wingler</surname></string-name>,
<string-name><given-names>M.</given-names>
<surname>Elgeti</surname></string-name>,
<string-name><given-names>D.</given-names>
<surname>Hilger</surname></string-name>, <string-name><given-names>N.
R.</given-names>
<surname>Latorraca</surname></string-name>, <string-name><given-names>M.
T.</given-names>
<surname>Lerch</surname></string-name>, <string-name><given-names>D.
P.</given-names>
<surname>Staus</surname></string-name>, <string-name><given-names>R.
O.</given-names>
<surname>Dror</surname></string-name>, <string-name><given-names>B.
K.</given-names>
<surname>Kobilka</surname></string-name>, <string-name><given-names>W.
L.</given-names>
<surname>Hubbell</surname></string-name>, <string-name><given-names>R.
J.</given-names>
<surname>Lefkowitz</surname></string-name></person-group>,
<article-title>Analogs with divergent bias stabilize distinct receptor
conformations</article-title>. <source>Cell</source>
<volume>176</volume>, <fpage>468</fpage>&#x02013;<lpage>478.e11</lpage>
(<year>2019</year>).<pub-id pub-id-type="pmid">30639099</pub-id>
</mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J. J.</given-names>
<surname>Liu</surname></string-name>,
<string-name><given-names>R.</given-names>
<surname>Horst</surname></string-name>,
<string-name><given-names>V.</given-names>
<surname>Katritch</surname></string-name>, <string-name><given-names>R.
C.</given-names>
<surname>Stevens</surname></string-name>,
<string-name><given-names>K.</given-names>
<surname>W&#x000fc;thrich</surname></string-name></person-group>,
<article-title>Biased signaling pathways in &#x003b2;<sub>2</sub>-adrenergic
receptor characterized by <sup>19</sup>F-NMR</article-title>.
<source>Science</source>
<volume>335</volume>, <fpage>1106</fpage>&#x02013;<lpage>1110</lpage>
(<year>2012</year>).<pub-id pub-id-type="pmid">22267580</pub-id>
</mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>R.</given-names>
<surname>Rahmeh</surname></string-name>,
<string-name><given-names>M.</given-names>
<surname>Damian</surname></string-name>,
<string-name><given-names>M.</given-names>
<surname>Cottet</surname></string-name>,
<string-name><given-names>H.</given-names>
<surname>Orcel</surname></string-name>,
<string-name><given-names>C.</given-names>
<surname>Mendre</surname></string-name>,
<string-name><given-names>T.</given-names>
<surname>Durroux</surname></string-name>, <string-name><given-names>K.
S.</given-names>
<surname>Sharma</surname></string-name>,
<string-name><given-names>G.</given-names>
<surname>Durand</surname></string-name>,
<string-name><given-names>B.</given-names>
<surname>Pucci</surname></string-name>,
<string-name><given-names>E.</given-names>
<surname>Trinquet</surname></string-name>, <string-name><given-names>J.
M.</given-names>
<surname>Zwier</surname></string-name>,
<string-name><given-names>X.</given-names>
<surname>Deupi</surname></string-name>,
<string-name><given-names>P.</given-names>
<surname>Bron</surname></string-name>,
<string-name><given-names>J.-L.</given-names>
<surname>Ban&#x000e8;res</surname></string-name>,
<string-name><given-names>B.</given-names>
<surname>Mouillac</surname></string-name>,
<string-name><given-names>S.</given-names>
<surname>Granier</surname></string-name></person-group>,
<article-title>Structural insights into biased G protein-coupled receptor
signaling revealed by fluorescence spectroscopy</article-title>.
<source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>109</volume>, <fpage>6733</fpage>&#x02013;<lpage>6738</lpage>
(<year>2012</year>).<pub-id pub-id-type="pmid">22493271</pub-id>
</mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names>
<surname>Wang</surname></string-name>,
<string-name><given-names>K.</given-names>
<surname>Hanada</surname></string-name>, <string-name><given-names>D.
P.</given-names>
<surname>Staus</surname></string-name>, <string-name><given-names>M.
A.</given-names>
<surname>Makara</surname></string-name>, <string-name><given-names>G.
R.</given-names>
<surname>Dahal</surname></string-name>,
<string-name><given-names>Q.</given-names>
<surname>Chen</surname></string-name>,
<string-name><given-names>A.</given-names>
<surname>Ahles</surname></string-name>,
<string-name><given-names>S.</given-names>
<surname>Engelhardt</surname></string-name>,
<string-name><given-names>H. A.</given-names>
<surname>Rockman</surname></string-name></person-group>,
<article-title>G&#x003b1;<sub>i</sub> is required for carvedilol-induced
&#x003b2;1 adrenergic receptor &#x003b2;-arrestin biased
signaling</article-title>. <source>Nat. Commun.</source>
<volume>8</volume>, <fpage>1706</fpage> (<year>2017</year>).<pub-id pub-id-type="pmid">29167435</pub-id>
</mixed-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A. Y.-H.</given-names>
<surname>Woo</surname></string-name>,
<string-name><given-names>Y.</given-names>
<surname>Song</surname></string-name>,
<string-name><given-names>R.-P.</given-names>
<surname>Xiao</surname></string-name>,
<string-name><given-names>W.</given-names>
<surname>Zhu</surname></string-name></person-group>,
<article-title>Biased &#x003b2;<sub>2</sub>-adrenoceptor signalling in heart
failure: Pathophysiology and drug discovery</article-title>. <source>Br. J.
Pharmacol.</source>
<volume>172</volume>, <fpage>5444</fpage>&#x02013;<lpage>5456</lpage>
(<year>2015</year>).<pub-id pub-id-type="pmid">25298054</pub-id>
</mixed-citation></ref><ref id="R27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A.</given-names>
<surname>Chesley</surname></string-name>, <string-name><given-names>M.
S.</given-names>
<surname>Lundberg</surname></string-name>,
<string-name><given-names>T.</given-names>
<surname>Asai</surname></string-name>,
<string-name><given-names>R.-P.</given-names>
<surname>Xiao</surname></string-name>,
<string-name><given-names>S.</given-names>
<surname>Ohtani</surname></string-name>, <string-name><given-names>E.
G.</given-names>
<surname>Lakatta</surname></string-name>, <string-name><given-names>M.
T.</given-names>
<surname>Crow</surname></string-name></person-group>, <article-title>The
&#x003b2;<sub>2</sub>-adrenergic receptor delivers an antiapoptotic
signal to cardiac myocytes through G<sub>i</sub>-dependent coupling to
phosphatidylinositol 3&#x02032;-kinase</article-title>. <source>Circ.
Res.</source>
<volume>87</volume>, <fpage>1172</fpage>&#x02013;<lpage>1179</lpage>
(<year>2000</year>).<pub-id pub-id-type="pmid">11110775</pub-id>
</mixed-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>W. Z.</given-names>
<surname>Zhu</surname></string-name>,
<string-name><given-names>M.</given-names>
<surname>Zheng</surname></string-name>, <string-name><given-names>W.
J.</given-names>
<surname>Koch</surname></string-name>, <string-name><given-names>R.
J.</given-names>
<surname>Lefkowitz</surname></string-name>, <string-name><given-names>B.
K.</given-names>
<surname>Kobilka</surname></string-name>, <string-name><given-names>R.
P.</given-names>
<surname>Xiao</surname></string-name></person-group>,
<article-title>Dual modulation of cell survival and cell death by
&#x003b2;<sub>2</sub>-adrenergic signaling in adult mouse cardiac
myocytes</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>98</volume>, <fpage>1607</fpage>&#x02013;<lpage>1612</lpage>
(<year>2001</year>).<pub-id pub-id-type="pmid">11171998</pub-id>
</mixed-citation></ref><ref id="R29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>G.</given-names>
<surname>Fajardo</surname></string-name>,
<string-name><given-names>M.</given-names>
<surname>Zhao</surname></string-name>,
<string-name><given-names>T.</given-names>
<surname>Urashima</surname></string-name>,
<string-name><given-names>S.</given-names>
<surname>Farahani</surname></string-name>,
<string-name><given-names>D.-Q.</given-names>
<surname>Hu</surname></string-name>,
<string-name><given-names>S.</given-names>
<surname>Reddy</surname></string-name>,
<string-name><given-names>D.</given-names>
<surname>Bernstein</surname></string-name></person-group>,
<article-title>Deletion of the &#x003b2;2-adrenergic receptor prevents the
development of cardiomyopathy in mice</article-title>. <source>J. Mol. Cell.
Cardiol.</source>
<volume>63</volume>, <fpage>155</fpage>&#x02013;<lpage>164</lpage>
(<year>2013</year>).<pub-id pub-id-type="pmid">23920331</pub-id>
</mixed-citation></ref><ref id="R30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Y.</given-names>
<surname>Kofuku</surname></string-name>,
<string-name><given-names>T.</given-names>
<surname>Ueda</surname></string-name>,
<string-name><given-names>J.</given-names>
<surname>Okude</surname></string-name>,
<string-name><given-names>Y.</given-names>
<surname>Shiraishi</surname></string-name>,
<string-name><given-names>K.</given-names>
<surname>Kondo</surname></string-name>,
<string-name><given-names>M.</given-names>
<surname>Maeda</surname></string-name>,
<string-name><given-names>H.</given-names>
<surname>Tsujishita</surname></string-name>,
<string-name><given-names>I.</given-names>
<surname>Shimada</surname></string-name></person-group>,
<article-title>Efficacy of the &#x003b2;<sub>2</sub>-adrenergic receptor is
determined by conformational equilibrium in the transmembrane
region</article-title>. <source>Nat. Commun.</source>
<volume>3</volume>, <fpage>1045</fpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22948827</pub-id>
</mixed-citation></ref><ref id="R31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>K. Y.</given-names>
<surname>Chung</surname></string-name>, <string-name><given-names>S. G.
F.</given-names>
<surname>Rasmussen</surname></string-name>,
<string-name><given-names>T.</given-names>
<surname>Liu</surname></string-name>,
<string-name><given-names>S.</given-names>
<surname>Li</surname></string-name>, <string-name><given-names>B.
T.</given-names>
<surname>DeVree</surname></string-name>, <string-name><given-names>P.
S.</given-names>
<surname>Chae</surname></string-name>,
<string-name><given-names>D.</given-names>
<surname>Calinski</surname></string-name>, <string-name><given-names>B.
K.</given-names>
<surname>Kobilka</surname></string-name>, <string-name><given-names>V.
L.</given-names>
<surname>Woods</surname></string-name>, <string-name><given-names>R.
K.</given-names>
<surname>Sunahara</surname></string-name></person-group>,
<article-title>Conformational changes in the G protein Gs induced by the
&#x003b2;2 adrenergic receptor</article-title>. <source>Nature</source>
<volume>477</volume>, <fpage>611</fpage>&#x02013;<lpage>615</lpage>
(<year>2011</year>).<pub-id pub-id-type="pmid">21956331</pub-id>
</mixed-citation></ref><ref id="R32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>G. G.</given-names>
<surname>Gregorio</surname></string-name>,
<string-name><given-names>M.</given-names>
<surname>Masureel</surname></string-name>,
<string-name><given-names>D.</given-names>
<surname>Hilger</surname></string-name>, <string-name><given-names>D.
S.</given-names>
<surname>Terry</surname></string-name>,
<string-name><given-names>M.</given-names>
<surname>Juette</surname></string-name>,
<string-name><given-names>H.</given-names>
<surname>Zhao</surname></string-name>,
<string-name><given-names>Z.</given-names>
<surname>Zhou</surname></string-name>, <string-name><given-names>J.
M.</given-names>
<surname>Perez-Aguilar</surname></string-name>,
<string-name><given-names>M.</given-names>
<surname>Hauge</surname></string-name>,
<string-name><given-names>S.</given-names>
<surname>Mathiasen</surname></string-name>, <string-name><given-names>J.
A.</given-names>
<surname>Javitch</surname></string-name>,
<string-name><given-names>H.</given-names>
<surname>Weinstein</surname></string-name>, <string-name><given-names>B.
K.</given-names>
<surname>Kobilka</surname></string-name>, <string-name><given-names>S.
C.</given-names>
<surname>Blanchard</surname></string-name></person-group>,
<article-title>Single-molecule analysis of ligand efficacy in
&#x003b2;<sub>2</sub>AR&#x02013;G-protein activation</article-title>.
<source>Nature</source>
<volume>547</volume>, <fpage>68</fpage>&#x02013;<lpage>73</lpage>
(<year>2017</year>).<pub-id pub-id-type="pmid">28607487</pub-id>
</mixed-citation></ref><ref id="R33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Y.</given-names>
<surname>Du</surname></string-name>, <string-name><given-names>N.
M.</given-names>
<surname>Duc</surname></string-name>, <string-name><given-names>S. G.
F.</given-names>
<surname>Rasmussen</surname></string-name>,
<string-name><given-names>D.</given-names>
<surname>Hilger</surname></string-name>,
<string-name><given-names>X.</given-names>
<surname>Kubiak</surname></string-name>,
<string-name><given-names>L.</given-names>
<surname>Wang</surname></string-name>,
<string-name><given-names>J.</given-names>
<surname>Bohon</surname></string-name>, <string-name><given-names>H.
R.</given-names>
<surname>Kim</surname></string-name>,
<string-name><given-names>M.</given-names>
<surname>Wegrecki</surname></string-name>,
<string-name><given-names>A.</given-names>
<surname>Asuru</surname></string-name>, <string-name><given-names>K.
M.</given-names>
<surname>Jeong</surname></string-name>,
<string-name><given-names>J.</given-names>
<surname>Lee</surname></string-name>, <string-name><given-names>M.
R.</given-names>
<surname>Chance</surname></string-name>, <string-name><given-names>D.
T.</given-names>
<surname>Lodowski</surname></string-name>, <string-name><given-names>B.
K.</given-names>
<surname>Kobilka</surname></string-name>,
<string-name><given-names>Y.</given-names>
<surname>ChungK</surname></string-name></person-group>,
<article-title>Assembly of a GPCR-G protein complex</article-title>.
<source>Cell</source>
<volume>3</volume>, <fpage>1045</fpage> (<year>2012</year>).</mixed-citation></ref><ref id="R34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Y.</given-names>
<surname>Daaka</surname></string-name>, <string-name><given-names>L.
M.</given-names>
<surname>Luttrell</surname></string-name>, <string-name><given-names>R.
J.</given-names>
<surname>Lefkowitz</surname></string-name></person-group>,
<article-title>Switching of the coupling of the
&#x003b2;<sub>2</sub>-adrenergic receptor to different G proteins by protein
kinase A</article-title>. <source>Nature</source>
<volume>390</volume>, <fpage>88</fpage>&#x02013;<lpage>91</lpage>
(<year>1997</year>).<pub-id pub-id-type="pmid">9363896</pub-id>
</mixed-citation></ref><ref id="R35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M. J.</given-names>
<surname>Strohman</surname></string-name>,
<string-name><given-names>S.</given-names>
<surname>Maeda</surname></string-name>,
<string-name><given-names>D.</given-names>
<surname>Hilger</surname></string-name>,
<string-name><given-names>M.</given-names>
<surname>Masureel</surname></string-name>,
<string-name><given-names>Y.</given-names>
<surname>Du</surname></string-name>, <string-name><given-names>B.
K.</given-names>
<surname>Kobilka</surname></string-name></person-group>,
<article-title>Local membrane charge regulates &#x003b2;2 adrenergic receptor
coupling to G<sub>i3</sub></article-title>. <source>Nat. Commun.</source>
<volume>10</volume>, <fpage>2234</fpage> (<year>2019</year>).<pub-id pub-id-type="pmid">31110175</pub-id>
</mixed-citation></ref><ref id="R36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>E.</given-names>
<surname>Devic</surname></string-name>,
<string-name><given-names>Y.</given-names>
<surname>Xiang</surname></string-name>,
<string-name><given-names>D.</given-names>
<surname>Gould</surname></string-name>,
<string-name><given-names>B.</given-names>
<surname>Kobilka</surname></string-name></person-group>,
<article-title>&#x003b2;-adrenergic receptor subtype-specific signaling in
cardiac myocytes from &#x003b2;<sub>1</sub> and &#x003b2;<sub>2</sub>
adrenoceptor knockout mice</article-title>. <source>Mol. Pharmacol.</source>
<volume>60</volume>, <fpage>577</fpage>&#x02013;<lpage>583</lpage>
(<year>2001</year>).<pub-id pub-id-type="pmid">11502890</pub-id>
</mixed-citation></ref><ref id="R37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J. I.</given-names>
<surname>Mobbs</surname></string-name>, <string-name><given-names>M.
J.</given-names>
<surname>Belousoff</surname></string-name>, <string-name><given-names>K.
G.</given-names>
<surname>Harikumar</surname></string-name>, <string-name><given-names>S.
J.</given-names>
<surname>Piper</surname></string-name>,
<string-name><given-names>X.</given-names>
<surname>Xu</surname></string-name>, <string-name><given-names>S. G.
B.</given-names>
<surname>Furness</surname></string-name>,
<string-name><given-names>H.</given-names>
<surname>Venugopal</surname></string-name>,
<string-name><given-names>A.</given-names>
<surname>Christopoulos</surname></string-name>,
<string-name><given-names>R.</given-names>
<surname>Danev</surname></string-name>,
<string-name><given-names>D.</given-names>
<surname>Wootten</surname></string-name>, <string-name><given-names>D.
M.</given-names>
<surname>Thal</surname></string-name>, <string-name><given-names>L.
J.</given-names>
<surname>Miller</surname></string-name>, <string-name><given-names>P.
M.</given-names>
<surname>Sexton</surname></string-name></person-group>,
<article-title>Structures of the human cholecystokinin 1 (CCK1) receptor
bound to Gs and Gq mimetic proteins provide insight into mechanisms of G
protein selectivity</article-title>. <source>PLOS Biol.</source>
<volume>19</volume>, <fpage>e3001295</fpage>
(<year>2021</year>).<pub-id pub-id-type="pmid">34086670</pub-id>
</mixed-citation></ref><ref id="R38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names>
<surname>Masureel</surname></string-name>,
<string-name><given-names>Y.</given-names>
<surname>Zou</surname></string-name>,
<string-name><given-names>L.-P.</given-names>
<surname>Picard</surname></string-name>,
<string-name><given-names>E.</given-names>
<surname>van der Westhuizen</surname></string-name>,
<string-name><given-names>J. P.</given-names>
<surname>Mahoney</surname></string-name>, <string-name><given-names>J.
P. G. L. M.</given-names>
<surname>Rodrigues</surname></string-name>, <string-name><given-names>T.
J.</given-names>
<surname>Mildorf</surname></string-name>, <string-name><given-names>R.
O.</given-names>
<surname>Dror</surname></string-name>, <string-name><given-names>D.
E.</given-names>
<surname>Shaw</surname></string-name>,
<string-name><given-names>M.</given-names>
<surname>Bouvier</surname></string-name>,
<string-name><given-names>E.</given-names>
<surname>Pardon</surname></string-name>,
<string-name><given-names>J.</given-names>
<surname>Steyaert</surname></string-name>, <string-name><given-names>R.
K.</given-names>
<surname>Sunahara</surname></string-name>, <string-name><given-names>W.
I.</given-names>
<surname>Weis</surname></string-name>,
<string-name><given-names>C.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>B.
K.</given-names>
<surname>Kobilka</surname></string-name></person-group>,
<article-title>Structural insights into binding specificity, efficacy and
bias of a &#x003b2;<sub>2</sub>AR partial agonist</article-title>.
<source>Nat. Chem. Biol.</source>
<volume>14</volume>, <fpage>1059</fpage>&#x02013;<lpage>1066</lpage>
(<year>2018</year>).<pub-id pub-id-type="pmid">30327561</pub-id>
</mixed-citation></ref><ref id="R39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names>
<surname>Weatherall</surname></string-name>,
<string-name><given-names>M.</given-names>
<surname>Wijesinghe</surname></string-name>,
<string-name><given-names>K.</given-names>
<surname>Perrin</surname></string-name>,
<string-name><given-names>M.</given-names>
<surname>Harwood</surname></string-name>,
<string-name><given-names>R.</given-names>
<surname>Beasley</surname></string-name></person-group>,
<article-title>Meta-analysis of the risk of mortality with salmeterol and
the effect of concomitant inhaled corticosteroid therapy</article-title>.
<source>Thorax</source>
<volume>65</volume>, <fpage>39</fpage>&#x02013;<lpage>43</lpage>
(<year>2010</year>).<pub-id pub-id-type="pmid">20029037</pub-id>
</mixed-citation></ref><ref id="R40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>T.</given-names>
<surname>Kenakin</surname></string-name>,
<string-name><given-names>C.</given-names>
<surname>Watson</surname></string-name>,
<string-name><given-names>V.</given-names>
<surname>Muniz-Medina</surname></string-name>,
<string-name><given-names>A.</given-names>
<surname>Christopoulos</surname></string-name>,
<string-name><given-names>S.</given-names>
<surname>Novick</surname></string-name></person-group>, <article-title>A
simple method for quantifying functional selectivity and agonist
bias</article-title>. <source>ACS Chem. Nerosci.</source>
<volume>3</volume>, <fpage>193</fpage>&#x02013;<lpage>203</lpage>
(<year>2012</year>).</mixed-citation></ref><ref id="R41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>E. T.</given-names>
<surname>van der Westhuizen</surname></string-name>,
<string-name><given-names>B.</given-names>
<surname>Breton</surname></string-name>,
<string-name><given-names>A.</given-names>
<surname>Christopoulos</surname></string-name>,
<string-name><given-names>M.</given-names>
<surname>Bouvier</surname></string-name></person-group>,
<article-title>Quantification of ligand bias for clinically relevant
&#x003b2;<sub>2</sub>-adrenergic receptor ligands: Implications for drug
taxonomy</article-title>. <source>Mol. Pharmacol.</source>
<volume>85</volume>, <fpage>492</fpage>&#x02013;<lpage>509</lpage>
(<year>2014</year>).<pub-id pub-id-type="pmid">24366668</pub-id>
</mixed-citation></ref><ref id="R42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S.</given-names>
<surname>Ahn</surname></string-name>,
<string-name><given-names>B.</given-names>
<surname>Pani</surname></string-name>, <string-name><given-names>A.
W.</given-names>
<surname>Kahsai</surname></string-name>, <string-name><given-names>E.
K.</given-names>
<surname>Olsen</surname></string-name>,
<string-name><given-names>G.</given-names>
<surname>Husemoen</surname></string-name>,
<string-name><given-names>M.</given-names>
<surname>Vestergaard</surname></string-name>,
<string-name><given-names>L.</given-names>
<surname>Jin</surname></string-name>,
<string-name><given-names>S.</given-names>
<surname>Zhao</surname></string-name>, <string-name><given-names>L.
M.</given-names>
<surname>Wingler</surname></string-name>, <string-name><given-names>P.
K.</given-names>
<surname>Rambarat</surname></string-name>, <string-name><given-names>R.
K.</given-names>
<surname>Simhal</surname></string-name>, <string-name><given-names>T.
T.</given-names>
<surname>Xu</surname></string-name>, <string-name><given-names>L.
D.</given-names>
<surname>Sun</surname></string-name>, <string-name><given-names>P.
J.</given-names>
<surname>Shim</surname></string-name>, <string-name><given-names>D.
P.</given-names>
<surname>Staus</surname></string-name>,
<string-name><given-names>L.-Y.</given-names>
<surname>Huang</surname></string-name>,
<string-name><given-names>T.</given-names>
<surname>Franch</surname></string-name>,
<string-name><given-names>X.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>R.
J.</given-names>
<surname>Lefkowitz</surname></string-name></person-group>,
<article-title>Small-molecule positive allosteric modulators of the
&#x003b2;<sub>2</sub>-adrenoceptor isolated from DNA-encoded
libraries</article-title>. <source>Mol. Pharmacol.</source>
<volume>94</volume>, <fpage>850</fpage>&#x02013;<lpage>861</lpage>
(<year>2018</year>).<pub-id pub-id-type="pmid">29769246</pub-id>
</mixed-citation></ref><ref id="R43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>X.</given-names>
<surname>Liu</surname></string-name>,
<string-name><given-names>A.</given-names>
<surname>Masoudi</surname></string-name>, <string-name><given-names>A.
W.</given-names>
<surname>Kahsai</surname></string-name>,
<string-name><given-names>L.-Y.</given-names>
<surname>Huang</surname></string-name>,
<string-name><given-names>B.</given-names>
<surname>Pani</surname></string-name>, <string-name><given-names>D.
P.</given-names>
<surname>Staus</surname></string-name>, <string-name><given-names>P.
J.</given-names>
<surname>Shim</surname></string-name>,
<string-name><given-names>K.</given-names>
<surname>Hirata</surname></string-name>, <string-name><given-names>R.
K.</given-names>
<surname>Simhal</surname></string-name>, <string-name><given-names>A.
M.</given-names>
<surname>Schwalb</surname></string-name>, <string-name><given-names>P.
K.</given-names>
<surname>Rambarat</surname></string-name>,
<string-name><given-names>S.</given-names>
<surname>Ahn</surname></string-name>, <string-name><given-names>R.
J.</given-names>
<surname>Lefkowitz</surname></string-name>,
<string-name><given-names>B.</given-names>
<surname>Kobilka</surname></string-name></person-group>,
<article-title>Mechanism of &#x003b2;<sub>2</sub>AR regulation by an
intracellular positive allosteric modulator</article-title>.
<source>Science</source>
<volume>364</volume>, <fpage>1283</fpage>&#x02013;<lpage>1287</lpage>
(<year>2019</year>).<pub-id pub-id-type="pmid">31249059</pub-id>
</mixed-citation></ref><ref id="R44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>V.</given-names>
<surname>Cherezov</surname></string-name>, <string-name><given-names>D.
M.</given-names>
<surname>Rosenbaum</surname></string-name>, <string-name><given-names>M.
A.</given-names>
<surname>Hanson</surname></string-name>, <string-name><given-names>S. G.
F.</given-names>
<surname>Rasmussen</surname></string-name>, <string-name><given-names>F.
S.</given-names>
<surname>Thian</surname></string-name>, <string-name><given-names>T.
S.</given-names>
<surname>Kobilka</surname></string-name>,
<string-name><given-names>H.-J.</given-names>
<surname>Choi</surname></string-name>,
<string-name><given-names>P.</given-names>
<surname>Kuhn</surname></string-name>, <string-name><given-names>W.
I.</given-names>
<surname>Weis</surname></string-name>, <string-name><given-names>B.
K.</given-names>
<surname>Kobilka</surname></string-name>, <string-name><given-names>R.
C.</given-names>
<surname>Stevens</surname></string-name></person-group>,
<article-title>High-resolution crystal structure of an engineered human
&#x003b2;<sub>2</sub>-adrenergic G protein&#x02013;coupled
receptor</article-title>. <source>Science</source>
<volume>318</volume>, <fpage>1258</fpage>&#x02013;<lpage>1265</lpage>
(<year>2007</year>).<pub-id pub-id-type="pmid">17962520</pub-id>
</mixed-citation></ref><ref id="R45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>C.</given-names>
<surname>Altenbach</surname></string-name>, <string-name><given-names>C.
J.</given-names>
<surname>L&#x000f3;pez</surname></string-name>,
<string-name><given-names>K.</given-names>
<surname>Hideg</surname></string-name>, <string-name><given-names>W.
L.</given-names>
<surname>Hubbell</surname></string-name></person-group>,
<article-title>Chapter three&#x02014;Exploring structure, dynamics, and
topology of nitroxide spin-labeled proteins using continuous-wave electron
paramagnetic resonance spectroscopy</article-title>. <source>Methods
Enzymol.</source>
<volume>564</volume>, <fpage>59</fpage>&#x02013;<lpage>100</lpage>
(<year>2015</year>).<pub-id pub-id-type="pmid">26477248</pub-id>
</mixed-citation></ref><ref id="R46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>G.</given-names>
<surname>Peleg</surname></string-name>,
<string-name><given-names>P.</given-names>
<surname>Ghanouni</surname></string-name>, <string-name><given-names>B.
K.</given-names>
<surname>Kobilka</surname></string-name>, <string-name><given-names>R.
N.</given-names>
<surname>Zare</surname></string-name></person-group>,
<article-title>Single-molecule spectroscopy of the &#x003b2;<sub>2</sub>
adrenergic receptor: Observation of conformational substates in a membrane
protein</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>98</volume>, <fpage>8469</fpage>&#x02013;<lpage>8474</lpage>
(<year>2001</year>).<pub-id pub-id-type="pmid">11438704</pub-id>
</mixed-citation></ref><ref id="R47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>P.</given-names>
<surname>Ghanouni</surname></string-name>,
<string-name><given-names>Z.</given-names>
<surname>Gryczynski</surname></string-name>,
<string-name><given-names>J. J.</given-names>
<surname>Steenhuis</surname></string-name>, <string-name><given-names>T.
W.</given-names>
<surname>Lee</surname></string-name>, <string-name><given-names>D.
L.</given-names>
<surname>Farrens</surname></string-name>, <string-name><given-names>J.
R.</given-names>
<surname>Lakowicz</surname></string-name>, <string-name><given-names>B.
K.</given-names>
<surname>Kobilka</surname></string-name></person-group>,
<article-title>Functionally different agonists induce distinct conformations
in the G protein coupling domain of the &#x003b2;2 adrenergic
receptor</article-title>. <source>J. Biol. Chem.</source>
<volume>276</volume>, <fpage>24433</fpage>&#x02013;<lpage>24436</lpage>
(<year>2001</year>).<pub-id pub-id-type="pmid">11320077</pub-id>
</mixed-citation></ref><ref id="R48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>C. H.</given-names>
<surname>Habrian</surname></string-name>,
<string-name><given-names>J.</given-names>
<surname>Levitz</surname></string-name>,
<string-name><given-names>V.</given-names>
<surname>Vyklicky</surname></string-name>,
<string-name><given-names>Z.</given-names>
<surname>Fu</surname></string-name>,
<string-name><given-names>A.</given-names>
<surname>Hoagland</surname></string-name>,
<string-name><given-names>I.</given-names>
<surname>McCort-Tranchepain</surname></string-name>,
<string-name><given-names>F.</given-names>
<surname>Acher</surname></string-name>, <string-name><given-names>E.
Y.</given-names>
<surname>Isacoff</surname></string-name></person-group>,
<article-title>Conformational pathway provides unique sensitivity to a
synaptic mGluR</article-title>. <source>Nat. Commun.</source>
<volume>10</volume>, <fpage>5572</fpage> (<year>2019</year>).<pub-id pub-id-type="pmid">31804469</pub-id>
</mixed-citation></ref><ref id="R49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>R.</given-names>
<surname>Vafabakhsh</surname></string-name>,
<string-name><given-names>J.</given-names>
<surname>Levitz</surname></string-name>, <string-name><given-names>E.
Y.</given-names>
<surname>Isacoff</surname></string-name></person-group>,
<article-title>Conformational dynamics of a class C G-protein-coupled
receptor</article-title>. <source>Nature</source>
<volume>524</volume>, <fpage>497</fpage>&#x02013;<lpage>501</lpage>
(<year>2015</year>).<pub-id pub-id-type="pmid">26258295</pub-id>
</mixed-citation></ref><ref id="R50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names>
<surname>Garc&#x000ed;a-Nafr&#x000ed;a</surname></string-name>,
<string-name><given-names>C. G.</given-names>
<surname>Tate</surname></string-name></person-group>,
<article-title>Cryo-EM structures of GPCRs coupled to G<sub>s</sub>,
G<sub>i</sub> and G<sub>o</sub></article-title>. <source>Mol. Cell.
Endocrinol.</source>
<volume>488</volume>, <fpage>1</fpage>&#x02013;<lpage>13</lpage>
(<year>2019</year>).<pub-id pub-id-type="pmid">30930094</pub-id>
</mixed-citation></ref><ref id="R51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M. M.</given-names>
<surname>Papasergi-Scott</surname></string-name>,
<string-name><given-names>G.</given-names>
<surname>P&#x000e9;rez-Hern&#x000e1;ndez</surname></string-name>,
<string-name><given-names>H.</given-names>
<surname>Batebi</surname></string-name>,
<string-name><given-names>Y.</given-names>
<surname>Gao</surname></string-name>,
<string-name><given-names>G.</given-names>
<surname>Eskici</surname></string-name>, <string-name><given-names>A.
B.</given-names>
<surname>Seven</surname></string-name>,
<string-name><given-names>O.</given-names>
<surname>Panova</surname></string-name>,
<string-name><given-names>D.</given-names>
<surname>Hilger</surname></string-name>,
<string-name><given-names>M.</given-names>
<surname>Casiraghi</surname></string-name>,
<string-name><given-names>F.</given-names>
<surname>He</surname></string-name>,
<string-name><given-names>L.</given-names>
<surname>Maul</surname></string-name>,
<string-name><given-names>P.</given-names>
<surname>Gmeiner</surname></string-name>, <string-name><given-names>B.
K.</given-names>
<surname>Kobilka</surname></string-name>, <string-name><given-names>P.
W.</given-names>
<surname>Hildebrand</surname></string-name>,
<string-name><given-names>G.</given-names>
<surname>Skiniotis</surname></string-name></person-group>,
<article-title>Time-resolved cryo-EM of G-protein activation by a
GPCR</article-title>. <source>Nature</source>
<volume>629</volume>, <fpage>1182</fpage>&#x02013;<lpage>1191</lpage>
(<year>2024</year>).<pub-id pub-id-type="pmid">38480881</pub-id>
</mixed-citation></ref><ref id="R52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names>
<surname>Choi</surname></string-name>, <string-name><given-names>D.
P.</given-names>
<surname>Staus</surname></string-name>, <string-name><given-names>L.
M.</given-names>
<surname>Wingler</surname></string-name>,
<string-name><given-names>S.</given-names>
<surname>Ahn</surname></string-name>,
<string-name><given-names>B.</given-names>
<surname>Pani</surname></string-name>, <string-name><given-names>W.
D.</given-names>
<surname>Capel</surname></string-name>, <string-name><given-names>R.
J.</given-names>
<surname>Lefkowitz</surname></string-name></person-group>,
<article-title>G protein&#x02013;coupled receptor kinases (GRKs) orchestrate
biased agonism at the &#x003b2;<sub>2</sub>-adrenergic
receptor</article-title>. <source>Sci. Signal.</source>
<volume>11</volume>, <fpage>eaar7084</fpage>
(<year>2018</year>).<pub-id pub-id-type="pmid">30131371</pub-id>
</mixed-citation></ref><ref id="R53"><label>53</label><mixed-citation publication-type="other">I. F. Skidmore, A. Naylor, L. H. C. Lunts,
H. Finch, Ethanolamine compounds (1985).</mixed-citation></ref><ref id="R54"><label>54</label><mixed-citation publication-type="other">I. F. Skidmore A. Naylor, H. Finch, L. H.
C. Lunts, I. B. Campbell, Phenethanolamine derivatives (1988).</mixed-citation></ref><ref id="R55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>X.</given-names>
<surname>Xu</surname></string-name>,
<string-name><given-names>J.</given-names>
<surname>Shonberg</surname></string-name>,
<string-name><given-names>J.</given-names>
<surname>Kaindl</surname></string-name>, <string-name><given-names>M.
J.</given-names>
<surname>Clark</surname></string-name>,
<string-name><given-names>A.</given-names>
<surname>St&#x000f6;&#x000df;el</surname></string-name>,
<string-name><given-names>L.</given-names>
<surname>Maul</surname></string-name>,
<string-name><given-names>D.</given-names>
<surname>Mayer</surname></string-name>,
<string-name><given-names>H.</given-names>
<surname>H&#x000fc;bner</surname></string-name>,
<string-name><given-names>K.</given-names>
<surname>Hirata</surname></string-name>, <string-name><given-names>A.
J.</given-names>
<surname>Venkatakrishnan</surname></string-name>,
<string-name><given-names>R. O.</given-names>
<surname>Dror</surname></string-name>, <string-name><given-names>B.
K.</given-names>
<surname>Kobilka</surname></string-name>, <string-name><given-names>R.
K.</given-names>
<surname>Sunahara</surname></string-name>,
<string-name><given-names>X.</given-names>
<surname>Liu</surname></string-name>,
<string-name><given-names>P.</given-names>
<surname>Gmeiner</surname></string-name></person-group>,
<article-title>Constrained catecholamines gain &#x003b2;<sub>2</sub>AR
selectivity through allosteric effects on pocket dynamics</article-title>.
<source>Nat. Commun.</source>
<volume>14</volume>, <fpage>2138</fpage> (<year>2023</year>).<pub-id pub-id-type="pmid">37059717</pub-id>
</mixed-citation></ref><ref id="R56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names>
<surname>Stanek</surname></string-name>,
<string-name><given-names>L.-P.</given-names>
<surname>Picard</surname></string-name>, <string-name><given-names>M.
F.</given-names>
<surname>Schmidt</surname></string-name>, <string-name><given-names>J.
M.</given-names>
<surname>Kaindl</surname></string-name>,
<string-name><given-names>H.</given-names>
<surname>H&#x000fc;bner</surname></string-name>,
<string-name><given-names>M.</given-names>
<surname>Bouvier</surname></string-name>,
<string-name><given-names>D.</given-names>
<surname>Weikert</surname></string-name>,
<string-name><given-names>P.</given-names>
<surname>Gmeiner</surname></string-name></person-group>,
<article-title>Hybridization of &#x003b2;-adrenergic agonists and antagonists
confers G protein bias</article-title>. <source>J. Med. Chem.</source>
<volume>62</volume>, <fpage>5111</fpage>&#x02013;<lpage>5131</lpage>
(<year>2019</year>).<pub-id pub-id-type="pmid">31042379</pub-id>
</mixed-citation></ref><ref id="R57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>O. H.</given-names>
<surname>Lowry</surname></string-name>, <string-name><given-names>N.
J.</given-names>
<surname>Rosebrough</surname></string-name>,
<string-name><given-names>A. L.</given-names>
<surname>Farr</surname></string-name>, <string-name><given-names>R.
J.</given-names>
<surname>Randall</surname></string-name></person-group>,
<article-title>Protein measurement with the Folin phenol
reagent</article-title>. <source>J. Biol. Chem.</source>
<volume>193</volume>, <fpage>265</fpage>&#x02013;<lpage>275</lpage>
(<year>1951</year>).<pub-id pub-id-type="pmid">14907713</pub-id>
</mixed-citation></ref><ref id="R58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Y.-C.</given-names>
<surname>Cheng</surname></string-name>, <string-name><given-names>W.
H.</given-names>
<surname>Prusoff</surname></string-name></person-group>,
<article-title>Relationship between the inhibition constant
(<italic toggle="yes">K<sub>I</sub></italic>) and the concentration of inhibitor
which causes 50 per cent inhibition (<italic toggle="yes">I</italic><sub>50</sub>) of an
enzymatic reaction</article-title>. <source>Biochem. Pharmacol.</source>
<volume>22</volume>, <fpage>3099</fpage>&#x02013;<lpage>3108</lpage>
(<year>1973</year>).<pub-id pub-id-type="pmid">4202581</pub-id>
</mixed-citation></ref><ref id="R59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>X.</given-names>
<surname>Liu</surname></string-name>,
<string-name><given-names>J.</given-names>
<surname>Kaindl</surname></string-name>,
<string-name><given-names>M.</given-names>
<surname>Korczynska</surname></string-name>,
<string-name><given-names>A.</given-names>
<surname>St&#x000f6;&#x000df;el</surname></string-name>,
<string-name><given-names>D.</given-names>
<surname>Dengler</surname></string-name>,
<string-name><given-names>M.</given-names>
<surname>Stanek</surname></string-name>,
<string-name><given-names>H.</given-names>
<surname>H&#x000fc;bner</surname></string-name>,
<string-name><given-names>M. J.</given-names>
<surname>Clark</surname></string-name>,
<string-name><given-names>J.</given-names>
<surname>Mahoney</surname></string-name>, <string-name><given-names>R.
A.</given-names>
<surname>Matt</surname></string-name>,
<string-name><given-names>X.</given-names>
<surname>Xu</surname></string-name>,
<string-name><given-names>K.</given-names>
<surname>Hirata</surname></string-name>, <string-name><given-names>B.
K.</given-names>
<surname>Shoichet</surname></string-name>, <string-name><given-names>R.
K.</given-names>
<surname>Sunahara</surname></string-name>, <string-name><given-names>B.
K.</given-names>
<surname>Kobilka</surname></string-name>,
<string-name><given-names>P.</given-names>
<surname>Gmeiner</surname></string-name></person-group>,
<article-title>An allosteric modulator binds to a conformational hub in the
&#x003b2;2 adrenergic receptor</article-title>. <source>Nat. Chem.
Biol.</source>
<volume>16</volume>, <fpage>749</fpage>&#x02013;<lpage>755</lpage>
(<year>2020</year>).<pub-id pub-id-type="pmid">32483378</pub-id>
</mixed-citation></ref><ref id="R60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names>
<surname>Zivanov</surname></string-name>,
<string-name><given-names>T.</given-names>
<surname>Nakane</surname></string-name>, <string-name><given-names>B.
O.</given-names>
<surname>Forsberg</surname></string-name>,
<string-name><given-names>D.</given-names>
<surname>Kimanius</surname></string-name>, <string-name><given-names>W.
J.</given-names>
<surname>Hagen</surname></string-name>,
<string-name><given-names>E.</given-names>
<surname>Lindahl</surname></string-name>, <string-name><given-names>S.
H. W.</given-names>
<surname>Scheres</surname></string-name></person-group>,
<article-title>New tools for automated high-resolution cryo-EM structure
determination in RELION-3</article-title>. <source>eLife</source>
<volume>7</volume>, <fpage>e42166</fpage> (<year>2018</year>).<pub-id pub-id-type="pmid">30412051</pub-id>
</mixed-citation></ref><ref id="R61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A.</given-names>
<surname>Rohou</surname></string-name>,
<string-name><given-names>N.</given-names>
<surname>Grigorieff</surname></string-name></person-group>,
<article-title>CTFFIND4: Fast and accurate defocus estimation from electron
micrographs</article-title>. <source>J. Struct. Biol.</source>
<volume>192</volume>, <fpage>216</fpage>&#x02013;<lpage>221</lpage>
(<year>2015</year>).<pub-id pub-id-type="pmid">26278980</pub-id>
</mixed-citation></ref><ref id="R62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A.</given-names>
<surname>Punjani</surname></string-name>,
<string-name><given-names>H.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>D.
J.</given-names>
<surname>Fleet</surname></string-name></person-group>,
<article-title>Non-uniform refinement: Adaptive regularization improves
single-particle cryo-EM reconstruction</article-title>. <source>Nat.
Methods</source>
<volume>17</volume>, <fpage>1214</fpage>&#x02013;<lpage>1221</lpage>
(<year>2020</year>).<pub-id pub-id-type="pmid">33257830</pub-id>
</mixed-citation></ref><ref id="R63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Y. Z.</given-names>
<surname>Tan</surname></string-name>, <string-name><given-names>P.
R.</given-names>
<surname>Baldwin</surname></string-name>, <string-name><given-names>J.
H.</given-names>
<surname>Davis</surname></string-name>, <string-name><given-names>J.
R.</given-names>
<surname>Williamson</surname></string-name>,
<string-name><given-names>C. S.</given-names>
<surname>Potter</surname></string-name>,
<string-name><given-names>B.</given-names>
<surname>Carragher</surname></string-name>,
<string-name><given-names>D.</given-names>
<surname>Lyumkis</surname></string-name></person-group>,
<article-title>Addressing preferred specimen orientation in single-particle
cryo-EM through tilting</article-title>. <source>Nat. Methods</source>
<volume>14</volume>, <fpage>793</fpage>&#x02013;<lpage>796</lpage>
(<year>2017</year>).<pub-id pub-id-type="pmid">28671674</pub-id>
</mixed-citation></ref><ref id="R64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>N. W.</given-names>
<surname>Moriarty</surname></string-name>, <string-name><given-names>R.
W.</given-names>
<surname>Grosse-Kunstleve</surname></string-name>,
<string-name><given-names>P. D.</given-names>
<surname>Adams</surname></string-name></person-group>,
<article-title>Electronic Ligand Builder and Optimization Workbench (eLBOW):
A tool for ligand coordinate and restraint generation</article-title>.
<source>Acta Crystallogr. D Biol. Crystallogr.</source>
<volume>65</volume>, <fpage>1074</fpage>&#x02013;<lpage>1080</lpage>
(<year>2009</year>).<pub-id pub-id-type="pmid">19770504</pub-id>
</mixed-citation></ref><ref id="R65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names>
<surname>Manna</surname></string-name>,
<string-name><given-names>M.</given-names>
<surname>Niemel&#x000e4;</surname></string-name>,
<string-name><given-names>J.</given-names>
<surname>Tynkkynen</surname></string-name>,
<string-name><given-names>M.</given-names>
<surname>Javanainen</surname></string-name>,
<string-name><given-names>W.</given-names>
<surname>Kulig</surname></string-name>, <string-name><given-names>D.
J.</given-names>
<surname>M&#x000fc;ller</surname></string-name>,
<string-name><given-names>T.</given-names>
<surname>Rog</surname></string-name>,
<string-name><given-names>I.</given-names>
<surname>Vattulainen</surname></string-name></person-group>,
<article-title>Mechanism of allosteric regulation of
&#x003b2;<sub>2</sub>-adrenergic receptor by cholesterol</article-title>.
<source>eLife</source>
<volume>5</volume>, <fpage>e18432</fpage> (<year>2016</year>).<pub-id pub-id-type="pmid">27897972</pub-id>
</mixed-citation></ref><ref id="R66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A.</given-names>
<surname>Casa&#x000f1;al</surname></string-name>,
<string-name><given-names>B.</given-names>
<surname>Lohkamp</surname></string-name>,
<string-name><given-names>P.</given-names>
<surname>Emsley</surname></string-name></person-group>,
<article-title>Current developments in <italic toggle="yes">Coot</italic> for
macromolecular model building of electron cryo-microscopy and
crystallographic data</article-title>. <source>Protein Sci.</source>
<volume>29</volume>, <fpage>1055</fpage>&#x02013;<lpage>1064</lpage>
(<year>2020</year>).</mixed-citation></ref><ref id="R67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A. M.</given-names>
<surname>Ring</surname></string-name>,
<string-name><given-names>A.</given-names>
<surname>Manglik</surname></string-name>, <string-name><given-names>A.
C.</given-names>
<surname>Kruse</surname></string-name>, <string-name><given-names>M.
D.</given-names>
<surname>Enos</surname></string-name>, <string-name><given-names>W.
I.</given-names>
<surname>Weis</surname></string-name>, <string-name><given-names>K.
C.</given-names>
<surname>Garcia</surname></string-name>, <string-name><given-names>B.
K.</given-names>
<surname>Kobilka</surname></string-name></person-group>,
<article-title>Adrenaline-activated structure of &#x003b2;2-adrenoceptor
stabilized by an engineered nanobody</article-title>.
<source>Nature</source>
<volume>502</volume>, <fpage>575</fpage>&#x02013;<lpage>579</lpage>
(<year>2013</year>).<pub-id pub-id-type="pmid">24056936</pub-id>
</mixed-citation></ref><ref id="R68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>E. F.</given-names>
<surname>Pettersen</surname></string-name>, <string-name><given-names>T.
D.</given-names>
<surname>Goddard</surname></string-name>, <string-name><given-names>C.
C.</given-names>
<surname>Huang</surname></string-name>, <string-name><given-names>G.
S.</given-names>
<surname>Couch</surname></string-name>, <string-name><given-names>D.
M.</given-names>
<surname>Greenblatt</surname></string-name>,
<string-name><given-names>E. C.</given-names>
<surname>Meng</surname></string-name>, <string-name><given-names>T.
E.</given-names>
<surname>Ferrin</surname></string-name></person-group>,
<article-title>UCSF Chimera&#x02014;A visualization system for exploratory
research and analysis</article-title>. <source>J. Comput. Chem.</source>
<volume>25</volume>, <fpage>1605</fpage>&#x02013;<lpage>1612</lpage>
(<year>2004</year>).<pub-id pub-id-type="pmid">15264254</pub-id>
</mixed-citation></ref><ref id="R69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>B.</given-names>
<surname>Webb</surname></string-name>,
<string-name><given-names>A.</given-names>
<surname>Sali</surname></string-name></person-group>,
<article-title>Comparative protein structure modeling using
MODELLER</article-title>. <source>Curr. Protoc. Bioinformatics</source>
<volume>54</volume>, <fpage>5.6.1</fpage>&#x02013;<lpage>5.6.37</lpage>
(<year>2016</year>).</mixed-citation></ref><ref id="R70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A.</given-names>
<surname>Ranganathan</surname></string-name>,
<string-name><given-names>R. O.</given-names>
<surname>Dror</surname></string-name>,
<string-name><given-names>J.</given-names>
<surname>Carlsson</surname></string-name></person-group>,
<article-title>Insights into the role of Asp79<sup>2.50</sup> in
&#x003b2;<sub>2</sub> adrenergic receptor activation from molecular
dynamics simulations</article-title>. <source>Biochemistry.</source>
<volume>53</volume>, <fpage>7283</fpage>&#x02013;<lpage>7296</lpage>
(<year>2014</year>).<pub-id pub-id-type="pmid">25347607</pub-id>
</mixed-citation></ref><ref id="R71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>R. O.</given-names>
<surname>Dror</surname></string-name>, <string-name><given-names>D.
H.</given-names>
<surname>Arlow</surname></string-name>, <string-name><given-names>D.
W.</given-names>
<surname>Borhani</surname></string-name>, <string-name><given-names>M.
&#x000d8;.</given-names>
<surname>Jensen</surname></string-name>,
<string-name><given-names>S.</given-names>
<surname>Piana</surname></string-name>, <string-name><given-names>D.
E.</given-names>
<surname>Shaw</surname></string-name></person-group>,
<article-title>Identification of two distinct inactive conformations of the
&#x003b2;<sub>2</sub> -adrenergic receptor reconciles structural and
biochemical observations</article-title>. <source>Proc. Natl. Acad. Sci.
U.S.A.</source>
<volume>106</volume>, <fpage>4689</fpage>&#x02013;<lpage>4694</lpage>
(<year>2009</year>).<pub-id pub-id-type="pmid">19258456</pub-id>
</mixed-citation></ref><ref id="R72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>D. M.</given-names>
<surname>Rosenbaum</surname></string-name>,
<string-name><given-names>C.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>J.
A.</given-names>
<surname>Lyons</surname></string-name>,
<string-name><given-names>R.</given-names>
<surname>Holl</surname></string-name>,
<string-name><given-names>D.</given-names>
<surname>Aragao</surname></string-name>, <string-name><given-names>D.
H.</given-names>
<surname>Arlow</surname></string-name>, <string-name><given-names>S. G.
F.</given-names>
<surname>Rasmussen</surname></string-name>,
<string-name><given-names>H.-J.</given-names>
<surname>Choi</surname></string-name>, <string-name><given-names>B.
T.</given-names>
<surname>DeVree</surname></string-name>, <string-name><given-names>R.
K.</given-names>
<surname>Sunahara</surname></string-name>, <string-name><given-names>P.
S.</given-names>
<surname>Chae</surname></string-name>, <string-name><given-names>S.
H.</given-names>
<surname>Gellman</surname></string-name>, <string-name><given-names>R.
O.</given-names>
<surname>Dror</surname></string-name>, <string-name><given-names>D.
E.</given-names>
<surname>Shaw</surname></string-name>, <string-name><given-names>W.
I.</given-names>
<surname>Weis</surname></string-name>,
<string-name><given-names>M.</given-names>
<surname>Caffrey</surname></string-name>,
<string-name><given-names>P.</given-names>
<surname>Gmeiner</surname></string-name>, <string-name><given-names>B.
K.</given-names>
<surname>Kobilka</surname></string-name></person-group>,
<article-title>Structure and function of an irreversible agonist-&#x003b2;2
adrenoceptor complex</article-title>. <source>Nature</source>
<volume>469</volume>, <fpage>236</fpage>&#x02013;<lpage>240</lpage>
(<year>2011</year>).<pub-id pub-id-type="pmid">21228876</pub-id>
</mixed-citation></ref><ref id="R73"><label>73</label><mixed-citation publication-type="book">D. A. Case, I. Y. Ben-Shalom, S. R. Brozell,
D. S. Cerutti, T. E. Cheatham III, V. W. D. Cruzeiro, T. A. Darden, R. E. Duke,
D. Ghoreishi, M. K. Gilson, H. Gohlke, A. W. Goetz, D. Greene, R. Harris, N.
Homeyer, S. Izadi, A. Kovalenko, T. Kurtzman, T. S. Lee, S. LeGrand, P. Li, C.
Lin, J. Liu, T. Luchko, R. Luo, D. J. Mermelstein, K. M. Merz, Y. Miao, G.
Monard, C. Nguyen, H. Nguyen, I. Omelyan, A. Onufriev, F. Pan, R. Qi, D. R. Roe,
A. Roitberg, C. Sagui, S. Schott-Verdugo, J. Shen, C. L. Simmerling, J. Smith,
R. Salomon-Ferrer, J. Swails, R. C. Walker, J. Wang, H. Wei, R. M. Wolf, X. Wu,
L. Xiao, D. M. York, P. A. Kollman, <italic toggle="yes">AMBER 2018</italic> (University of
California, San Francisco, 2018).</mixed-citation></ref><ref id="R74"><label>74</label><mixed-citation publication-type="book">M. J. Frisch, G. W. Trucks, H. B. Schlegel,
G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, G. A.
Petersson, H. Nakatsuji, X. Li, M. Caricato, A. V. Marenich, J. Bloino, B. G.
Janesko, R. Gomperts, B. Mennucci, H. P. Hratchian, J. V. Ortiz, A. F. Izmaylov,
J. L. Sonnenberg, D. Williams-Young, F. Ding, F. Lipparini, F. Egidi, J. Goings,
B. Peng, A. Petrone, T. Henderson, D. Ranasinghe, V. G. Zakrzewski, J. Gao, N.
Rega, G. Zheng, W. Liang, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa,
M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, K. Throssell,
J. A. Montgomery, Jr., J. E. Peralta, F. Ogliaro, M. J. Bearpark, J. J. Heyd, E.
N. Brothers, K. N. Kudin, V. N. Staroverov, T. A. Keith, R. Kobayashi, J.
Normand, K. Raghavachari, A. P. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi,
M. Cossi, J. M. Millam, M. Klene, C. Adamo, R. Cammi, J. W. Ochterski, R. L.
Martin, K. Morokuma, O. Farkas, J. B. Foresman, D. J. Fox, <italic toggle="yes">Gaussian 16,
version Revision C.01</italic> (Gaussian Inc., 2016).</mixed-citation></ref><ref id="R75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>C. I.</given-names>
<surname>Bayly</surname></string-name>,
<string-name><given-names>P.</given-names>
<surname>Cieplak</surname></string-name>,
<string-name><given-names>W.</given-names>
<surname>Cornell</surname></string-name>, <string-name><given-names>P.
A.</given-names>
<surname>Kollman</surname></string-name></person-group>,
<article-title>A well-behaved electrostatic potential based method using
charge restraints for deriving atomic charges: The RESP
model</article-title>. <source>J. Phys. Chem.</source>
<volume>97</volume>, <fpage>10269</fpage>&#x02013;<lpage>10280</lpage>
(<year>1993</year>).</mixed-citation></ref><ref id="R76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M. A.</given-names>
<surname>Lomize</surname></string-name>, <string-name><given-names>A.
L.</given-names>
<surname>Lomize</surname></string-name>, <string-name><given-names>I.
D.</given-names>
<surname>Pogozheva</surname></string-name>, <string-name><given-names>H.
I.</given-names>
<surname>Mosberg</surname></string-name></person-group>,
<article-title>OPM: Orientations of Proteins in Membranes
database</article-title>. <source>Bioinformatics</source>
<volume>22</volume>, <fpage>623</fpage>&#x02013;<lpage>625</lpage>
(<year>2006</year>).<pub-id pub-id-type="pmid">16397007</pub-id>
</mixed-citation></ref><ref id="R77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M. G.</given-names>
<surname>Wolf</surname></string-name>,
<string-name><given-names>M.</given-names>
<surname>Hoefling</surname></string-name>,
<string-name><given-names>C.</given-names>
<surname>Aponte-Santamar&#x000ed;a</surname></string-name>,
<string-name><given-names>H.</given-names>
<surname>Grubm&#x000fc;ller</surname></string-name>,
<string-name><given-names>G.</given-names>
<surname>Groenhof</surname></string-name></person-group>,
<article-title>g_membed: Efficient insertion of a membrane protein into an
equilibrated lipid bilayer with minimal perturbation</article-title>.
<source>J. Comput. Chem.</source>
<volume>31</volume>, <fpage>2169</fpage>&#x02013;<lpage>2174</lpage>
(<year>2010</year>).<pub-id pub-id-type="pmid">20336801</pub-id>
</mixed-citation></ref><ref id="R78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>R.
M.</given-names>
<surname>Wolf</surname></string-name>, <string-name><given-names>J.
W.</given-names>
<surname>Caldwell</surname></string-name>, <string-name><given-names>P.
A.</given-names>
<surname>Kollman</surname></string-name>, <string-name><given-names>D.
A.</given-names>
<surname>Case</surname></string-name></person-group>,
<article-title>Development and testing of a general amber force
field</article-title>. <source>J. Comput. Chem.</source>
<volume>25</volume>, <fpage>1157</fpage>&#x02013;<lpage>1174</lpage>
(<year>2004</year>).<pub-id pub-id-type="pmid">15116359</pub-id>
</mixed-citation></ref><ref id="R79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>C. J.</given-names>
<surname>Dickson</surname></string-name>, <string-name><given-names>B.
D.</given-names>
<surname>Madej</surname></string-name>,
<string-name><given-names>&#x000c5;. A.</given-names>
<surname>Skjevik</surname></string-name>, <string-name><given-names>R.
M.</given-names>
<surname>Betz</surname></string-name>,
<string-name><given-names>K.</given-names>
<surname>Teigen</surname></string-name>, <string-name><given-names>I.
R.</given-names>
<surname>Gould</surname></string-name>, <string-name><given-names>R.
C.</given-names>
<surname>Walker</surname></string-name></person-group>,
<article-title>Lipid14: The amber lipid force field</article-title>.
<source>J. Chem. Theory Comput.</source>
<volume>10</volume>, <fpage>865</fpage>&#x02013;<lpage>879</lpage>
(<year>2014</year>).<pub-id pub-id-type="pmid">24803855</pub-id>
</mixed-citation></ref><ref id="R80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J. A.</given-names>
<surname>Maier</surname></string-name>,
<string-name><given-names>C.</given-names>
<surname>Martinez</surname></string-name>,
<string-name><given-names>K.</given-names>
<surname>Kasavajhala</surname></string-name>,
<string-name><given-names>L.</given-names>
<surname>Wickstrom</surname></string-name>, <string-name><given-names>K.
E.</given-names>
<surname>Hauser</surname></string-name>,
<string-name><given-names>C.</given-names>
<surname>Simmerling</surname></string-name></person-group>,
<article-title>ff14SB: Improving the accuracy of protein side chain and
backbone parameters from ff99SB</article-title>. <source>J. Chem. Theory
Comput.</source>
<volume>11</volume>, <fpage>3696</fpage>&#x02013;<lpage>3713</lpage>
(<year>2015</year>).<pub-id pub-id-type="pmid">26574453</pub-id>
</mixed-citation></ref><ref id="R81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>H. J. C.</given-names>
<surname>Berendsen</surname></string-name>, <string-name><given-names>J.
R.</given-names>
<surname>Grigera</surname></string-name>, <string-name><given-names>T.
P.</given-names>
<surname>Straatsma</surname></string-name></person-group>,
<article-title>The missing term in effective pair
potentials</article-title>. <source>J. Phys. Chem.</source>
<volume>91</volume>, <fpage>6269</fpage>&#x02013;<lpage>6271</lpage>
(<year>1987</year>).</mixed-citation></ref><ref id="R82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>D.</given-names>
<prefix>Van Der</prefix>
<surname>Spoel</surname></string-name>,
<string-name><given-names>E.</given-names>
<surname>Lindahl</surname></string-name>,
<string-name><given-names>B.</given-names>
<surname>Hess</surname></string-name>,
<string-name><given-names>G.</given-names>
<surname>Groenhof</surname></string-name>, <string-name><given-names>A.
E.</given-names>
<surname>Mark</surname></string-name>, <string-name><given-names>H. J.
C.</given-names>
<surname>Berendsen</surname></string-name></person-group>,
<article-title>GROMACS: Fast, flexible, and free</article-title>. <source>J.
Comput. Chem.</source>
<volume>26</volume>, <fpage>1701</fpage>&#x02013;<lpage>1718</lpage>
(<year>2005</year>).<pub-id pub-id-type="pmid">16211538</pub-id>
</mixed-citation></ref><ref id="R83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M. J.</given-names>
<surname>Abraham</surname></string-name>,
<string-name><given-names>T.</given-names>
<surname>Murtola</surname></string-name>,
<string-name><given-names>R.</given-names>
<surname>Schulz</surname></string-name>,
<string-name><given-names>S.</given-names>
<surname>P&#x000e1;ll</surname></string-name>,
<string-name><given-names>J. C.</given-names>
<surname>Smith</surname></string-name>,
<string-name><given-names>B.</given-names>
<surname>Hess</surname></string-name>,
<string-name><given-names>E.</given-names>
<surname>Lindahl</surname></string-name></person-group>,
<article-title>GROMACS: High performance molecular simulations through
multi-level parallelism from laptops to supercomputers</article-title>.
<source>SoftwareX</source>
<volume>1&#x02013;2</volume>, <fpage>19</fpage>&#x02013;<lpage>25</lpage>
(<year>2015</year>).</mixed-citation></ref><ref id="R84"><label>84</label><mixed-citation publication-type="other">E. Lindahl, M. J. Abraham, B. Hess, V. D.
Spoel, <italic toggle="yes">GROMACS 2021 Manual</italic> (2021).</mixed-citation></ref><ref id="R85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>B.</given-names>
<surname>Hess</surname></string-name>,
<string-name><given-names>H.</given-names>
<surname>Bekker</surname></string-name>, <string-name><given-names>H. J.
C.</given-names>
<surname>Berendsen</surname></string-name>, <string-name><given-names>J.
G. E. M.</given-names>
<surname>Fraaije</surname></string-name></person-group>,
<article-title>LINCS: A linear constraint solver for molecular
simulations</article-title>. <source>J. Comput. Chem.</source>
<volume>18</volume>, <fpage>1463</fpage>&#x02013;<lpage>1472</lpage>
(<year>1997</year>).</mixed-citation></ref><ref id="R86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>T.</given-names>
<surname>Darden</surname></string-name>,
<string-name><given-names>D.</given-names>
<surname>York</surname></string-name>,
<string-name><given-names>L.</given-names>
<surname>Pedersen</surname></string-name></person-group>,
<article-title>Particle mesh Ewald: An <italic toggle="yes">N</italic>
log(<italic toggle="yes">N</italic>) method for Ewald sums in large
systems</article-title>. <source>J. Chem. Phys.</source>
<volume>98</volume>, <fpage>10089</fpage>&#x02013;<lpage>10092</lpage>
(<year>1993</year>).</mixed-citation></ref><ref id="R87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>D. R.</given-names>
<surname>Roe</surname></string-name>, <string-name><given-names>T.
E.</given-names>
<surname>Cheatham</surname></string-name></person-group>,
<article-title>PTRAJ and CPPTRAJ: Software for processing and analysis of
molecular dynamics trajectory data</article-title>. <source>J. Chem. Theory
Comput.</source>
<volume>9</volume>, <fpage>3084</fpage>&#x02013;<lpage>3095</lpage>
(<year>2013</year>).<pub-id pub-id-type="pmid">26583988</pub-id>
</mixed-citation></ref><ref id="R88"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J. D.</given-names>
<surname>Hunter</surname></string-name></person-group>,
<article-title>Matplotlib: A 2D graphics environment</article-title>.
<source>Comput. Sci. Eng.</source>
<volume>9</volume>, <fpage>90</fpage>&#x02013;<lpage>95</lpage>
(<year>2007</year>).</mixed-citation></ref><ref id="R89"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>I.</given-names>
<surname>Tkach</surname></string-name>,
<string-name><given-names>U.</given-names>
<surname>Diederichsen</surname></string-name>,
<string-name><given-names>M.</given-names>
<surname>Bennati</surname></string-name></person-group>,
<article-title>Studies of transmembrane peptides by pulse dipolar
spectroscopy with semi-rigid TOPP spin labels</article-title>. <source>Eur.
Biophys. J.</source>
<volume>50</volume>, <fpage>143</fpage>&#x02013;<lpage>157</lpage>
(<year>2021</year>).<pub-id pub-id-type="pmid">33640998</pub-id>
</mixed-citation></ref><ref id="R90"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>B.</given-names>
<surname>Joseph</surname></string-name>, <string-name><given-names>E.
A.</given-names>
<surname>Jaumann</surname></string-name>,
<string-name><given-names>A.</given-names>
<surname>Sikora</surname></string-name>,
<string-name><given-names>K.</given-names>
<surname>Barth</surname></string-name>, <string-name><given-names>T.
F.</given-names>
<surname>Prisner</surname></string-name>, <string-name><given-names>D.
S.</given-names>
<surname>Cafiso</surname></string-name></person-group>,
<article-title>In situ observation of conformational dynamics and protein
ligand&#x02013;substrate interactions in outer-membrane proteins with
DEER/PELDOR spectroscopy</article-title>. <source>Nat. Protoc.</source>
<volume>14</volume>, <fpage>2344</fpage>&#x02013;<lpage>2369</lpage>
(<year>2019</year>).<pub-id pub-id-type="pmid">31278399</pub-id>
</mixed-citation></ref><ref id="R91"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>C. E.</given-names>
<surname>Tait</surname></string-name>,
<string-name><given-names>S.</given-names>
<surname>Stoll</surname></string-name></person-group>,
<article-title>Coherent pump pulses in double electron electron resonance
spectroscopy</article-title>. <source>Phys. Chem. Chem. Phys.</source>
<volume>18</volume>, <fpage>18470</fpage>&#x02013;<lpage>18485</lpage>
(<year>2016</year>).<pub-id pub-id-type="pmid">27339858</pub-id>
</mixed-citation></ref><ref id="R92"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names>
<surname>Teucher</surname></string-name>,
<string-name><given-names>E.</given-names>
<surname>Bordignon</surname></string-name></person-group>,
<article-title>Improved signal fidelity in 4-pulse DEER with Gaussian
pulses</article-title>. <source>J. Magn. Reson.</source>
<volume>296</volume>, <fpage>103</fpage>&#x02013;<lpage>111</lpage>
(<year>2018</year>).<pub-id pub-id-type="pmid">30241017</pub-id>
</mixed-citation></ref><ref id="R93"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>H.</given-names>
<surname>Russell</surname></string-name>,
<string-name><given-names>R.</given-names>
<surname>Stewart</surname></string-name>,
<string-name><given-names>C.</given-names>
<surname>Prior</surname></string-name>, <string-name><given-names>V.
S.</given-names>
<surname>Oganesyan</surname></string-name>, <string-name><given-names>T.
G.</given-names>
<surname>Gaule</surname></string-name>, <string-name><given-names>J.
E.</given-names>
<surname>Lovett</surname></string-name></person-group>,
<article-title>DEER and RIDME measurements of the nitroxide-spin labelled
copper-bound amine oxidase homodimer from arthrobacter
globiformis</article-title>. <source>Appl Magn Reson</source>
<volume>52</volume>, <fpage>995</fpage>&#x02013;<lpage>1015</lpage>
(<year>2021</year>).<pub-id pub-id-type="pmid">34720439</pub-id>
</mixed-citation></ref><ref id="R94"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>O.</given-names>
<surname>Schiemann</surname></string-name>, <string-name><given-names>C.
A.</given-names>
<surname>Heubach</surname></string-name>,
<string-name><given-names>D.</given-names>
<surname>Abdullin</surname></string-name>,
<string-name><given-names>K.</given-names>
<surname>Ackermann</surname></string-name>,
<string-name><given-names>M.</given-names>
<surname>Azarkh</surname></string-name>, <string-name><given-names>E.
G.</given-names>
<surname>Bagryanskaya</surname></string-name>,
<string-name><given-names>M.</given-names>
<surname>Drescher</surname></string-name>,
<string-name><given-names>B.</given-names>
<surname>Endeward</surname></string-name>, <string-name><given-names>J.
H.</given-names>
<surname>Freed</surname></string-name>,
<string-name><given-names>L.</given-names>
<surname>Galazzo</surname></string-name>,
<string-name><given-names>D.</given-names>
<surname>Goldfarb</surname></string-name>,
<string-name><given-names>T.</given-names>
<surname>Hett</surname></string-name>, <string-name><given-names>L.
E.</given-names>
<surname>Hofer</surname></string-name>, <string-name><given-names>L.
F.</given-names>
<surname>Ib&#x000e1;&#x000f1;ez</surname></string-name>,
<string-name><given-names>E. J.</given-names>
<surname>Hustedt</surname></string-name>,
<string-name><given-names>S.</given-names>
<surname>Kucher</surname></string-name>,
<string-name><given-names>I.</given-names>
<surname>Kuprov</surname></string-name>, <string-name><given-names>J.
E.</given-names>
<surname>Lovett</surname></string-name>,
<string-name><given-names>A.</given-names>
<surname>Meyer</surname></string-name>,
<string-name><given-names>S.</given-names>
<surname>Ruthstein</surname></string-name>,
<string-name><given-names>S.</given-names>
<surname>Saxena</surname></string-name>,
<string-name><given-names>S.</given-names>
<surname>Stoll</surname></string-name>, <string-name><given-names>C.
R.</given-names>
<surname>Timmel</surname></string-name>,
<string-name><given-names>M.</given-names>
<surname>Di Valentin</surname></string-name>,
<string-name><given-names>H. S.</given-names>
<surname>Mchaourab</surname></string-name>, <string-name><given-names>T.
F.</given-names>
<surname>Prisner</surname></string-name>, <string-name><given-names>B.
E.</given-names>
<surname>Bode</surname></string-name>,
<string-name><given-names>E.</given-names>
<surname>Bordignon</surname></string-name>,
<string-name><given-names>M.</given-names>
<surname>Bennati</surname></string-name>,
<string-name><given-names>G.</given-names>
<surname>Jeschke</surname></string-name></person-group>,
<article-title>Benchmark test and guidelines for DEER/PELDOR experiments on
nitroxide-labeled biomolecules</article-title>. <source>J. Am. Chem.
Soc.</source>
<volume>143</volume>, <fpage>17875</fpage>&#x02013;<lpage>17890</lpage>
(<year>2021</year>).<pub-id pub-id-type="pmid">34664948</pub-id>
</mixed-citation></ref><ref id="R95"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names>
<surname>Keeley</surname></string-name>,
<string-name><given-names>T.</given-names>
<surname>Choudhury</surname></string-name>,
<string-name><given-names>L.</given-names>
<surname>Galazzo</surname></string-name>,
<string-name><given-names>E.</given-names>
<surname>Bordignon</surname></string-name>,
<string-name><given-names>A.</given-names>
<surname>Feintuch</surname></string-name>,
<string-name><given-names>D.</given-names>
<surname>Goldfarb</surname></string-name>,
<string-name><given-names>H.</given-names>
<surname>Russell</surname></string-name>, <string-name><given-names>M.
J.</given-names>
<surname>Taylor</surname></string-name>, <string-name><given-names>J.
E.</given-names>
<surname>Lovett</surname></string-name>,
<string-name><given-names>A.</given-names>
<surname>Eggeling</surname></string-name>,
<string-name><given-names>L.</given-names>
<surname>F&#x000e1;bregas Ib&#x000e1;&#x000f1;ez</surname></string-name>,
<string-name><given-names>K.</given-names>
<surname>Keller</surname></string-name>,
<string-name><given-names>M.</given-names>
<surname>Yulikov</surname></string-name>,
<string-name><given-names>G.</given-names>
<surname>Jeschke</surname></string-name>,
<string-name><given-names>I.</given-names>
<surname>Kuprov</surname></string-name></person-group>,
<article-title>Neural networks in pulsed dipolar spectroscopy: A practical
guide</article-title>. <source>J. Magn. Reson.</source>
<volume>338</volume>, <fpage>107186</fpage>
(<year>2022</year>).<pub-id pub-id-type="pmid">35344921</pub-id>
</mixed-citation></ref><ref id="R96"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>L.</given-names>
<surname>F&#x000e1;bregas Ib&#x000e1;&#x000f1;ez</surname></string-name>,
<string-name><given-names>G.</given-names>
<surname>Jeschke</surname></string-name>,
<string-name><given-names>S.</given-names>
<surname>Stoll</surname></string-name></person-group>,
<article-title>DeerLab: A comprehensive software package for analyzing
dipolar electron paramagnetic resonance spectroscopy data</article-title>.
<source>Magn. Reson.</source>
<volume>1</volume>, <fpage>209</fpage>&#x02013;<lpage>224</lpage>
(<year>2020</year>).</mixed-citation></ref><ref id="R97"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M. F.</given-names>
<surname>Juette</surname></string-name>, <string-name><given-names>D.
S.</given-names>
<surname>Terry</surname></string-name>, <string-name><given-names>M.
R.</given-names>
<surname>Wasserman</surname></string-name>, <string-name><given-names>R.
B.</given-names>
<surname>Altman</surname></string-name>,
<string-name><given-names>Z.</given-names>
<surname>Zhou</surname></string-name>,
<string-name><given-names>H.</given-names>
<surname>Zhao</surname></string-name>, <string-name><given-names>S.
C.</given-names>
<surname>Blanchard</surname></string-name></person-group>,
<article-title>Single-molecule imaging of non-equilibrium molecular
ensembles on the millisecond timescale</article-title>. <source>Nat.
Methods.</source>
<volume>13</volume>, <fpage>341</fpage>&#x02013;<lpage>344</lpage>
(<year>2016</year>).<pub-id pub-id-type="pmid">26878382</pub-id>
</mixed-citation></ref><ref id="R98"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>G.</given-names>
<surname>Haran</surname></string-name></person-group>,
<article-title>Noise reduction in single-molecule fluorescence trajectories
of folding proteins</article-title>. <source>Chem. Phys.</source>
<volume>307</volume>, <fpage>137</fpage>&#x02013;<lpage>145</lpage>
(<year>2004</year>).</mixed-citation></ref><ref id="R99"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Q.</given-names>
<surname>Wan</surname></string-name>,
<string-name><given-names>N.</given-names>
<surname>Okashah</surname></string-name>,
<string-name><given-names>A.</given-names>
<surname>Inoue</surname></string-name>,
<string-name><given-names>R.</given-names>
<surname>Nehm&#x000e9;</surname></string-name>,
<string-name><given-names>B.</given-names>
<surname>Carpenter</surname></string-name>, <string-name><given-names>C.
G.</given-names>
<surname>Tate</surname></string-name>, <string-name><given-names>N.
A.</given-names>
<surname>Lambert</surname></string-name></person-group>,
<article-title>Mini G protein probes for active G protein&#x02013;coupled
receptors (GPCRs) in live cells</article-title>. <source>J. Biol.
Chem.</source>
<volume>293</volume>, <fpage>7466</fpage>&#x02013;<lpage>7473</lpage>
(<year>2018</year>).<pub-id pub-id-type="pmid">29523687</pub-id>
</mixed-citation></ref><ref id="R100"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>R.</given-names>
<surname>Nehm&#x000e9;</surname></string-name>,
<string-name><given-names>B.</given-names>
<surname>Carpenter</surname></string-name>,
<string-name><given-names>A.</given-names>
<surname>Singhal</surname></string-name>,
<string-name><given-names>A.</given-names>
<surname>Strege</surname></string-name>, <string-name><given-names>P.
C.</given-names>
<surname>Edwards</surname></string-name>, <string-name><given-names>C.
F.</given-names>
<surname>White</surname></string-name>,
<string-name><given-names>H.</given-names>
<surname>Du</surname></string-name>,
<string-name><given-names>R.</given-names>
<surname>Grisshammer</surname></string-name>,
<string-name><given-names>C. G.</given-names>
<surname>Tate</surname></string-name></person-group>,
<article-title>Mini-G proteins: Novel tools for studying GPCRs in their
active conformation</article-title>. <source>PLOS ONE</source>
<volume>12</volume>, <fpage>e0175642</fpage>
(<year>2017</year>).<pub-id pub-id-type="pmid">28426733</pub-id>
</mixed-citation></ref></ref-list></back></article>